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INTRODUCTION
Multimorbidity is the co-existence of several diseases at the same time in one patient.1, 2 In 
general, multimorbidity refers to chronic diseases or conditions, although some definitions 
also include acute or transient conditions. Different from the term ‘multimorbidity’, that 
does not specify the presence of particular diseases, ‘comorbidity’ refers to the presence 
of an additional condition in a patient with an index disease (a particular condition of 
interest).1-3 
Multimorbidity is a prevalent phenomenon. Depending on which definition is applied and 
how many diseases are considered, most studies report a prevalence of multimorbidity 
around 20-30% among adult patients in primary care, with increasing percentages in 
ageing persons.4-10 
Multimorbidity has negative consequences on patients’ physical and mental wellbeing,11,12 
quality of life,13-16 and mortality.16, 17 It also has negative consequences on health care 
utilisation, e.g. doctor visit frequency, length of hospital stay, referral and (re)admission 
rates, and costs.4, 16-19 Patients with a high morbidity burden have a higher visit frequency 
to specialists, even for common diseases that are normally dealt with in primary care.20 
This Introduction will further outline some background of multimorbidity and the types 
of problems it brings, both to patients and practitioners. The focus of this thesis will be 
on the general practitioner’s (GP’s) perspective on multimorbidity, since this is, in contrary 
to the patients’ perspective, relatively underexposed. By generating more knowledge on 
associations between specific combinations of diseases, and by applying GPs’ empirical 
knowledge on the theme multimorbidity - thus by using mixed methods - this thesis may 
help to improve the care for patients with multimorbidity.
In the last two decades, attention for the phenomenon multimorbidity has clearly 
increased in the medical scientific literature. This is illustrated by the growing number 
of publications on multimorbidity over time.21 However, the phenomenon on itself is 
not ‘new’. Management of chronic diseases has been described as ‘the very stuff of 
general practice’.22 Consequently, the care for patients with multiple diseases has always 
been a component of primary care. Huygen’s narrative and epidemiological description 
of the medical life histories of numerous families in his practice, published in 1978, 
includes descriptions of multimorbidity, although at that time not yet labelled as such.23 
Some early papers on multimorbidity provided prevalence data of comorbidity or 
multimorbidity in primary care, and defined its consequences for practice and research, 
such as limited validity of clinical trial results for patients with multimorbidity, who 
are generally excluded from these trials.24, 25 This occurred shortly after the launch of 
‘evidence based medicine’ as a new paradigm for medical practice, stressing that evidence 
from clinical research would become more important for clinical decision making than 
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intuition, pathophysiologic rationale and unsystematic clinical experience.26 In the years 
that followed, evidence based medicine experienced heydays with an enormous amount 
of randomised trials and observational studies, resulting in large numbers of evidence-
based clinical guidelines providing advice on how best to treat single diseases. 
Accompanied by a growing understanding that the evidence produced under randomised 
clinical trial circumstances, with its focus on single diseases and often originating from 
secondary care, generally does not correspond to an older patient in a complex care 
situation, attention for multimorbidity started to increase. Not surprisingly, researchers 
in primary care took up a large part of this ‘new’ interest. After conceptualising and 
defining ‘multimorbidity’,1 many subsequent papers on comorbidity or multimorbidity 
described the magnitude of this phenomenon in epidemiologic reports, mostly as 
retrospective or cross-sectional studies.16, 27 Only six prospective cohort studies from 
five completed studies on multimorbidity in primary care were found in a systematic 
review.28 A Cochrane systematic review identified ten studies examining the effect of an 
intervention designed to improve outcomes of patients with multimorbidity in primary 
care and community settings.29 All contained a complex multi-component intervention, 
most addressing organisation of care, and some were patient-oriented interventions. 
The authors summarised that the more effective interventions to improve outcomes in 
patients with multimorbidity may be those focusing on particular risk factors or functional 
problems. It was only recently that studies of nonrandom associations of diseases started 
to receive more interest.30
Evidence-based guidelines, written for single diseases in general, do not specify how they 
should be used in combination, and lack recommendations on how to prioritise treatment 
options for patients with multimorbidity.31-34 Advices in guidelines for a specific disease 
may be outright contradictory to those for another disease. The recommendations for 
medication prescriptions in guidelines aim to induce disease-specific benefits in patients 
resembling those included in randomised controlled trials.31 If the same disease-specific 
benefits may be expected from implementing such treatment for patients who are older, 
have comorbidity, and simultaneously use other medication regimes for other diseases, 
remains unclear. What the advantages for patients with multimorbidity are from the combi-
nation of guideline-recommended (medication) regimes in terms of generic outcomes such 
as daily functioning, quality of life, or overall mortality, is completely obscure. 
Presence of comorbidity may importantly influence the management of another 
chronic disease. Nevertheless, reports on the effects of specific comorbid diseases on 
the outcomes of other diseases are scarce, especially when unrelated (‘discordant’) 
diseases are considered.34, 35 More knowledge of interactions, i.e. how one disease 
affects outcomes of the other when present within the same individual, is necessary to 
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develop evidence-based recommendations and in this way improve care for patients with 
multimorbidity. 
In the absence of relevant and applicable evidence for patients with multimorbidity, it 
may be difficult for a clinician how to balance benefits and harms of all recommendations 
given in multiple guidelines. Moreover, it may differ between patients which outcomes 
contribute most to their preferred health status. Shared decision making is important 
and can help to target treatment at the most desirable health outcome for a particular 
patient. Especially in these cases it is important to incorporate patient preferences and 
personal circumstances in the clinical decisions made. The space that current guidelines 
provide to bring this into practice is limited.33, 36 
Given the high prevalence of multimorbidity, it is not surprising that taking care of 
patients with multimorbidity is daily practice for general practitioners (GPs). GPs, being 
generalists, traditionally take care of all presented health problems without prioritising 
one condition over another beforehand. Multimorbidity and the existing gap in evidence-
based recommendations for its management are highly relevant for GPs. They especially 
may perceive multimorbidity as an important and challenging problem. Best practice 
develops empirically in daily practice, in the absence of evidence-based medicine. Much 
can be learned from experiences of patients and health care providers who deal with 
multimorbidity on a daily basis. Qualitative research has the capacity to study experiences 
of illness, meanings attributed to disease, diagnosis and treatment, and reasons and 
considerations regarding choices made in these processes. Exactly when not much is 
known on a particular topic, qualitative research is ideally suited to explore the field. 
Studies describing experiences of patients with multimorbidity showed that they have 
problems with medication management and organisation of care.37-41 They feel a need to 
rely on self-care, and aim for maintenance of functional independence and management 
of symptoms.42-45 This type of knowledge brings important information to doctors who 
aim to achieve shared decision making with their patients with multimorbidity. 
Fewer papers however report on the experiences of practitioners with their care for 
patients with multimorbidity. The experiences that practitioners have also bring their 
contribution to a shared-decision making process. Some qualitative papers identified lack 
of time and organisational challenges as important problems for doctors in the care for 
patients with multimorbidity.46-49 Previous papers paid limited attention to strategies or 
solutions that practitioners have developed to deal with multimorbidity in daily practice 
- in the absence of evidence-based guidelines to support this management. This relative 
lack of insight into the (general) practitioner’s perspective on multimorbidity was a major 
reason to focus on the GP’s perspective in this thesis, since it is to be expected that a 
large part of the outcomes of care for patients with multimorbidity is defined by the way 
how this is realised by doctors who deal with it on a daily basis. 
INTRODUCTION
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AIMS OF THE THESIS
To address some important gaps in the knowledge about multimorbidity, as outlined in 
this Introduction, several research objectives were formulated:
- To describe the prevalence and incidence density of comorbidity in type 2 diabetes 
patients in primary care. 
- To explore the long-term associations between comorbidity and longitudinal diabetes 
control parameters in type 2 diabetes in primary care. 
- To study GPs’ considerations and main aims in their care for patients with multi-
morbidity, and to explore factors influencing their management of multimorbidity. 
- To explore how GPs value guidelines when applied to patients with multimorbidity, 
and which benefits and barriers they experience from adherence to guidelines in 
these patients. 
OUTLINE OF THE THESIS
The results of the research questions that were formulated will be described in the 
following chapters of this thesis. This thesis applies mixed methods to address the 
research questions defined: it contains both quantitative and qualitative research. 
The first, quantitative part takes type 2 diabetes mellitus as an example of a common 
chronic disease in primary care to prospectively study the effects of comorbidity on 
disease control parameters. Type 2 diabetes is here defined as the index disease. Since 
knowledge of the epidemiology of comorbidity in diabetes is essential to evaluate its 
effects on diabetes outcomes, but robust and representative data were lacking, Chapter 
2 starts with an investigation of the epidemiology of comorbid diseases in type 2 
diabetes. In a primary care cohort of patients with newly diagnosed type 2 diabetes, 
the prevalence of existing chronic diseases and the incidence density of new chronic 
comorbid diseases over time is established. Any type of comorbidity is included, in order 
to provide an overview of the entire range of chronic diseases that may interfere with 
the diabetes management. Clusters of diseases are composed so that prevalence and 
incidence density can also be calculated for diseases from the same (organ) clusters. 
Next, Chapter 3 explores the long-term effects of chronic comorbidity on glycaemic 
control and systolic blood pressure longitudinally within the same cohort of diabetes 
patients in primary care. This is studied both as outcome of the total number of comorbid 
diseases, and as presence or absence of five specific types of comorbid diseases: 
cardiovascular disease, malignancy, musculoskeletal disease, mental health disease, and 
COPD. Potential differences in the trends of HbA1c and systolic blood pressure according 
to the total amount of comorbid diseases are studied for effect modification by age, sex, 
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body mass index, and socioeconomic status in subgroup effect analyses. 
Chapter 4 specifically explores in-depth the association between comorbid COPD and 
longitudinal diabetes control parameter trends over five years of follow-up in the type 
2 diabetes patients cohort. Differences in glycaemic and systolic blood pressure trends 
are compared between patients with and without comorbid COPD. In subgroup effect 
analyses, potential effect modification of these trends (according to presence or absence 
of COPD) by age, sex, body mass index, and socioeconomic status is explored. 
All research in the first, quantitative part of this thesis is explorative and hypothesis-
generating, without much comparable work preceding it in the literature. 
The second part of this thesis contains qualitative research. It utilises the broad 
experience GPs have in the management of multimorbidity to explore their ideas and 
considerations with regard to multimorbidity, and which challenges they experience and 
solutions they create. Such information may importantly contribute to the knowledge 
in this area and shape the future research agenda. Chapter 5 describes the main aims 
that GPs formulate in their care for patients with multimorbidity, which considerations 
they have in this respect, and their perceived facilitators and barriers in multimorbidity 
management. Chapter 6 describes the value GPs attribute to medical guidelines when 
these are applied to patients with multimorbidity. It identifies benefits and limitations 
perceived from guideline adherence in these patients and ways to counteract some 
obstacles they come across in guideline adherence in multimorbidity. Chapters 5 and 
6 contain qualitative analyses of a series of focus group interviews with Dutch GPs. 
Separate qualitative analyses are performed for the specific objectives of these studies, 
using the constant comparative analysis technique. 
The general discussion of this thesis (Chapter 7) discusses the interpretation of the overall 
findings from the explorative studies in the first, quantitative part, and the qualitative 
results in the second part of this mixed methods thesis. It furthermore describes how 
these findings relate to the existing literature and what they contribute to the research 
field of multimorbidity in primary care. Moreover, it gives implications for practice, for 
future research, and for medical guidelines.
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Prevalence and incidence density rates of chronic comorbidity in type 2 diabetes 
patients: an exploratory cohort study
ABSTRACT
Background 
Evidence-based diabetes guidelines generally neglect comorbidity, which may interfere 
with diabetes management. The prevalence of comorbidity described in patients with 
type 2 diabetes shows a wide range depending on the population selected and the 
comorbid diseases studied. This exploratory study aimed to establish comorbidity rates in 
an unselected primary care population of patients with type 2 diabetes.
Methods 
This was a cohort study of 714 adult patients with newly diagnosed type 2 diabetes within 
the study period (1985-2007) in a practice-based research network in the Netherlands. 
The main outcome measures were prevalence and incidence density rates of chronic 
comorbid diseases and disease clusters. All chronic disease episodes registered in the 
practice-based research network were considered as comorbidities. We categorised 
comorbidity into ‘concordant’ (that is, shared aetiology, risk factors, and management 
plans with diabetes) and ‘discordant’ comorbidity. Prevalence and incidence density were 
assessed for both categories of comorbidity.
Results 
The mean observation period was 17.3 years. At the time of diabetes diagnosis, 84.6% 
of the patients had one or more chronic comorbid disease of ‘any type’, 70.6% had one 
or more discordant comorbid disease, and 48.6% and 27.2% had three or more chronic 
comorbid diseases of ‘any type’ or of ‘discordant only’, respectively. A quarter of those 
without any comorbid disease at the time of their diabetes diagnosis developed at least 
one comorbid disease in the first year afterwards. Cardiovascular diseases (considered 
concordant comorbidity) were the most common, but there were also high rates of 
musculoskeletal and mental health disease. Discordant comorbid diseases outnumbered 
concordant diseases.
Conclusions 
We found high prevalence and incidence density rates for both concordant and 
discordant comorbidity. The latter may interfere with diabetes management, thus future 
research and clinical practice should take discordant comorbidity in patients with type 2 
diabetes into account.
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BACKGROUND
Ageing of the population contributes to the increasing prevalence of diabetes1-4 and 
of multimorbidity, that is, the co-occurrence of multiple diseases within one person.5 
The prevalence of multimorbidity is estimated at 16 to 58% in adults in primary care or 
population-based settings.6-9 Diabetes mellitus (type 2 diabetes) is a chronic disease with 
marked effects on mortality and healthcare expenditure,2 and its prevalence in the USA 
was estimated at 8% in 2010.10 
When referring to a specific disease such as diabetes as an index condition, any co-
occurring conditions are considered comorbidity.5, 11 In primary care, over 40% of patients 
with diabetes also have comorbidity,12 which is as high as 70 to 95% in selected diabetes 
cohorts.13, 14 Diabetes treatment may provide lower benefit to patients with diabetes and 
comorbidity.15, 16 Comorbidity has a negative effect on the quality of life of patients with 
diabetes,17-20 and substantially increases their healthcare utilisation.12, 14 It also negatively 
influences their self-management and emotional well-being.21
The number of studies on comorbidity in type 2 diabetes is limited. Previous studies 
focused mainly on ‘concordant’ comorbidity, that is, conditions that share pathogenesis, 
risk factors, and/or management plans with type 2 diabetes (for instance, hypertension).22 
‘Discordant’ combinations,22 that is, diseases without shared pathogenesis, risk factors, 
or management, remain largely unexplored. Diabetes patients with concordant and 
discordant comorbidity show similarly increased healthcare utilisation.12 Recommendations 
for clinical approaches to comorbidity in general and of discordant combinations in 
particular are rarely provided in evidence-based (diabetes) guidelines.23
Epidemiologic descriptions of both concordant and discordant comorbidity in an 
unselected type 2 diabetes population may increase understanding of the heterogeneity 
of populations with type 2 diabetes, and may encourage consideration of co-existing 
discordant comorbid conditions in current type 2 diabetes management. To date, 
epidemiological research on comorbidity in type 2 diabetes has been limited to 
prevalence estimates from cross-sectional studies only. The frequency and sequence in 
which comorbid diseases occur may have important implications for aetiology, prognosis, 
and management.11 Consequently, it would be useful to assess the prevalence and the 
incidence of comorbid diseases in patients with type 2 diabetes.
The aims of this study were to establish the prevalence and types of an extensive range of 
chronic comorbid diseases in patients with type 2 diabetes at the time of their diabetes 
diagnosis, and to establish the incidence density of new chronic comorbid diseases 
in these patients over time. We limited neither the number nor the types of chronic 
comorbid diseases to be studied in advance.
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METHODS
Design, setting, and patients
We performed a cohort study in a population of 714 patients with newly diagnosed 
type 2 diabetes (patient demographics are shown in Table 1), using morbidity data 
from all patients with newly diagnosed type 2 diabetes from the Continuous Morbidity 
Registration (CMR), a practice-based research network in the Nijmegen region located 
in the eastern part of the Netherlands. In the Netherlands, all patients are listed with a 
general practitioner (GP) and receive professional healthcare through this GP. The CMR 
consists of four general practices, in which the GPs have been recording prospectively all 
episodes of morbidity for all enlisted patients from 1967 onwards, including diagnoses 
made by specialists after referral.24 Diagnoses recorded in the CMR have been shown 
to have high validity.25, 26 In general, longitudinal data collected in research networks 
such as the CMR are representative of primary care.27 The CMR contains each patient’s 
date of birth, gender and socioeconomic status (SES), based on the Dutch Standard 
Classification of Occupations,28 classified as low, moderate, or high.29 For many years, 
the total population in these practices had been relatively stable, at around 12,000 
patients, with approximately 80% being adults. From 1998 onwards, the population 
increased steadily, reaching 14,000 in 2006.30 Data from the CMR are representative for 
distribution of age, sex, and SES in the Netherlands.30, 31
Studies based on CMR data comply with the Code of Conduct for Health Research, which 
has been approved by the Data Protection Authorities for conformity with the applicable 
Dutch privacy legislation. For this study, approval of an external ethics committee was 
not required.
This explorative study period covered the years 1985 to 2007. During this period, the 
CMR’s morbidity classification system was not changed, which enabled us to compare 
identical diagnoses consistently over time. Our study population had a dynamic 
composition, that is, observation period from start to end points varied between patients. 
The observation time for individual patients began with the start of the study period 
(1 January 1985), including for patients who had already been registered in the CMR 
database before 1985, or the date of a patient’s enrolment as a patient in the CMR, 
whichever occurred first. The observation period for patients terminated either at the 
end of our study period (31 December 2006), or with a patient’s death or deregistration 
from the practice, whichever occurred first. We included all adult patients (aged 18 years 
or over) with type 2 diabetes. The diabetes diagnosis had to be made within the study 
period (that is, incident cases) in accordance with universally accepted criteria,32 and was 
verified in the patient’s medical record when the age at the time of diagnosis was less 
than 45 years. Diabetes care in the CMR practices has been shown to achieve outcomes 
comparable with those reported under randomised controlled trial conditions.33
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TABLE 1: Characteristics of the 714 patients included in the study
Variables
Sex, n (%)
 Male
 Female
351 (49.2)
363 (50.8)
SES,1 n (%)
 Low
 Middle
 High
 Missing
362 (50.7)
282 (39.5)
62 (8.7)
8 (1.1)
Age at diabetes diagnosis, years, mean (± SD, range)
 Total
 Males
 Females
63.2 (± 12.8; 21-95)2
61.9 (± 12.8; 21-94)
64.4 (± 12.7; 23-95)
Time after diabetes,3 years, mean (± SD)
 Males
 Females
6.2 (± 4.7)2
5.9 (± 4.5)
6.6 (± 4.9)
Time before diabetes,4 years, mean (± SD) 11.1 (± 6.3)
Time in study population, years, mean (± SD) 17.3 (± 6.0)
Year of diagnosis,5 n (%)
 1985-1989
 1990-1999
 2000-2006 
100 (14.0)
276 (38.7)
338 (47.3)
Reason for follow-up ending, n (%)
 End of study period
 Deceased
 Moved / left practice
462 (64.7)
155 (21.7)
97 (13.6)
1SES, socioeconomic status. 
2Significant difference for males and females (P < 0.05). Non-significant sex differences not shown. 
3Observation time in the study population after diabetes diagnosis. 
4Observation time in the study population before diabetes diagnosis. 
5Year of diagnosis of diabetes, classified into categories corresponding to the latest issues of the Dutch 
College of General Practitioner’s type 2 diabetes guideline. The first, second and third issues were 
published in 1989, 1999, and 2006 respectively. 
 
Comorbidity
We considered all chronic diseases as comorbidities, regardless of whether they occurred 
before or after the patient’s diabetes diagnosis. The CMR distinguishes approximately 500 
diagnostic codes (the ‘E-list codes’). The GPs label each code as a new or ongoing episode 
for a known disease. No generally accepted definition of ‘chronicity’ exists, but frequently 
used criteria for chronicity include duration, pattern with recurrence or deterioration, and 
consequences on a patient’s life measured by various outcomes.34 For the current study, 
we defined chronic conditions as diseases (a) that are persistent (duration of 6 months 
or longer); (b) from which the patient does not recover; and (c) that require healthcare 
attention. Those conditions that did not evidently fulfil all three criteria were presented to 
a panel of eight experienced GPs from the CMR practices, who categorised each condition 
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as chronic, non-chronic or conditionally chronic. We distinguished ‘conditionally chronic’ 
diseases as those that can but do not need to have a chronic course, depending on the 
individual; examples are depression, asthma, and epilepsy. In these cases, the ongoing 
episodes at patient level defined the presence or absence of chronicity for this individual. 
When the expert panel unanimously judged a specific disease as chronic, we considered 
this particular disease as chronic in further analyses. In cases of disagreement between the 
panel members, the disease was labelled as conditionally chronic. In these cases, ongoing 
episodes at the patient level defined individual chronicity. All chronic diseases were 
regarded as cases of comorbidity of type 2 diabetes. The final list contained 67 chronic and 
63 conditionally chronic disorders (see Appendix A).
Finally, comorbid diseases were classified into clusters, in accordance with the following 
chapters of The International Classification of Primary Care (ICPC)-1: cardiovascular, mus-
culoskeletal, mental, eye, ear, urology, male and female genital system, respiratory, skin, 
digestive, endocrine and metabolic, neurologic, blood(-forming organs) and lymphatics, 
and general and unspecified diseases.35 We also distinguished the sub components 
of infectious diseases and neoplasms (malignancies) as separate clusters. Small and 
mutually related clusters were combined into one category (see Appendix B for the 
cluster arrangement).
Using type 2 diabetes as the index disease, we considered all chronic diseases from the 
cardiovascular cluster as concordant and all other diseases as discordant comorbidity.
Statistical analysis
We calculated the prevalence of chronic comorbidity at the date of diabetes diagnosis as 
the number of patients with a specified (cluster of) chronic comorbidity, divided by the 
total number of patients, and expressed it as a proportion, with 95% confidence interval 
(CI). A cluster was present if at least one of the chronic diseases within this cluster had 
been diagnosed in an individual patient. 
We also calculated the incidence density rate of chronic comorbidity for the first year 
before diabetes diagnosis, and for the first year, the first 5 years, and the first 10 years 
after diabetes diagnosis. We divided the number of new cases of (a cluster of) chronic 
comorbid diseases within the specified time period by the number of person-years at risk 
for a diagnosis of that particular comorbidity, and expressed the incidence density rate as 
the number of new cases per 1,000 patient-years at risk (with 95% CI). Patients who had 
already developed the particular comorbid disease before the specified period were no 
longer considered to be at risk, because a chronic disease can be diagnosed only once, 
and persists subsequently. For incident cases of chronic comorbidity, only the time until 
diagnosis of this comorbid disease contributed to the number of patient-years.
To analyse the overall burden of comorbidity in our study population, we counted the 
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total number of comorbid chronic diseases and clusters at the time of diabetes diagnosis, 
and calculated the mean and standard deviation. We also calculated the prevalence and 
the incidence density for having ‘any’ chronic comorbidity and for having three or more 
chronic comorbid diseases or clusters. 
We tested patient characteristics for gender differences with the independent t-test for conti-
nuous variables and the χ2 tests for categorical variables. In all cases, significance was set at 
P ≤ 0.05. SPSS software (version 18.0; SPSS Inc., Chicago, IL, USA) supported the analyses.
RESULTS
Patient characteristics
The mean ± SD age at diabetes diagnosis was 63.2 ± 12.8 years, and the mean 
observation time was 17.3 ± 6.0 years. Generally, patients had a longer period before 
than after diabetes diagnosis within our study period. Patient age showed a normal 
distribution, whereas time before/after diabetes did not, with over-representation of 
extreme values (maximum observation time within study period). Women were generally 
older than men at the time of their diabetes diagnosis and had a longer follow-up, 
but the total observation time did not differ between women and men. Table 1 shows 
the patient characteristics; values are shown by sex only for those characteristics with 
significant sex differences.
Prevalence of chronic comorbidity at time of diabetes diagnosis
We assessed the prevalence of chronic comorbidity at the time of diabetes diagnosis 
(Table 2, Table 3). Only 15.4% of the patients did not have chronic comorbidity. Counting 
discordant diseases only (that is, excluding cardiovascular disease; CVD) showed that 
70.6% (95% CI 67.2-73.9%) had at least one discordant comorbid disease in addition 
to type 2 diabetes.
TABLE 2: Mean ±SD number of (clusters of) chronic comorbid diseases at date of diabetes diagnosis 1,2
Single chronic diseases Clusters of comorbidity3
All Discordant only4 All Discordant only4
Number 2.9 ± 2.4 1.7 ± 1.7 2.1 ± 1.5 1.5 ± 1.3
1This table describes the mean of chronic comorbid diseases present in our total population (n = 714) at 
the date of diagnosis of type 2 diabetes. 
2Data are displayed both for the total count of single comorbid diseases and for the number of clusters 
of chronic comorbid diseases. We also distinguished ‘any type’ of comorbid diseases and ‘discordant 
diseases only’. 
3Clusters: comorbid diseases were classified into clusters, following The International Classification of 
Primary Care (ICPC)-1 chapters.
4Discordant: without shared pathogenesis, risk factors or management. 
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Having three or more chronic comorbid diseases when type 2 diabetes was diagnosed 
was not uncommon: approximately half (48.6%; 95% CI 44.9-52.3) of the population 
had at least one chronic comorbid disease, and approximately a quarter (27.2%; 
95% CI 24.0-30.5) had three or more discordant chronic comorbid diseases. From the 
prevalence data of diseases from different clusters (Table 3), it follows that this was often 
a heterogeneous mix of diseases.
CVDs were the most prevalent comorbid diseases at the time of diabetes diagnosis: 
64.0% (95% CI 60.4-67.5, Table 4). Musculoskeletal and mental health diseases 
were also very common. There was a high prevalence of chronic functional somatic 
symptoms36 and deafness as single diseases. Table 5 shows data on the most common 
chronic comorbid diseases from every cluster.
Prevalent chronic psychosis, obsessive compulsive disorder, phobia, schizophrenia, 
dementia, mental retardation, or Down’s syndrome were combined as a heterogeneous 
group of chronic diseases affecting patients’ mental states, which were found to affect 
3.8% of the total population at time of diabetes diagnosis. 
Chronic comorbidity before diabetes diagnosis
The incidence density rate of any chronic comorbidity (both concordant and discordant) 
in the year before diabetes diagnosis was very high (Table 3). In general, comorbid disease 
clusters with high prevalence rates at diabetes diagnosis also had high incidence density 
rates in the year before diabetes diagnosis (Table 4). For some diseases and clusters, the 
incidence density rate in the year before diabetes was particularly high compared with 
the prevalence rate at this time, and also with the incidence density rate after diabetes 
diagnosis. Examples are CVD (especially myocardial infarction) and male urogenital 
diseases (Table 4, Table 5). 
Chronic comorbidity after diabetes diagnosis 
In the years after diabetes diagnosis, the incidence density rate of chronic comorbidity 
remained high. A quarter of those without any chronic comorbid disease at the time of 
diabetes diagnosis developed at least one comorbid disease in the first subsequent year 
(263.7 new cases per 1,000 patient-years at risk, 95% CI 160.3-367.0, Table 3).
Eye and ear diseases (cataract in particular) had a high incidence density rate after 
diabetes diagnosis as compared with the year before diagnosis, and also compared with 
the prevalence rate at diabetes diagnosis: 46.9 per 1,000 patient-years at risk during the 
first year. Skin diseases and respiratory and endocrine diseases had a lower incidence 
density rate after diabetes diagnosis than before. The incidence density rate of mental 
health diseases was particularly low in the first year after diabetes diagnosis, with no 
new cases of chronic depression the first year after diabetes diagnosis (Table 4, Table 5).
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DISCUSSION
Principal findings
In this study, we established the prevalence and incidence of comorbidity in patients 
with type 2 diabetes. We found that 84.6% of the patients with newly diagnosed type 
2 diabetes in a primary care population had at least one chronic comorbid disease at the 
time of their diagnosis, and both concordant and discordant comorbidity were common. 
Incidence density rates after diabetes diagnosis showed that rates of chronic comorbidity 
further increased after diabetes onset. This study clearly showed the heterogeneity of 
this primary care population with type 2 diabetes in terms of comorbidity.
Relation to other studies
The prevalence of comorbidity in patients with type 2 diabetes in this study was similar 
to14, 37 or higher than12, 13 those of previous studies. The number of comorbid diseases 
considered in a study contributes to any prevalence estimate,7, 38 and our work had 
the largest number. The relatively high prevalence of comorbidity we found is more 
pronounced when one considers that we investigated a primary-care population 
including all adult type 2 diabetes patients, as opposed to studies that included only 
patients over 65 years of age14, 37 or those requiring inpatient diabetes treatment.13 
Patients with discordant comorbidity outnumbered those with concordant comorbidity, 
a finding similar to earlier CMR-based research on comorbidity in patients with heart 
failure as the index disease.39 Diabetes is not necessarily causally related to additional 
diseases, but co-existing chronic diseases may interfere with diabetes management in 
several ways.14-20 These results encourage us to reflect on the general lack of attention to 
(discordant) comorbidity in evidence-based diabetes guidelines.23 
Patients with comorbidity may prioritise one condition over another, and experience 
overwhelming effects of an individual disease.21, 40 A recent study showed that physician-
experienced complexity of patients with diabetes increased with prevalent discordant 
comorbidity, but not with concordant comorbidity, implying that improvement in 
diabetes management could be made merely by focusing on patient-centred rather 
than disease-specific interventions.41 Patient-centred management is exactly what GPs 
prioritise in the management of multimorbidity;42 however, the current tendency is to 
incentivise disease-specific instead of holistic care, thereby counteracting patient-centred 
approaches.43-46 The extent of chronic comorbidity in patients with type 2 diabetes, 
as shown in the current study, urges an approach of complementing disease-specific 
strategies with a personalised, generalist approach for the management of patients with 
multimorbidity.6, 42
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Strengths and limitations of the study
To our knowledge, this study is the first to describe the development of chronic 
comorbidity over time in patients with type 2 diabetes. We were able to identify 
comorbidity diagnosed before diabetes diagnosis. Selection of patients with a diagnosis 
of type 2 diabetes and all comorbidity data were based on the most reliable source, that 
is, physician diagnoses, rather than patient self-report17, 37 or extraction of medication 
prescriptions.47 
Diabetes in this study served as an example of a common chronic disease with stan-
dardised management plans. The objectives of this exploratory study were to establish the 
prevalence rates of a range of chronic comorbid conditions and their development over 
time. Given the nature of the CMR database, comparing comorbidity data in our diabetes 
population with a control group with another index disease, such as osteo arthritis, would 
have been possible. However, this would have distracted from the intended epidemiologic 
description of chronic comorbidity in type 2 diabetes patients. This study did not aim to 
quantify the comorbidity rate in patients with type 2 diabetes compared with patients with 
other chronic diseases, or to compare the rates within specific subgroups of patients with 
type 2 diabetes or at different time periods within the study. Considering the large number 
of comorbid conditions and clusters studied, such comparisons would have resulted in 
numerous statistically significant differences or interactions of uncertain clinical relevance. 
Instead, the current epidemiologic description may lead to more detailed exploration of 
specific conditions or subgroups for future research. 
The particular strengths of the study are that the diabetes population we studied was 
unselected, and that we did not restrict comorbidity only to prevalent or concordant 
chronic diseases. Our data reflect the total burden of chronic comorbidity in patients 
with type 2 diabetes in general. 
Currently, no universally accepted definition of ‘chronic diseases’ is available. Within 
any definition, personalisation of the concept of chronicity to the individual patient 
level is preferred, although often not attained.34, 48 An Australian primary care code set 
applied the same criteria for chronicity as we did.34 However, by adding the distinction of 
conditional chronicity based on physician-assigned ongoing episodes, we were able to 
personalise chronicity in our analyses. For diseases from which patients may recover (for 
example, depression), or for diseases with either episodic or chronic courses (for example, 
asthma, gout), we consider our classification comes closer to the correct description of 
chronicity than would a list with invariable chronic diseases.
Comments on specific comorbid diseases
Concordant comorbidity (that is, CVDs) showed the highest prevalence and incidence 
density rates. Although this cluster contained a large number of diseases, the main 
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explanation for the high rate is the concordance with type 2 diabetes. Care-related 
factors will have added to this finding. For instance, a GP will be more attentive for 
type 2 diabetes in a patient who has had a myocardial infarction. The suggestion that 
presence of a disease enhances attention for other diseases49, 50 might be particularly the 
case for concordant combinations.
For discordant combinations also, care-dependent factors might contribute to the high 
rates of comorbidity. There was an evidently increased incidence of cataract in the 
year after diabetes diagnosis. The reason for this may be that screening for diabetic 
retinopathy resulted in earlier diagnosis of, or otherwise unobserved cataract diagnoses. 
Moreover, people might not raise certain issues until they visit their doctor for other 
health problems; such restraints can contribute to a higher incidence of conditions such 
as incontinence in the first years after diabetes diagnosis. These examples illustrate that 
despite the high rate of comorbidity reported, our results may still be an underestimation, 
as the comorbidity data refer to disease episodes truly experienced by patients and 
presented to their GP.
Musculoskeletal diseases have an antagonistic effect on physical exercise, which is part 
of the recommended treatment for diabetes.11 Around 30% (3/10) patients with type 
2 diabetes had musculoskeletal disease at time of diagnosis, and of those unaffected, 
an additional 32 new cases per 1,000 patient-years at risk followed during the next 
10 years. These are substantial figures, which are higher than chronic musculoskeletal 
diseases in the overall CMR population,30 and these cases are likely to interfere with 
diabetes management.
Diabetes treatment focuses on prevention of complications.51 The presence of a 
malignancy may overshadow the importance of co-existing diabetes, and thus treatment 
priorities may alter. Dutch researchers found that patients with diabetes who had cancer 
received less aggressive cancer treatment than those without diabetes.52
Parallel to the reluctance of GPs to prescribe interventions for depression in patients 
with comorbidity,53 Dutch GPs might be conservative in ‘adding’ a chronic mental health 
disease diagnosis after a diagnosis of diabetes. Including less prevalent diseases in our 
study enabled us to localise a heterogeneous group of patients with chronic comorbidity 
who possibly have difficulties in self-managing their diabetes. One in 25 patients had 
chronic psychosis, obsessive compulsive disorder, phobia, schizophrenia, dementia, 
mental retardation, or Down’s syndrome when diagnosed with diabetes. A ‘standard’ 
approach to diabetes would often not respond to these patients’ abilities or needs.
Conclusions
This study illustrated the complexity of the type 2 diabetes population under GP care, 
in terms of chronic comorbidity. We have shown that the ‘straightforward’ patient with 
CHAPTER 2
34
type 2 diabetes without (discordant) comorbidity is relatively rare. Management of 
diabetes demands management of comorbidity, including discordant diseases. Clinical 
guidelines have an important role in diabetes management, but their external validity 
may be questioned by taking comorbidity into consideration.23, 43, 44 A patient-centred 
approach can be of added value in the management of patients with diabetes with 
chronic comorbidity. 
In conclusion, this study provides new knowledge on the epidemiology of chronic 
comorbidity in type 2 diabetes. We hope it will inform ongoing research in this area, and 
is taken into account in diabetes management.
APPENDICES
Appendix A: Chronic diseases regarded as comorbidity. 
Appendix B: Clusters of chronic comorbidity.
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The effect of comorbidity on glycaemic control and systolic blood pressure in 
type 2 diabetes: a cohort study with 5 year follow-up in primary care
ABSTRACT 
Aims
To explore the longitudinal effect of chronic comorbid diseases on glycaemic control 
(HbA1c) and systolic blood pressure (SBP) in type 2 diabetes patients. 
Methods
In a representative primary care cohort of patients with newly diagnosed type 2 diabetes 
in The Netherlands (n = 610), we tested differences in the five year trend of HbA1c and 
SBP according to comorbidity profiles. In a mixed model analysis technique we corrected 
for relevant covariates. Influence of comorbidity (a chronic disease already present 
when diabetes was diagnosed) was tested as total number of comorbid diseases, and 
as presence of specific disease groups, i.e. cardiovascular, mental, and musculoskeletal 
disease, malignancies, and COPD. In subgroup effect analyses we tested if potential 
differences were modified by age, sex, socioeconomic status, and BMI. 
Results
The number of comorbid diseases significantly influenced the SBP trend, with highest 
values after five years for diabetes patients without comorbidity (P = 0.005). The number 
of diseases did not influence the HbA1c trend (P = 0.075). Comorbid musculoskeletal 
disease resulted in lower HbA1c at the time of diabetes diagnosis, but in higher values 
after five years (P = 0.044). Patients with cardiovascular diseases had sustained elevated 
levels of SBP (P = 0.014). Effect modification by socioeconomic status was observed in 
some comorbidity subgroups.
Conclusions
Presence of comorbidity in type 2 diabetes patients affected the long-term course of 
HbA1c and SBP in this primary care cohort. Numbers and types of comorbidity showed 
differential effects: not the simple sum of diseases, but specific types of comorbid 
disease had a negative influence on long-term diabetes control parameters. The complex 
interactions between comorbidity, diabetes control and effect modifiers require further 
investigation and may help to personalise treatment goals. 
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INTRODUCTION
Important reasons to achieve good diabetes control are to prevent (progression of) 
diabetes-related complications and occurrence of cardiovascular disease.1, 2 However, 
diabetes patients with extensive comorbidity may benefit less from intensive blood glucose 
control, which was associated with reduced 5-year incidence of cardiovascular events in 
an observational study, but not in patients with high comorbidity scores.3 Comorbidity, 
the co-occurrence of other medical conditions in addition to a specific index disease 
such as diabetes,4, 5 is a prevalent phenomenon among diabetes patients.6-10 More than 
70% have at least one chronic non-cardiovascular disease when diabetes is diagnosed.7 
Comorbidity is related to unfavourable outcomes in terms of quality of life and health 
care utilisation.11-14
Knowledge of the impact of patient characteristics such as sex,15 socioeconomic status 
(SES),16 and body mass index (BMI)17 on the prognosis of diabetes helps in making 
individualised diabetes treatment plans, and its importance is increasingly recognised. 
Comorbidity can be regarded as yet another patient characteristic that needs to be 
accounted for when formulating individualised diabetes treatment targets.2, 18 However, 
specific recommendations on how to take these important characteristics into account 
in daily practice are scarce.19 Studies quantifying the effect of comorbidity on diabetes 
control in type 2 diabetes reported inconsistent findings, describing beneficial, negative, 
and no effects of comorbidity on diabetes control.20-24 These studies had several 
limitations: they looked at a small or unclear selection of comorbid diseases only, they 
generally had follow-up periods of six months or less, and looked at study samples that 
were not representative for the overall population of patients with diabetes. These factors 
may contribute to differences in the results found. Particular disease combinations have 
received more interest in the literature, for example diabetes and depression, although 
the direction in their relationship and any association with diabetes outcomes remain 
unclear.25 This stresses the importance to investigate the impact of comorbidity on 
long-term diabetes outcomes in representative samples of diabetes patients, with close 
monitoring of diabetes control and comprehensive recording of comorbidity. More 
knowledge of the types of comorbidity associated with diabetes control in ‘real life daily 
practice’ could help clinicians in further developing diabetes management, in which 
treatment goals better account for individual patients’ comorbidity profiles. 
The aim of this observational study was to explore the long-term longitudinal effects 
of chronic comorbid disease(s) on glycaemic control and systolic blood pressure (SBP) 
in an unselected primary care cohort of patients with type 2 diabetes receiving care as 
usual. Our primary interest was in the effect of patients’ number of comorbid diseases, 
secondary interest in the effect of specific types of comorbid disease. We did not exclude 
any type of chronic comorbid disease to be studied in advance. We distinguished 
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comorbid diseases that are either related or unrelated to diabetes and explored the 
effects in different subgroups.
MATERIALS AND METHODS
Design and study subjects
We used data from a dynamic cohort of diabetes patients registered in the Continuous 
Morbidity Registration (CMR), a general practice registration network in the Nijmegen 
region, the Netherlands. These four CMR practices have been recording all morbidity 
that is presented to the general practitioner (GP) on a daily basis from 1967 onwards.26 
The database reflects the health care system in the Netherlands,27 where patients are 
registered with a general practice and access all healthcare through that practice. GPs 
have an overview of all health problems of their patients. Details on the composition of 
our dynamic diabetes cohort are described elsewhere.7 In short, we included all adult 
patients (≥ 18 years of age) with a new diagnosis of type 2 diabetes within the study’s 
observation period (1 January 1985 to 31 December 2006). The observation time for 
individual patients began with the start of the study period (1 January 1985), also capturing 
the data from patients who had already been registered in a CMR practice before 1985, 
or the date of a patient’s enrolment as a patient in a CMR practice, whichever occurred 
first. The observation period ended either at the end of our study period (31 December 
2006), or with a patient’s death or deregistration from the practice, whichever occurred 
first. The CMR contains each patient’s date of birth, gender and socioeconomic status 
(SES), based on the Dutch Standard Classification of Occupations,28 classified as low, 
moderate, or high.29 
As part of the Nijmegen Monitoring Project (NMP), founded in 1985, the four CMR 
practices have also been participating in the systematic recording of diagnostic and 
monitoring measurements of diabetes and hypertension.30 The NMP database includes 
demographic data, relevant medical history, physical diagnostics (e.g. blood pressure, 
weight, height), and laboratory data (e.g. HbA1c, glucose levels). Monitoring data 
are collected by the GPs and practice nurses during routine diabetes check-up visits 4 
times per year for all diabetes patients under GP care. Since 1992, once a year a more 
extensive control visit includes screening for complications of diabetes and hypertension 
(i.e. retinopathy, nephropathy, and risk of diabetic foot ulceration). The general practices 
involved have shown to provide good quality diabetes care.30 
For the current study we used data from the four practices who provide data to both the 
CMR and the NMP database. The CMR database provided the comorbidity data and the 
NMP database the diabetes control and outcome data for the same patients. Patients 
did not specifically consent for use of their medical data concerning the current study. 
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All GPs gave permission to extract data from the electronic medical records for research 
purposes and informed their patients, who could object to the use of their data. Those 
who opt-out for data extraction for research purposes continue to receive care as usual. 
Data are collected for observational studies and extraction from the medical records 
occurs de-identified. The CMR and NMP registries comply with the Code of Conduct 
for Health Research, which has been approved by the Dutch Data Protection Authorities 
(College Bescherming Persoonsgegevens, CBP) for conformity with the applicable Dutch 
privacy legislation. For this study, approval of an external ethics committee was not 
required.
Outcome measures
We assessed the longitudinal development of the variables of interest: HbA1c (in %; DCCT 
aligned - the current unit during the study period), and SBP (in mmHg). Measurement of 
HbA1c is performed at the annual check-up visits and samples are analysed in certified 
laboratories.31 Practices retained the same laboratories throughout the study period. 
Blood pressure measurement is performed in the general practice at every check-up visit. 
Data collection from the diabetes diagnosis onwards occurred as part of routine care 
throughout patients’ registration with the practice, thus led to longitudinal data to be 
collected at irregular time intervals. In order to include patients with sufficient follow-
up time starting from the diagnosis, we included patients with their first measurement 
performed within the first four months after the diabetes diagnosis, and labelled these 
as baseline measurements. All subsequent measurements were also included. Patients 
with the first measurement more than four months after the diabetes diagnosis were 
excluded from further analyses.
Comorbidity
The CMR enabled us to distinguish an extensive range of comorbid diseases. Details 
on the recording of comorbidity are described elsewhere.7 In short, we considered any 
chronic disease as comorbidity. Only chronic diseases present at the time of the diabetes 
diagnosis (‘at baseline’) were included. We classified comorbid diseases into disease 
clusters, in accordance with The International Classification of Primary Care (ICPC)-
1.32 Consequently, the effect of comorbidity could be analysed for single diseases, for 
patients’ total number of comorbid diseases, and for clusters of diseases. The number of 
comorbid diseases was the main focus of this study. In the analysis of specific types of 
comorbidity we were particularly interested in comorbidity that is expected to interact 
with diabetes management in various ways: diseases that may influence GPs’ and 
patients’ priority setting regarding the healthcare provided, or patients’ opportunities 
to adhere to lifestyle advices, and also diseases with either comparable -or conflicting- 
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management plans. Therefore we distinguished ‘concordant’ comorbidity: diseases with 
similar pathogenesis and disease management plans as diabetes (cardiovascular diseases 
in the current study).7, 33 All other types of comorbidity were regarded as ‘discordant’ 
comorbidity (diseases unrelated to diabetes). For our longitudinal analysis we selected 
comorbid malignancies, cardiovascular, mental, and musculoskeletal diseases as disease 
clusters, and comorbid COPD as a single disease of particular interest. We refer to these 
selected conditions as ‘selected comorbidity’ from here onwards. Appendix C provides 
further details on the classification of disease clusters included in this study. 
Because the CMR database contains longitudinal data we were able to distinguish 
prevalent comorbidity in a particular patient at the date of the diabetes diagnosis, and 
incident comorbidity after the diabetes diagnosis. For the current study we only analysed 
the effect of existing (prevalent) comorbid diseases on diabetes outcomes over time. The 
CMR’s internal quality control and the extensive experience in morbidity recording before 
the start of our observation period ensured optimal consistency in diagnoses throughout 
our cohort.26
This paper describes the main results from a larger research project, studying the effects 
of a number of comorbid diseases on long-term diabetes control parameters. Description 
of the effects of some specific types of comorbidity on diabetes control parameters 
in complex interaction models fell beyond the scope of the current paper and will be 
reported separately.34 
STATISTICAL ANALYSIS
SPSS (version 20.0) and SAS (version 9.02) supported the analyses. We used descriptive 
statistics to provide characteristics of the study population and comorbidity profiles at 
baseline. Differences in outcomes between male and female patients and between 
patients from different socioeconomic classes were compared using Chi-square tests 
and independent t-tests for categorical and continuous variables, respectively.
To address our research question we explored linear trends for both HbA1c and SBP in 
the five years after the diabetes diagnosis for patients with different baseline comorbidity 
profiles. 
First we tested if the number of comorbid diseases at baseline (categorised as 0; 1 or 2; or 
≥ 3) influenced the HbA1c and SBP trend. We applied a random intercept mixed model 
analysis using measurements nested within patients.35 All measurements within the first 
five years after the diabetes diagnosis contributed to this mixed model. With the same 
approach we tested the potential influence of the presence of selected comorbidity. We 
added an interaction term ‘time’ by ‘comorbidity’ (total number, or type of comorbidity) 
to the model to explore differences in the HbA1c and SBP trends according to comorbidity. 
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Separate analyses were performed for different types of selected comorbidity. In these 
comparisons of diabetes patients with different comorbidity profiles, we entered sex, 
age at diabetes diagnosis, SES, and BMI (handled as ‘last observation carried forward’35) 
as potential confounders. Values for age and BMI were handled as continuous variables 
in the mixed model, but we categorised them as ‘low’, ‘intermediate’, and ‘high’ values 
to facilitate (graphical) presentation of the results. The categorisation was based on the 
limits of the first, second (i.e., the median) and third quartile of the distribution of age 
and BMI values of the patients who contributed to the analysis. When exploring the 
effect of selected comorbidity (e.g., malignancy) on the five year HbA1c and SBP trend, 
‘presence of other selected comorbidity’ was also entered as potential confounder. 
Second, we performed subgroup effect analyses, to explore if potential differences 
in the trend of HbA1c and SBP, according to the number of comorbid diseases, were 
modified by sex, age, SES, or BMI. The confounders in the initial analysis were now 
tested for potential effect modification separately by adding an interaction term ‘time’ 
by ‘comorbidity’ by ‘potential effect modifier’ (e.g., ‘sex’) to the model. Non-significant 
terms were removed in a stepwise hierarchical backward elimination procedure.35 In the 
cases where no significant results arose from the subgroup effect analysis, the first model 
(without subgroup effect analysis) defined the results. 
P-values < 0.05 were considered statistically significant. 
Sensitivity analysis
Since our observation period covered a lengthy time frame, we performed a sensitivity 
analysis to test if the calendar period in which patients’ diabetes was diagnosed, influenced 
the findings. Diabetes diagnosis calendar period was categorised, corresponding to the 
prevailing diabetes guidelines (i.e., 1985-1989, 1990-1999, 2000-2006), as published by 
the Dutch College of General Practitioner’s (publication of first, second, and third version 
in 1989, 1999, and 2006 respectively).36 We performed a subgroup analysis including 
this variable ‘calendar period’. 
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RESULTS
Study subjects and baseline characteristics
We identified 714 patients with a new diagnosis of type 2 diabetes within the study 
period (1985-2006). Outcome measurements were available in 684 patients. Of these, 
610 patients had a first measurement of HbA1c and/or SBP within four months from 
diagnosis and were included for longitudinal analysis. Figure 1 shows a flow chart of our 
study population.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
New diagnosis of type 2 diabetes  
in CMR practice  
between 1985-2006: 
n = 714 
HbA1c and SBP unavailable: 
n = 30 
HbA1c and/or SBP available:1 
n = 684 
No ‘baseline measurement’2 
available:  
n = 74 
‘Baseline measurement’ available 
(included for longitudinal analysis): 
n = 610 
FIGURE 1: Flow chart of patient selection from the CMR general practice database
1Patients with the general practitioner responsible for diabetes treatment.
2A patient’s first outcome measurements collected from a diabetes check-up visit within the first 4 months 
since the diabetes diagnosis was labelled as ‘baseline measurement’. 
CMR, Continuous Morbidity Registration.
SBP, systolic blood pressure.
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Mean age at diabetes diagnosis was 63.0 (SD 12.5) years. 48.2% of the patients included 
were males. For some comorbid diseases the baseline prevalence differed between males 
and females and by SES class. Table 1 shows the baseline characteristics for the total 
sample, and by sex and SES separately. For both sexes the mean HbA1c at baseline was 
7.4% (SD 1.7% for males, 2.0% for females). Mean SBP at baseline was 147.4 (SD 19.4) 
for males, 153.8 (SD 20.3) for females. 
Patients without baseline measurements (n = 104, Figure 1) tended to be more often male 
and to have higher SES, higher age, and more comorbid diseases (including more often 
malignancy) at the time of their diabetes diagnosis, compared to those with baseline 
measurements available. None of these differences reached statistical significance.
Influence of comorbidity on the HbA1c and SBP trends
HbA1c at time of diabetes diagnosis tended to be lower when patients had a higher 
number of comorbid diseases at baseline, but the number of comorbid diseases at baseline 
did not significantly influence the longitudinal development of HbA1c (P = 0.075). After 
five years, patients without baseline comorbidity had worst glycaemic control. The 
number of comorbid diseases at baseline significantly influenced the development of 
SBP over time (P = 0.005). Absolute differences in mmHg were small. Patients without 
comorbid disease at baseline showed to have highest SBP after five years.
For the selected comorbidity we observed a different time trend of HbA1c for patients 
with versus without musculoskeletal disease at baseline (P = 0.044). Those with 
musculoskeletal disease started with lower HbA1c values but had higher values after five 
years. Cardiovascular comorbidity significantly affected the longitudinal development of 
SBP (P = 0.014), resulting in higher SBP values from the diabetes diagnosis onwards. No 
statistically significant effects were observed for the other types of selected comorbidity.
Figures 2 and 3 present the direction of effects graphically. The lines represent the 
predicted values for HbA1c or SBP over five years from the mixed models. Corresponding 
P-values indicate the statistical significance of the difference between their slopes. The 
Figure Footnotes provide information about the definition of the ‘reference category’. 
These Figure Footnotes also show which covariates in the models had statistically 
significant associations with the course of diabetes control parameters. High BMI was 
associated with increased HbA1c and SBP values and higher age with increased SBP 
values. In the analysis of the effect of selected comorbidity we corrected for presence of 
other selected comorbidity and found, for instance, that baseline cardiovascular disease 
increased SBP, and comorbid mental disease decreased both HbA1c and SBP. 
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Additional effects on course of HbA1c (Panel A): 
 
Variable Effect on HbA1c (%) P-value 
BMI: low -0.07 0.004* 
BMI: high +0.10 
Age: low +0.07 0.17 
Age: high -0.06 
Sex: female -0.01 0.90 
SES: middle -0.09 0.72 
SES: high -0.03 
 
 
Additional effects on course of SBP (Panel B): 
 
Variable Effect on SBP (mmHg) P-value 
BMI: low -2.4 < 0.001* 
BMI: high +3.3 
Age: low -5.7 < 0.001* 
Age: high +4.5 
Sex: female +1.9 0.13 
SES: middle -1.9 0.27 
SES: high +0.7 
 
 
Additional effects on course of HbA1c (Panel A): 
 
Variable Effect on HbA1c (%) P-value 
BMI: low -0.07 0.004* 
BMI: high +0.10 
Age: low +0.07 0.17 
Age: high -0.06 
Sex: female -0.01 0.90 
SES: middle -0.09 0.72 
SES: high -0.03 
 
 
Additional effects on course of SBP (Panel B): 
 
Variable Effect on SBP (mmHg) P-value 
BMI: low -2.4 < 0.001* 
BMI: high +3.3 
Age: low -5.7 < 0.001* 
Age: high +4.5 
Sex: female +1.9 0.13 
SES: middle -1.9 0.27 
SES: high +0.7 
 
 
FIGURE 2: Effect o  number of comorbid diseases on five year trends of HbA1c (P = 0.075)  
and SBP (P = 0.005*)
The following explanations apply to Figures 2, 3, and 4. 
Comorbid diseases: absence and presence are determined on the date of diabetes diagnosis. 
Age and BMI categories: Based on the distribution of age and BMI values of the patients who contributed 
to the analysis, limits for ‘low’, ‘intermediate’, and ‘high’ values were 54, 64 and 72 years for age, and 
26.0, 28.5 and 31.8 kg/m2 for BMI. 
Graphs for reference categories: We define the (theoretical) combination of specific patient characteristics 
(e.g., sex, age, SES) as ‘reference category’. In the graphic presentation, graph lines represent HbA1c or 
SBP trends for subjects from this ‘reference category’. The additional effects tables below each graph 
contain information needed to construct lines of predicted outcomes, based on the mixed model results, 
for other subjects than the ‘reference category’. It shows the additional effects (to be added to the graphs 
displayed above) for other covariates included in the model. These values are not time dependent and 
apply to any of the comorbidity groups displayed in this Figure. 
Example: Figure 3A shows predicted HbA1c time trends for patients with and without comorbid 
musculoskeletal disease (mixed model results). The reference category for these graph lines includes male 
sex. The additional effects table for Figure 3A shows an additional effect of +0.04 (% HbA1c) for female 
sex. This means 0.04 should be added to the blue line for female patients without musculoskeletal disease 
and 0.04 should be added to the red line for female patients with musculoskeletal disease. The P-value 
of 0.69 shows that this additional effect of sex on HbA1c in this analysis is not statistically significant. 
Number of patients with complete contribution up to and including a specific year (follow-up ≥ x years) 
was as follows: after 0 years: 610, after 1 year: 554, after 2 years: 484, after 3 years: 430, after 4 years: 
379, after 5 years: 342. 
Abbreviations: BMI, Body Mass Index. SBP, systolic blood pressure. SES, socioeconomic status. 
*P-values < 0.05. 
The following explanation is specific for Figure 2. 
Graphs are shown for ‘reference categories’, i.e. male sex, low SES, median age, median BMI. 
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Additional effects on course of HbA1c (Panel A): 
 
Variable Effect on HbA1c (%) P-value 
BMI: low -0.07 < 0.005* 
BMI: high +0.09 
Mental disease  -0.30 0.01*  
Cardiovascular disease -0.10 0.37 
Malignancy -0.07 0.73 
COPD 0.18 0.30 
Sex: female +0.04 0.69 
SES: middle -0.08 0.77 
SES: high -0.06 
Age: low +0.09 0.09 
Age: high -0.07 
 
 
Additional effects on course of SBP (Panel B): 
 
Variable Effect on SBP (mmHg) P-value 
BMI: low -2.3 < 0.001* 
BMI: high +3.1 
Age: low -5.0 < 0.001* 
Age: high +4.0 
Mental disease -3.5 0.02* 
Musculoskeletal disease -0.2 0.84 
Malignancy -4.1 0.10 
COPD -0.3 0.08 
Sex: female +2.0 0.11 
SES: middle -2.4 0.15 
SES: high +0.1 
 
 
Additional effects on course of HbA1c (Panel A): 
 
Variable Effect on HbA1c (%) P-value 
BMI: low -0.07 < 0.005* 
BMI: high +0.09 
Mental disease  -0.30 0.01*  
Cardiovascular disease -0.10 0.37 
Malignancy -0.07 0.73 
COPD 0.18 0.30 
Sex: female +0.04 0.69 
SES: middle -0.08 0.77 
SES: high -0.06 
Age: low +0.09 0.09 
Age: high -0.07 
 
 
Additional effects on course of SBP (Panel B): 
 
Variable Effect on SBP (mmHg) P-value 
BMI: low -2.3 < 0.001* 
BMI: high +3.1 
Age: low -5.0 < 0.001* 
Age: high +4.0 
Mental disease -3.5 0.02* 
Musculoskeletal disease -0.2 0.84 
Malignancy -4.1 0.10 
COPD -0.3 0.08 
Sex: female +2.0 0.11 
SES: middle -2.4 0.15 
SES: high +0.1 
 
 
FIGURE 3: Effect of comorbid musculoskeletal disease on five year HbA1c trend (P = 0.044*) 
and of comorbid cardiovascular disease on five year SBP trend (P = 0.014*)
Please also see the legend from Figure 2. Graphs are shown for ‘reference categories’, i.e. male sex, low 
SES, median age, median BMI, and ‘absence of other comorbidity’. 
 
Subgroup effect analyses 
In the subgroup effect analyses no modification was found for the effect of the number 
of comorbid diseases on the course of HbA1c. The relationship between the number 
of comorbid diseases at baseline and the course of SBP was significantly modified by 
SES (P < 0.001). Since the direction of effects is not readily understood in complex 
interaction models, Figure 4 (Panels A-C) shows the longitudinal development of SBP 
for subgroup differences. In the high SES group, patients without baseline comorbid 
diseases showed a clear decrease of SBP over time, with high baseline values and much 
lower values after five years. The Figure Footnotes provide information about additional 
effects of covariates. Note that non-significant terms were removed from the model in 
the hierarchical backward elimination approach. 
Sensitivity analysis
No statistically significant effect modifications were found for the ‘calendar period’ subgroups 
on the effect of the number of comorbid diseases on HbA1c; or for musculoskeletal disease 
on HbA1c; or for CVD on SBP. We did observe a significant subgroup effect of ‘calendar 
period’ in the analysis of the number of comorbid diseases on longitudinal SBP (P = 0.023).
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Additional effects on course of SBP, all Panels  
  (i.e. contributing significantly to the model): 
 
Variable Effect on SBP (mmHg) P-value 
BMI: low -2.5 < 0.001* 
BMI: high +3.4 
Age: low -5.8 < 0.001* 
Age: high +4.6 
 
FIGURE 4: Subgroup effect analysis: Effect of number of comorbid diseases on five year SBP 
trend: modified by SES (P < 0.001*). 
Please also see the legend from Figure 2. Graphs are shown for median age and median BMI. Other 
variables are specified. 
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DISCUSSION
In this observational study we explored the effects of chronic comorbid diseases on 
the long-term longitudinal development of HbA1c and SBP in newly diagnosed type 
2 diabetes patients in primary care. Our results show that the number of comorbid 
diseases at baseline influenced longitudinal development of SBP, an effect that was 
modified by SES. The effect of comorbidity on the longitudinal development of HbA1c 
was limited, but present in specific types of discordant comorbidity (musculoskeletal 
disease). Concordant cardiovascular comorbidity negatively impacted on the longitudinal 
SBP development. These results indicate that comorbid diseases affect long-term 
diabetes control parameters, with distinct patterns for different numbers and types of 
comorbidity, and modification of some patterns by SES. The specific information on 
the relation between comorbidity and diabetes control parameters provided by this 
explorative study needs replication first, but has the potential to offer new opportunities 
to deliver more personalised diabetes treatment, by taking specific types of comorbidity 
into account that may require different therapeutic approaches. 
Our longitudinal data cover a lengthy study period, which is a major strength of this 
work. By deliberately including patients of all ages and with any type of comorbidity, 
our data are representative for the diabetes population in primary care. The data have 
their origin in an experienced general practice registration network and practices provide 
good quality diabetes care. The diabetes control parameters we used (HbA1c and SBP) 
are relevant when studying long-term diabetes control. Surrogate outcomes such as 
‘intensification of medication treatment’ reflect mainly physicians’ actions, not patients’ 
responsiveness, and do not necessarily result in better diabetes control.22-24 Since we only 
included newly diagnosed diabetes patients, comparison of diabetes control parameters 
over time was meaningful. 
During this study period, diagnosis and treatment of some diseases studied may have 
changed, which could influence our findings – although it is not obvious if this would 
alter our findings in a specific direction, or if this would only be the case for specific types 
of comorbidity. This type of limitation is inherent to analysing longitudinal data with an 
extensive follow-up period. In a sensitivity analysis, only the association between the 
number of comorbid diseases and SBP trend was significantly affected by the calendar 
period of the diabetes diagnosis. Exploration of this association suggested that this 
resulted from altered treatment of diabetes itself throughout our study period – not 
changes in categorising or managing ‘comorbidity’. After all, monthly meetings ensured 
maximum consistency in CMR’s diagnostic labels, which are known for their high 
validity.37, 38 
The extensiveness of our data did not allow for detailed elaboration on complex subgroup 
effect analyses results for various types of comorbid diseases within the current paper. 
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Although we had smaller numbers of repeated measurements available for HbA1c than 
for SBP, in further subgroup effect analyses we observed that comorbid malignancy (the 
smallest group of selected comorbidity) had significant effects on the HbA1c trend of 
diabetes patients, with modification by some effect modifiers (to be reported separately). 
This makes lack of statistical power an unlikely explanation for the limited effects of 
comorbidity on HbA1c development observed in this study. 
Among the 30 patients in our cohort without outcome data, some had not been 
included in the NMP registration due to extensive multimorbidity. These patients should 
be regarded as seriously ill patients with comorbid diabetes, in whom low priority was 
given to the diabetes monitoring. Some other patients without outcome measurements 
had their diagnosis of diabetes assigned towards the end of our study period, allowing 
insufficient time for the first outcome measurement registration to occur in the NMP 
database within the study period. Any potential bias here is probably small, since no 
statistically significant differences in baseline characteristics were observed between 
patients with and without baseline measurements. The higher proportion of diabetes 
diagnoses made at the end of our study period may be caused by increased attention to 
early detection of diabetes and by targeted screening for diabetes in the same period.39 
Due to the extensive length of the study period this did not result in insufficient long-
term follow-up data.
Inclusion of lipids as diabetes control parameter would have provided added value to 
this study. However, after the first recognition of the importance of lipid regulation in 
diabetes,40 the revised version of the Dutch College of General Practitioners diabetes 
guideline in 1999 resulted in increased attention to the role of lipids halfway our study 
period. We decided to look at one glycaemic and one major cardiovascular risk outcome 
measure only - which already resulted in an extensive dataset. 
The longitudinal outcomes are obviously influenced by prescribed medication and non-
pharmacological interventions for the treatment of diabetes and comorbid diseases. 
In this dynamic cohort study, it was not possible to compare pharmacotherapy and 
lifestyle interventions longitudinally between diabetes patients with and without specific 
types of comorbidity. Therefore, we cannot tell if and how potential differences in 
therapeutic regimes may have contributed to the outcomes observed. However, such 
a comparison fell beyond the scope of this observational, explorative study, in which 
we aimed to explore the long-term associations between comorbidity and diabetes 
control parameters in patients receiving care as usual. The presence of comorbidity may 
influence GPs’ perception of benefits and feasibility of therapeutic regimes.41, 42 Specific 
types of prescriptions may be less appropriate or less safe in patients with particular types 
of comorbidity, which may influence the diabetes treatment options for these patient 
groups. Future longitudinal research should pay attention to the role of medication 
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prescriptions in the association between diabetes control parameters and comorbidity. 
Prescription data may be handled as a potential confounder, or even as an outcome 
measure. 
We used a well-documented, comprehensive definition of comorbidity to describe the 
effect of comorbidity on trends of diabetes control parameters in diabetes patients. 
The study design enabled accurate distinction between ‘no’, ‘some’ (one or two) and 
‘many’ (three and more) comorbid diseases. This contrasts with other studies in which 
comorbidity could be either present or absent in a limited selection of diseases, where 
absence of selected comorbidity does not exclude presence of unselected types of 
comorbidity.21-23 We made a clinically important distinction between related (concordant) 
comorbidity and unrelated (discordant) comorbidity.33 The slightly better long-term 
outcomes for SBP and HbA1c for patients with ‘much’ comorbidity (≥ 3 diseases at 
baseline) compared to patients without comorbidity (0 diseases) are new findings that 
need further investigation. Different types of comorbidity appeared to affect diabetes 
outcomes in different ways.
The mixed model analysis technique we used was the most appropriate model to address 
our research question, and enabled us to optimally use the available longitudinal data. 
Absolute values of HbA1c and SBP are difficult to interpret in this study since the mixed 
model reports predicted values for specific (reference) groups. We deliberately formulated 
a broad research question. Our results should be regarded as a starting point for further 
research, hence care must be taken not to ‘over-interpret’ the results before they are 
confirmed in larger cohorts with deeper investigation of prominent associations found.
Little is known about the long-term ‘natural development’ of HbA1c and SBP in type 
2 diabetes patients from the diabetes onset onwards. Best estimations of this ‘natural 
course’ probably come from control groups of large diabetes trials, of which only 
UKPDS43 included newly diagnosed patients, but they excluded patients with ‘serious 
illness’. Our findings, showing different longitudinal outcomes according to the 
absence or presence of (particular types of) comorbidity, add knowledge on the ‘natural 
development’ of diabetes outcomes from diabetes diagnosis onwards, and especially 
how they are influenced by comorbidity and other effect modifiers. In other words, 
it showed that long-term diabetes control parameters in patients without comorbidity 
(typically the patients that are included in RCTs) are not representative for the entire 
diabetes population. Studies that look at the effectiveness of diabetes treatment but 
overlook comorbidity may have seriously limited generalisability of their results.
Detection of type 2 diabetes may occur in an earlier stage of the disease if comorbidity is 
present. The lower baseline values shortly after the diabetes diagnosis among patients with 
musculoskeletal disease (for HbA1c) or with ‘three and more’ comorbid diseases (HbA1c 
and SBP) compared to those without comorbidity suggest existence of such patterns. It 
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may occur for example by more frequently performed laboratory tests including glucose 
levels in patients who already have other chronic diseases. In the group with pre-existing 
musculoskeletal comorbidity, HbA1c increased in subsequent years, resulting in worse 
glycaemic control after five years compared to patients without musculoskeletal disease 
at baseline. Impaired ability for physical exercise seems a plausible explanation for the 
longitudinal differences. Similarly, we assume that the consistent additional effects 
from comorbid mental disease (reduced HbA1c and SBP values) is explained by a higher 
contact frequency of these patients with their GP,44 resulting in additional opportunities 
to diagnose and treat diabetes in an early stage with slightly better outcomes. The nature 
of comorbid cardiovascular disease, concordant with diabetes, probably explains its 
augmenting effect observed for SBP. It should be noted that patients with cardiovascular 
disease might be diagnosed with ‘hypertension’. However, the presence of the diagnostic 
label ‘hypertension’ alone (without presence of other cardiovascular disease, such as 
myocardial infarction or CVA) did not classify as ‘cardiovascular disease’ in the longitudinal 
analysis for the current study, and therefore ‘hypertension’ could be diagnosed also 
among the patients in the group ‘without cardiovascular disease’. Diabetes guidelines 
recommend good SBP control in ‘all’ diabetes patients - independent from presence 
of (cardiovascular or non-cardiovascular) comorbidity.1, 2 In this observational study we 
analysed whether presence of particular numbers or types of comorbidity was associated 
with the attainment of different longitudinal diabetes control parameters in diabetes 
patients receiving care as usual from their GP. From this objective, the impossibility to 
correct for use of antihypertensive medication is of minor importance since, according to 
current guidelines, lowering SBP if values are increased is regarded as equally important 
in all patients. 
A large number of comorbid diseases at baseline (three and more) did not result in a 
less favourable course of HbA1c and SBP, but particular types of comorbidity did. This 
observation - not the simple sum of diseases, but specific types of comorbid disease 
influence the course of diabetes control parameters - emphasises that the diabetes 
care as provided by GPs is part of general healthcare delivered to ‘whole persons’, i.e. 
‘person-centred care’. Apparently, the patient-specific context intervenes, in which GPs 
integrate disease-specific and generic patient characteristics and treatment goals as part 
of diabetes-specific care.
The observed effect modification of the number of comorbid diseases on the course of 
SBP by SES warrants further exploration. Other studies already highlighted SES as an 
important patient characteristic in comorbidity6 and in diabetes research,16 but little has 
been reported on its role as effect modifier as described here. Further subgroup effect 
analysis from our own data showed that SES also modifies the effect of long-term SBP 
control compared between diabetes patients with and without comorbid COPD.34 The 
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explorative design of the current study does not allow us to give possible explanations, 
such as patients’ delay (to visit a doctor) or greater ability for long term risk factor control 
among specific SES groups. 
 
In conclusion, this observational study showed that presence of chronic comorbid diseases 
affected the longitudinal course of HbA1c and SBP in a representative sample of newly 
diagnosed type 2 diabetes patients receiving care as usual. Different numbers and types 
of comorbid diseases showed specific patterns of influence on these outcomes. Further 
investigation of the complex association between diabetes, comorbidity and effect 
modifiers is needed to replicate our findings and to elaborate on the consequences of 
specific levels of diabetes control. Our observations illustrate that future diabetes studies 
should take the presence of comorbidity into account, and suggest that GPs’ diabetes 
care requires a person-centred approach, especially when comorbidity is present.
APPENDICES
Appendix C: Classification of comorbidity. 
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Exploring the impact of chronic obstructive pulmonary disease (COPD) on diabetes 
control in diabetes patients: a prospective observational study in general practice
ABSTRACT
Background 
Little is known about the association between COPD and diabetes control parameters.
Aims 
To explore the association between comorbid COPD and longitudinal glycaemic control 
(HbA1c) and systolic blood pressure (SBP) in a primary care cohort of diabetes patients.
Methods 
This is a prospective cohort study of type 2 diabetes patients in the Netherlands. In 
a mixed model analysis, we tested differences in the 5-year longitudinal development 
of HbA1c and SBP according to COPD comorbidity (present/absent). We corrected for 
relevant covariates. In subgroup effect analyses, we tested whether potential differences 
between diabetes patients with/without COPD were modified by age, sex, socioeconomic 
status (SES) and body mass index (BMI).
Results 
We analysed 610 diabetes patients. A total of 63 patients (10.3%) had comorbid COPD. 
The presence of COPD was not significantly associated with the longitudinal development 
of HbA1c (P = 0.54) or SBP (P = 0.33), but subgroup effect analyses showed significant 
effect modification by SES (P < 0.01) and BMI (P = 0.03) on SBP. Diabetes patients without 
COPD had a flat SBP trend over time, with higher values in patients with a high BMI. For 
diabetes patients with COPD, SBP gradually increased over time in the middle- and high-
SES groups, and it decreased over time in those in the low-SES group.
Conclusions 
The longitudinal development of HbA1c was not significantly associated with comorbid 
COPD in diabetes patients. The course of SBP in diabetes patients with COPD is 
significantly associated with SES (not BMI) in contrast to those without COPD. Comorbid 
COPD was associated with longitudinal diabetes control parameters, but it has complex 
interactions with other patient characteristics. Further research is needed.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is typically diagnosed in middle-aged 
subjects who also have an increased risk for other chronic conditions.1 The presence 
of other diseases in addition to an ‘index disease’ is defined as comorbidity.2 Among 
patients with mild-to-moderate COPD, the main causes of death are comorbid diseases 
such as lung cancer and cardiovascular diseases.3 COPD has a large impact on morbidity 
and mortality.4
Another example of a chronic disease with marked effects on global health and health 
care is type 2 diabetes.4,5 Of all patients with COPD, 9-13% of the patients have 
comorbid diabetes,6–9 and 4-13% of patients with diabetes have comorbid COPD.9–11 
Although these numbers originate from different studies and consequently are not 
directly comparable, they clearly illustrate that the combination of COPD and diabetes is 
a rather common one.
In recent years, knowledge and awareness of the importance of patient-specific factors 
in the treatment of COPD12 and diabetes13 has grown, resulting in an increased tendency 
to individualise disease management. An important characteristic of a patient with a 
specific chronic disease, such as COPD, is the comorbidity that may also be present. 
However, current guidelines for COPD and diabetes have limited applicability for patients 
with comorbid conditions.14 Very little is known on how the presence of a specific 
disease, such as COPD, influences the long-term outcomes of another disease, such 
as diabetes. This type of information is important if health care professionals aim to 
personalise disease management plans for COPD and diabetes patients. In addition, 
other characteristics such as age, sex, body mass index (BMI) and socioeconomic status 
(SES) may have well-known effects on COPD15–17 and on diabetes,18,19 but how they 
interact if both diseases are present in one and the same patient is unknown. Detailed 
data on comorbidity, patient characteristics, and disease control parameters from a 
representative patient population may inform us about the interaction between the two 
diseases and the impact on patients’ prognosis. 
The aim of this explorative, hypothesis-generating paper was to investigate the association 
between COPD as a comorbid condition and longitudinal diabetes control parameters in 
patients with type 2 diabetes in primary care. We also explored the role of sex, age, BMI 
and SES in the relationship between COPD and diabetes control.
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MATERIALS AND METHODS
Design and study subjects
We used available data from a dynamic prospective cohort of diabetes patients registered 
in the Continuous Morbidity Registration (CMR), a general practice registration network 
in the Nijmegen region, the Netherlands. The four practices constituting the CMR have 
been recording all morbidities that are presented to the general practitioners (GPs) on a 
daily basis since 1967.20 The database reflects the health care system in the Netherlands,21 
where patients are registered with a general practice and have access to specialist care 
through that practice. In this system, where GPs receive capitation payment, the nature 
of medical conditions or treatment does not influence the GPs’ performances. Details on 
the composition of our diabetes cohort are described elsewhere.10 In short, we included 
all adult patients with a new diagnosis of type 2 diabetes within the observation period 
of the study (1 January 1985 to 31 December 2006). Time from the start to the end of 
observation varied between patients, beginning with either the start of the study period 
or the date of a patient’s enrolment in a CMR practice. The observation period ended 
either at the end of our study period or with a patient’s death or deregistration from the 
practice.
All four CMR practices also participate in the so-called ‘Nijmegen Monitoring Project’ 
(NMP),22 which was initiated in 1985 to systematically record diagnostic and monitoring 
measurements of patients with diabetes and/or hypertension. The NMP database 
includes demographic data, physical diagnostics (e.g., blood pressure, weight, height) 
and laboratory data (e.g., HbA1c, glucose levels). Monitoring data are collected by the 
GPs and practice nurses during routine 3-monthly diabetes check-up visits for all diabetes 
patients under GP care. The practices involved have been shown to provide good-quality 
diabetes care.22 We linked data from these two databases to study the effects of chronic 
comorbidity (data originating from the CMR) on the course of diabetes control over 
time (data from the NMP). The current paper presents results from the effect of COPD, 
as selected comorbid disease, on longitudinal diabetes control parameters, and effect 
modification by a number of patient characteristics in subgroup effect analyses. This 
analysis is part of a larger project studying the effects of different types of comorbid 
diseases on diabetes control parameters.
The CMR and NMP registries comply with the Code of Conduct for Health Research, 
which has been approved by the Data Protection Authorities for conformity with the 
applicable Dutch privacy legislation. For this study, approval of an ethics committee was 
not required.
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Selection of COPD and other comorbidities
The presence of COPD was identified as a doctor diagnosis recorded in the CMR 
database. The CMR has previously been used to study cohorts of patients with COPD,23,24 
and the diagnoses correlate well with spirometry results.25 Details on the recording of 
comorbidity have been reported in a previous paper.10 We selected comorbid COPD as 
a single disease of particular interest for the analysis of possible associations between 
comorbid conditions and the course of diabetes control parameters, and we were, in 
addition, interested especially in comorbid malignancies and cardiovascular, mental, and 
musculoskeletal diseases.
Study outcomes
HbA1c (in %, the current unit during our study period) and systolic blood pressure (SBP, 
in mmHg) were the primary study outcomes. Measurement of HbA1c is performed at 
the annual check-up visits. Blood pressure measurement is generally performed at every 
check-up visit. To include patients with sufficient follow-up starting from the diagnosis, 
we only included patients with their first measurement performed within the first 4 
months after the diabetes diagnosis and labelled these as ‘baseline measurements’. 
All subsequent measurements were regarded as repeated measurements for individual 
patients and contributed to the longitudinal analysis. We studied the development of 
these outcomes during the 5-year follow-up.
Statistical analysis
SPSS (version 20.0) and SAS (version 9.02) software supported the analysis. Characteristics 
of the study population are provided using descriptive statistics. We compared linear 
trends for both HbA1c and SBP in the 5 years after the diabetes diagnosis between 
patients with and patients without comorbid COPD. We applied a random intercept 
mixed model analysis using measurements nested within patients.26 In this model, the 
presence of existing COPD, i.e., recorded before the diabetes diagnosis, was the variable 
of interest. We added an interaction term ‘time’ by ‘COPD’ (absent/present) to the model 
to explore differences in HbA1c and SBP trends according to the absence or presence 
of COPD. In this comparison between patients with and without COPD, we entered 
sex, age at diabetes diagnosis, SES, BMI (handled as ‘last observation carried forward’26) 
and the presence of other comorbidities (as specified above) as potential confounders. 
Values for age and BMI were handled as continuous variables in the mixed model, but 
we categorised them as ‘low’, ‘intermediate’ and ‘high’ values to facilitate (graphical) 
presentation of the results. The categorisation was based on the limits of the first, 
second (i.e., the median) and third quartiles of the distribution of age and BMI values of 
the patients who contributed to the analysis. 
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Furthermore, we performed subgroup effect analyses to test whether potential differences 
in the HbA1c and SBP trends between diabetes patients with or without comorbid COPD 
were modified by sex, age, SES, or BMI. The confounders in the initial analysis were now 
tested for potential effect modification separately by adding an interaction term ‘time’ 
by ‘COPD’ (absent/present) by ‘potential effect modifier’ to the model. Nonsignificant 
interaction terms were removed in a stepwise backward elimination procedure.26 In these 
subgroup effect analyses, we added the presence of other comorbidities as potential 
confounders (not as potential effect modifiers). In cases in which no significant results 
arose from the subgroup effect analysis, the first model (without subgroup effect analysis) 
defined the results.
Not only comorbid COPD already present at the study start may be associated with 
the longitudinal diabetes outcomes, the same may be the case for incident COPD after 
the patient’s diabetes diagnosis. Therefore, we performed sensitivity analyses excluding 
the patients who did not have COPD at their diabetes diagnosis date but who were 
diagnosed with COPD during the 5-year follow-up. 
A P-value < 0.05 was considered statistically significant.
RESULTS
Study subjects and baseline characteristics
Figure 1 shows a flowchart of our study population. We included 610 patients with 
a mean age of 63 years (SD 12.5, Table 1) for longitudinal analysis. In all, 63 patients 
(10.3%) had comorbid COPD at the date of their diabetes diagnosis, and another 8 
patients were diagnosed with COPD during the 5-year follow-up period. Patients with 
pre-existing COPD were older and had more additional comorbid conditions, apart from 
COPD, compared with patients without COPD (i.e., musculoskeletal disease, 51 vs. 
30%). Note that in the longitudinal analyses we corrected for the presence of selected 
comorbidity.
Influence of comorbid COPD on the course of HbA1c and SBP
After correction for covariates, comorbid COPD was not significantly associated with 
the course of HbA1c (P = 0.54) or SBP (P = 0.33) values over time in the initial analyses. 
Figure 2 shows the time trends for patients with and without comorbid COPD and 
the additional effects of covariates. The Figure Footnotes provide information for the 
definition of the ‘reference category’.
IMPACT OF COPD ON DIABETES CONTROL
4
67
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
New diagnosis of type 2 diabetes  
in CMR practice  
between 1985-2006:  
n = 714 
HbA1c and SBP unavailable: 
n = 30 
HbA1c and/or SBP available:1 
n = 684 
No ‘baseline measurement’2 
available: 
n = 74 
‘Baseline measurement’ available 
(included for  
longitudinal analysis): 
n = 610 
Patients without pre-existent 
comorbid COPD 
n = 547 
Patients with pre-existent 
comorbid COPD: 
n = 63 
Patients with incident comorbid 
COPD during 5 years of follow-up 
n = 8 
FIGURE 1: Flow chart of patient selection from the CMR general practice database
1Patients with the GP responsible for diabetes treatment.
2A patient’s first outcome measurements collected from a diabetes check-up visit within the first 4 months 
since the diabetes diagnosis was labelled as ‘baseline measurement’. 
CMR, Continuous Morbidity Registration; COPD, chronic obstructive pulmonary disease; GP, general 
practitioner; SBP, systolic blood pressure.
CHAPTER 4
68
TA
BL
E 
1:
 B
as
el
in
e 
ch
ar
ac
te
ri
st
ic
s 
of
 p
at
ie
nt
 p
op
ul
at
io
n,
 a
cc
or
di
ng
 t
o 
th
e 
pr
es
en
ce
 / 
ab
se
nc
e 
of
 C
O
PD
To
ta
l i
n
cl
u
d
ed
n
 =
 6
10
C
O
PD
 p
re
se
n
t1
n
 =
 6
3
C
O
PD
 a
b
se
n
t1
n
 =
 5
47
P-
va
lu
e1
Pa
ti
en
t 
ch
ar
ac
te
ri
st
ic
s
Se
x:
 m
al
e,
 n
 (%
)
29
4 
(4
8.
2)
34
 (5
4.
0)
26
0 
(4
7.
5)
0.
33
A
ge
 a
t 
D
M
 d
ia
gn
os
is
, y
ea
rs
; m
ea
n 
(S
D
)
63
.0
 (1
2.
5)
69
.0
 (1
1.
0)
62
.3
 (1
2.
5)
<
 0
.0
01
Fo
llo
w
-u
p 
tim
e,
 y
ea
rs
; m
ea
n 
(S
D
, r
an
ge
)
6.
2 
(4
.6
; 0
.1
-2
1.
9)
4.
1 
(3
.6
; 0
.3
-1
5.
6)
6.
5 
(4
.7
; 0
.1
-2
1.
9)
<
 0
.0
01
M
ea
su
re
m
en
ts
 p
er
 p
at
ie
nt
, t
ot
al
 n
um
be
r, 
 
m
ea
n 
(m
ed
ia
n;
 S
D
; r
an
ge
)
21
.8
 (1
7.
5;
 1
8.
2;
 1
-1
06
)
15
.7
 (1
0;
 1
4.
9;
 1
-8
6)
22
.5
 (1
9;
 1
8.
4;
 1
-1
06
)
0.
00
1
BM
I a
t 
ba
se
lin
e,
2  
m
ea
n 
(S
D
), 
kg
/m
2
29
.8
 (5
.1
)
29
.5
 (5
.2
)
29
.8
 (5
.1
)
0.
57
SE
S,
2  
n 
(%
)
 
Lo
w
 
M
id
dl
e
 
H
ig
h
31
5 
(5
2.
1)
24
2 
(4
0.
0)
48
 (7
.9
)
37
 (5
8.
7)
24
 (3
8.
1)
2 
(3
.2
)
27
8 
(5
1.
3)
21
8 
(4
0.
2)
46
 (8
.5
)
0.
26
Ye
ar
 o
f 
di
ab
et
es
 d
ia
gn
os
is
, n
 (%
)
 
19
85
-1
98
9
 
19
90
-1
99
9
 
20
00
-2
00
6
83
 (1
3.
6)
23
5 
(3
8.
5)
29
2 
(4
7.
9)
3 
(4
.8
)
24
 (3
8.
1)
36
 (5
7.
1)
80
 (1
4.
6)
21
1 
(3
8.
6)
25
6 
(4
6.
8)
0.
07
C
o
m
o
rb
id
it
y 
d
at
a
C
om
or
bi
d 
di
se
as
es
,3
 m
ea
n 
nu
m
be
r 
(S
D
; r
an
ge
)
2.
7 
(2
.3
; 0
-1
1)
4.
0 
(2
.5
; 0
-1
1)
2.
6 
(2
.2
; 0
-1
1)
<
 0
.0
01
C
om
or
bi
d 
di
se
as
es
,3
 (c
at
eg
or
is
ed
), 
n 
(%
)
 
0
 
1 
or
 2
 
3 
an
d 
m
or
e
10
0 
(1
6.
4)
22
7 
(3
7.
2)
28
3 
(4
6.
4)
4 
(6
.3
)
17
 (2
7.
0)
42
 (6
6.
7)
96
 (1
7.
6)
21
0 
(3
8.
4)
24
1 
(4
4.
1)
0.
00
2
C
ar
di
ov
as
cu
la
r 
co
m
or
bi
di
ty
,3
 p
re
se
nt
, n
 (%
)
39
0 
(6
3.
9)
44
 (6
9.
8)
34
6 
(6
3.
3)
0.
30
M
us
cu
lo
sk
el
et
al
 c
om
or
bi
di
ty
,3
 p
re
se
nt
, n
 (%
)
19
7 
(3
2.
3)
32
 (5
0.
8)
16
5 
(3
0.
2)
0.
00
1
M
en
ta
l c
om
or
bi
di
ty
,3
 p
re
se
nt
, n
 (%
)
14
0 
(2
3.
0)
18
 (2
8.
6)
12
2 
(2
2.
3)
0.
26
C
om
or
bi
d 
m
al
ig
na
nc
y,
3  
pr
es
en
t,
 n
 (%
)
42
 (6
.9
)
4 
(6
.3
)
38
 (6
.9
)
0.
86
In
ci
de
nt
 c
om
or
bi
d 
C
O
PD
 a
ft
er
 D
M
 d
ia
gn
os
is
,4
 n
 (%
)
12
 (2
.0
)
N
A
12
 (2
.2
)
N
A
In
ci
de
nt
 C
O
PD
 in
 fi
rs
t 
ye
ar
 a
ft
er
 D
M
 d
ia
gn
os
is
, n
 (%
)
1 
(0
.2
)
N
A
1 
(0
.2
)
N
A
In
ci
de
nt
 C
O
PD
 in
 fi
rs
t 
fiv
e 
ye
ar
s 
af
te
r 
D
M
 d
ia
gn
os
is
, n
 (%
)
8 
(1
.3
)
N
A
8 
(1
.5
)
N
A
IMPACT OF COPD ON DIABETES CONTROL
4
69
C
ha
ra
ct
er
is
tic
s 
of
 p
at
ie
nt
s 
at
 b
as
el
in
e,
 i.
e.
, a
t 
th
e 
da
te
 o
f 
th
e 
di
ab
et
es
 d
ia
gn
os
is
.
A
bb
re
vi
at
io
ns
: B
M
I, 
bo
dy
 m
as
s 
in
de
x;
 D
M
, t
yp
e 
2 
di
ab
et
es
 m
el
lit
us
; N
A
, n
ot
 a
pp
lic
ab
le
; S
ES
, s
oc
io
ec
on
om
ic
 s
ta
tu
s.
1 C
O
PD
 p
re
se
nc
e/
ab
se
nc
e:
 a
ss
es
se
d 
on
 t
he
 d
at
e 
of
 d
ia
be
te
s 
di
ag
no
si
s.
 P
-v
al
ue
s 
di
sp
la
ye
d 
ar
e 
ca
lc
ul
at
ed
 f
or
 t
he
 d
iff
er
en
ce
 b
et
w
ee
n 
th
e 
gr
ou
p 
w
ith
 v
er
su
s 
w
ith
ou
t 
co
m
or
bi
d 
C
O
PD
. 
W
e 
pe
rf
or
m
ed
 C
hi
-s
qu
ar
e 
te
st
s 
fo
r 
co
nt
in
uo
us
 v
ar
ia
bl
es
 a
nd
 i
nd
ep
en
de
nt
 t
-t
es
ts
 f
or
 c
on
tin
uo
us
 v
ar
ia
bl
es
. 
P-
va
lu
es
 <
 0
.0
5 
w
er
e 
co
ns
id
er
ed
 s
ta
tis
tic
al
ly
 s
ig
ni
fic
an
t.
2 N
um
be
r o
f m
ea
su
re
m
en
ts
 a
va
ila
bl
e 
fo
r B
M
I a
t b
as
el
in
e:
 5
76
 (m
is
si
ng
 a
t b
as
el
in
e:
 n
 =
 3
4)
. N
um
be
r o
f m
ea
su
re
m
en
ts
 a
va
ila
bl
e 
fo
r S
ES
 a
t b
as
el
in
e:
 6
05
 (m
is
si
ng
 
at
 b
as
el
in
e:
 n
 =
 5
).
3 P
re
se
nc
e 
of
 a
ny
 ty
pe
 o
f c
om
or
bi
d 
di
se
as
e 
w
as
 a
ss
es
se
d 
at
 th
e 
da
te
 o
f d
ia
be
te
s 
di
ag
no
si
s.
 F
or
 th
e 
di
ab
et
es
 p
at
ie
nt
s 
w
ith
 c
om
or
bi
d 
C
O
PD
 p
re
se
nt
 a
t t
he
 d
ia
be
te
s 
di
ag
no
si
s 
da
te
, w
e 
ex
cl
ud
ed
 C
O
PD
 in
 th
e 
co
un
t o
f t
he
 to
ta
l n
um
be
r o
f c
om
or
bi
d 
di
se
as
es
 to
 m
ak
e 
a 
m
ea
ni
ng
fu
l c
om
pa
ris
on
 w
ith
 th
e 
to
ta
l n
um
be
r o
f c
om
or
bi
d 
di
se
as
es
 in
 p
at
ie
nt
s 
w
ith
ou
t 
C
O
PD
.
4 M
ea
n 
tim
e 
(a
ft
er
 t
he
 d
ia
be
te
s 
di
ag
no
si
s 
da
te
) u
nt
il 
th
e 
da
te
 o
f 
co
m
or
bi
d 
C
O
PD
 d
ia
gn
os
is
, f
or
 in
ci
de
nt
 c
as
es
, i
s 
4.
6 
ye
ar
s.
CHAPTER 4
70
	  
	  
	  
	  
	  
	  
	  
	  
6,5
6,7
6,9
7,1
7,3
7,5
7,7
7,9
0 1 2 3 4 5
Hb
A1
c 
(%
)
Years after diabetes diagnosis
Panel A: 5-year course of HbA1c (P = 0.54)
COPD absent
COPD present
125
130
135
140
145
150
155
160
165
0 1 2 3 4 5
SB
P 
(m
m
Hg
)
Years after diabetes diagnosis
Panel B: 5-year course of SBP (P = 0.33)
COPD absent
COPD present
	  
	  
	  
	  
	  
	  
	  
	  
6,5
6,7
6,9
7,1
7,3
7,5
7,7
7,9
0 1 2 3 4 5
Hb
A1
c 
(%
)
Years after diabetes diagnosis
Panel A: 5-year course of HbA1c (P = 0.54)
COPD absent
COPD present
125
130
135
140
145
150
155
160
165
0 1 2 3 4 5
SB
P 
(m
m
Hg
)
Years after diabetes diagnosis
Panel B: 5-year course of SBP (P = 0.33)
COPD absent
COPD present
Additional effects on course of HbA1c (Panel A): 
Variable Effect on 
HbA1c (%) 
P-value 
Female sex +0.04 0.70 
Middle SES -0.08 0.77 
High SES -0.05 
Low BMI -0.07 <0.01* 
High BMI +0.09 
Young age -0.07 0.08 
Old age +0.07 
Comorbid malignancy present -0.07 0.75 
Comorbid musculoskeletal disease present -0.06 0.59 
Comorbid cardiovascular disease present -0.10 0.37 
Comorbid mental disease present -0.29 0.01* 
 
Additional effects on course of SBP (Panel B):  
Variable Effect on SBP 
(mmHg) 
P-value 
Female sex +2.0 0.11 
Middle SES -2.5 0.14 
High SES -0.02 
Low BMI -2.3 <0.01* 
High BMI +3.2 
Young age -4.0 <0.01* 
Old age +4.0 
Comorbid malignancy present -4.1 0.11 
Comorbid musculoskeletal disease present -0.3 0.83 
Comorbid cardiovascular disease present  +4.3 <0.01* 
Comorbid mental disease present -3.5 0.02* 
 
 
Additional effects on course of HbA1c (Panel A): 
Variable Effect on 
HbA1c (%) 
P-value 
Female sex +0.04 0.70 
Middle SES -0.08 0.77 
High SES -0.05 
Low BMI -0.07 <0.01* 
High BMI +0.09 
Young age -0.07 0.08 
Old age +0.07 
Comorbid malignancy present -0.07 0.75 
Comorbid musculoskeletal disease present -0.06 0.59 
Comorbid cardiovascular disease present -0.10 0.37 
Comorbid mental disease present -0.29 0.01* 
 
Additional effects on course of SBP (Panel B):  
Variable Effect on SBP 
(mmHg) 
P-value 
Female sex +2.0 0.11 
Middle SES -2.5 0.14 
High SES -0.02 
Low BMI -2.3 <0.01* 
High BMI +3.2 
Young age -4.0 <0.01* 
Old age +4.0 
Comorbid malignancy present -4.1 0.11 
Comorbid musculoskeletal disease present -0.3 0.83 
Comorbid cardiovascular disease present  +4.3 <0.01* 
Comorbid mental disease present -3.5 0.02* 
 
 
FIGURE 2: Mixed model results (no subgroup effect analysis)
Longitudinal HbA1c (A) and SBP (B) outcomes of diabetes patients with and without comorbid COPD. 
Comorbid diseases: absence and presence are assessed on the date of diabetes diagnosis. Number (n) 
of cases with completed longitudinal analysis (no missing data on any of the variables included in the 
mixed model throughout): 582. Cases with missing values for BMI: n = 23, cases with missing values for 
SES: n = 5. *P-values < 0.05. Age and BMI categories: based on the distribution of age and BMI values 
of patients contributing to the analyses, limits for ‘low’, ‘intermediate’ and ‘high’ values were 54, 64 and 
72 years for ge, and 26.0, 28.5 and 31.8 kg/m2 for BMI, respectively. Graphs for ‘reference categories’: 
in the graphic presentation, graph lines represent HbA1c or SBP courses for specific patient variables - for 
example, a male patient from the low-SES group with a specific age and BMI. We define the (theoretical) 
combination of the patient characteristics ‘male sex, low SES, median age, median BMI and absence 
of other comorbidity’ as ‘reference category’. The ‘Additional effects table’ below each graph contains 
information needed to construct lines of predicted outcomes, based on the mixed model results, for 
other subjects than the ‘reference category’. It shows the additional effects (to be added to the graphs 
displayed above) for other covariates included in the model. These values are not time dependent and 
not dependent on the absence or presence of COPD. Example: HbA1c courses over time for patients with 
and without comorbid COPD are shown in A. The ‘Additional effects table’ shows an additional effect of 
+0.04 (% HbA1c) for female sex. This means 0.04 should be added to the blue line for female patients 
without COPD and 0.04 should be added to the red line for female patients with COPD. The P-value 
of 0.70 shows that this additional effect of sex on HbA1c in this analysis is not statistically significant. 
BMI, body mass index; COPD, chronic obstructive pulmonary disease; SBP, systolic blood pressure; SES, 
socioeconomic status.
In the subgroup effect analyses, however, we found a statistically significant association 
between comorbid COPD and the course of SBP, with effect modification of SES (P < 
0.01) and BMI (P = 0.03). To express these complex findings in a comprehensible way, 
Figure 3 shows a graphical representation of the direction of effects, with separate 
graphs for combinations of SES and BMI. The Figure shows that in the absence of COPD 
(blue lines), longitudinal SBP values are relatively stable over time, with higher values 
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when BMI is higher (compare Panels A, C, and E). Diabetes patients with comorbid 
COPD (red lines) showed a more variable course of SBP over time, with SES more than 
BMI defining the direction of effects and absolute SBP values. Note that, in the subgroup 
effect analysis, nonsignificant terms were removed from the model; i.e., all variables 
presented contributed significantly to the model predicting the outcome. Age (P < 0.01), 
presence of comorbid mental (P = 0.03) and comorbid cardiovascular disease (P < 0.01) 
had additional effects on the subgroup effect analysis results (not dependent on the 
presence or absence of comorbid COPD, additional effects). Absolute values depended 
on the mix of patient characteristics. No significant effect modification was found from 
any of the defined subgroups on the longitudinal development of HbA1c in the presence 
of comorbid COPD. 
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Additional effects on course of SBP (all Panels): 
 
Variable Effect on SBP (mmHg) P-value 
Young age -4.0 <0.01* 
Old age +4.0 
Comorbid cardiovascular disease present  +4.1 <0.01* 
Comorbid mental disease present -3.2 0.03* 
 
FIGURE 3: Mixed model results for subgroup effect analysis
5-year course of SBP for diabetes patients with and without comorbid COPD, modified by SES (P < 0.01) 
and BMI (P = 0.03). The explanations are the same as Figure 2. Graphs are shown for the ‘reference 
category’ (i.e., male sex, median age, absence of other comorbidity), but SES and BMI vary as specified 
in the figure. BMI, body mass index; COPD, chronic obstructive pulmonary disease; SBP, systolic blood 
pressure; SES, socioeconomic status.
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Sensitivity analysis
After exclusion of cases with incident COPD during the 5-year follow-up period, we did 
not observe a significantly different association between COPD and HbA1c (P = 0.54) 
or SBP (P = 0.34), nor did we observe significant differences in the results from the 
subgroup effect analyses.
DISCUSSION
Main findings
In the current study, we explored the association between comorbid COPD and the 
longitudinal development of HbA1c and SBP in a representative cohort of newly 
diagnosed type 2 diabetes patients in primary care during 5 years of follow-up. The initial 
analyses showed no significant associations between COPD and these outcomes, but 
subgroup effect analysis indicated that, in the presence of COPD, the development of 
SBP was different for patients from different SES and BMI subgroups. This suggests that 
comorbid COPD, in relation with these particular patient characteristics, may influence 
long-term diabetes control parameters. 
STRENGTHS AND LIMITATIONS OF THIS STUDY
In this dynamic cohort study, we used data from robust datasets that originate from 
decades of experience in morbidity recording in a practice-based research network from 
our department20 and good quality of diabetes care.22 We studied relevant diabetes 
control parameters as study outcomes (not ‘treatment intensification’27,28) over a 
follow-up period that was long enough to assess potential associations with comorbid 
COPD. Comparison of outcomes over time between patients was meaningful, as we 
included only newly diagnosed diabetes patients. Another strength is that we studied 
an unselected population with ‘real patients’ receiving regular primary health care, i.e., a 
representative sample of the type 2 diabetes patient population.
It is important to realise that, within our study period, the criteria for the diagnosis of COPD 
and diabetes have changed. The current criteria for diagnosing COPD were introduced in 
Dutch general practice in 2001.29 Towards the end of our observation period, there was a 
higher rate of diabetes diagnoses.30 This implies that COPD and diabetes data from early 
in the observation period may not be fully comparable to similar data at the end of the 
period. This type of limitation is inherent to working with longitudinal data. In general, 
the CMR has shown to record diagnoses with high validity.31
One limitation of this study is that we were unable to account for smoking in the analyses, 
because this has not been consistently recorded in the CMR and NMP databases, nor 
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did we have data available on the severity of COPD (i.e., degree of airflow obstruction, 
exacerbation rate, severity of dyspnoea). From a previous study, we know that the 
majority of COPD patients in the NMP registry have mild or moderate COPD,25 but from 
our current work we cannot tell whether and how the severity of underlying COPD may 
be associated with the course of diabetes outcomes.
Clearly, the development of HbA1c and SBP over time as observed will have been 
influenced by the diabetes treatment as provided by GPs. This treatment may include 
stimulation of physical exercise (which is beneficial not only for the diabetes but also for 
the COPD) and prescription of glucose-lowering medication.32 Medication prescribed for 
COPD (e.g., oral or inhaled corticosteroids) may increase the glucose level and SBP in 
patients with diabetes.33,34 In this dynamic cohort study, it was not possible to compare 
therapeutic regimes between diabetes patients with and without COPD. Differences in 
medication or lifestyle regimes may have contributed to the observed differences.
Twenty-eight cases with missing data for SES or BMI throughout the follow-up period 
(variables included in the linear model) dropped out. Their numbers were relatively low, 
which makes it unlikely that they introduced bias.
The percentage of diabetes patients with comorbid COPD in our cohort corresponds 
with prevalence numbers described in the literature.9–11 Although the absolute number 
of patients with COPD (n = 63) was relatively low, one of the subgroup effect analyses did 
show significant results. In a larger sample of diabetes patients with comorbid COPD, it 
would have been possible that some nonsignificant trends observed would have reached 
statistical significance.
The current paper is one result of a larger project with an explorative design aimed at 
investigating associations between several types of comorbidities on diabetes control 
parameters. These results generate new hypotheses and may guide further research 
elaborating on the early findings. It helps increase the evidence base for the complex 
care to patients with multimorbidity. We believe that the most important strength of 
the current work is precisely this novelty. To the best of our knowledge, this is the first 
study exploring longitudinal associations between COPD and another common chronic 
disease, in this case diabetes. Because the combined occurrence of diabetes and COPD 
is common, assessing possible interactions in terms of long-term outcomes is important. 
Our observation that, in some subgroups, comorbid COPD was associated with altered 
diabetes outcomes warrants further research in this area. Our study may serve as an 
example of how to investigate the complex relationships between two or more chronic 
conditions (i.e., multimorbidity) on patients’ prognoses for the diseases involved.
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Interpretation of findings in relation to previously published work
The unfavourable effect of increasing BMI on systolic blood pressure is not surprising.35 
Our observations indicate that for diabetes patients with comorbid COPD, patient 
characteristics that predict long-term outcomes may be different from those without 
COPD. Our study design had an explorative nature in which we tested several associations; 
hence, care needs to be taken in the interpretation of our findings. We did not find 
significant associations between comorbid COPD and all study outcomes tested. It is 
possible that the significant associations between longitudinal SBP and comorbid COPD 
among diabetes patients may not be replicated in a future study. It cannot be concluded 
from observational research only whether and how our findings should be translated 
into therapeutic consequences. One could reason that, in patients with diabetes and 
comorbid COPD, factors related to a patient’s SES are more important in achieving 
longterm SBP control than just reducing BMI. Our finding that among COPD patients 
the lower SES group had the best long-term SBP control is surprising, but this finding 
would first need to be confirmed in a larger study before we should speculate about 
possible explanations. In our cohort, diabetes patients with comorbid COPD had different 
(comorbidity) characteristics than those without COPD – an important notion for the 
treatment of patients with either or both of these diseases. The observed differences 
may result from disease-specific or from generic factors such as obesity, lifestyle and 
smoking. The need for more research aiming at profoundly investigating the associations 
between COPD, SES and diabetes control parameters is obvious. Previous studies 
described negative associations between low SES and COPD36 and diabetes19 prognosis. 
Studies reporting on the relationship between SES and prevalence of multimorbidity 
in general described negative associations.37–39 We have not been able to trace any 
previously published papers paying attention to the role of SES in relation to the specific 
combination of COPD and diabetes.
After the first recognition of the importance of lipid regulation in diabetes,40 the revised 
version of the Dutch College of General Practitioners diabetes guideline in 1999 resulted 
in increased attention to the role of lipids halfway through our study period. For this 
reason, and as studying one glycaemic and one nonglycaemic control parameter already 
resulted in a large data set with many associations tested, we decided not to include 
lipids as diabetes control parameters. 
Some covariates showed significant additional effects, both on the nonsignificant 
results from the initial models and on the significant subgroup effect analysis results. 
Note that these are independent from time and from the presence/absence of COPD. 
Augmenting effects from increasing BMI and age (on both study outcomes) and from 
comorbid cardiovascular disease (on SBP) can be expected among diabetes patients. We 
assume that the consistent diminishing effect of comorbid mental diseases is related to 
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a higher consultation frequency among these patients,41 offering more opportunities to 
diagnose and manage diabetes (or hypertension) in an early stage, resulting in slightly 
better outcomes.
Pathophysiologic mechanisms that have been suggested to have a role in the relationship 
between respiratory impairment in COPD patients and diabetes include an increased BMI, 
altered respiratory compliance, weakness of the respiratory muscles or neuropathies.7
GPs’ beliefs about the feasibility and benefits of medication regimes may be influenced 
by the presence of comorbidity,42–44 which might result in deliberate flexible medication 
prescriptions in patients with comorbidities. Given these considerations, we believe that 
the absence of an association between comorbid COPD and long-term HbA1c outcomes 
among diabetes patients implies that GPs responsible for treatment provide good-quality 
diabetes care despite the presence of comorbidities such as COPD.
Implications for future research, policy and practice
The current study provides novel observational data in a research area that is still 
underdeveloped, i.e., multimorbidity. It focuses on the impact of COPD as a comorbid 
disease in patients with diabetes. Comorbidity should be regarded as a patient characte-
ristic that may influence relevant outcomes of another disease. Instead of focusing mainly 
on disease-specific outcomes, future research should pay more attention to the effects 
of comorbidity and other patient characteristics such as sociodemographic background.
Moreover, future work may study the effects of (other) incident comorbidity on diabetes 
outcomes in more detail. Further investigations of potential associations between 
diabetes, and other prevalent chronic diseases, with relevant COPD outcomes are desired 
too, as well as other combinations of diseases. 
The majority of practitioners caring for patients with either COPD or diabetes will see 
several patients with these diseases combined, and our findings may help raise awareness 
on the importance of formulating personalised management plans that aim for sensible 
outcomes taking into account both diseases. The current explorations do not yet allow 
for concrete recommendations for daily practice changes – our findings need to be repli-
cated in larger diabetes cohorts.
Knowledge of the impact of comorbidity on disease outcomes is also important to 
support pay-for-performance initiatives that facilitate patient-centred care. Therefore, 
ongoing research in this area should be prioritised by funding bodies and policymakers.
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Conclusions
Comorbid COPD was associated with longitudinal control parameters of newly diagnosed 
type 2 diabetes patients in general practice. This association was observed on SBP (but 
not on HbA1c) and was modified by SES and BMI. Although these results need to be 
verified first, this exploratory study provides new information on the interaction between 
multiple chronic diseases, and may guide further development of personalised care that 
accounts for patients’ comorbidity.
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GPs’ considerations in multimorbidity management: a qualitative study
ABSTRACT
Background
Scientific evidence on how to manage multimorbidity is limited, but GPs have extensive 
practical experience with multimorbidity management.
Aim
To explore GPs’ considerations and main objectives in the management of multimorbidity 
and to explore factors influencing their management of multimorbidity.
Design and setting
Focus group study of Dutch GPs, with heterogeneity in characteristics such as sex, age 
and urbanisation.
Method
The moderator used an interview guide in conducting the interviews. Two researchers 
performed the analysis as an iterative process, based on verbatim transcripts and by 
applying the technique of constant comparative analysis. Data collection proceeded until 
saturation was reached.
Results
Five focus groups were conducted with 25 participating GPs. The main themes 
concerning multimorbidity management were individualisation, applying an integrated 
approach, medical considerations placed in perspective, and sharing decision making 
and responsibility. A personal patient–doctor relationship was considered a major factor 
positively influencing the management of multimorbidity. Mental health problems and 
interacting conditions were regarded as major barriers in this respect and participants 
experienced several practical problems. The concept of patient-centredness overarches 
the participants’ main objectives.
Conclusion
GPs’ main objective in multimorbidity management is applying a patient-centred 
approach. This approach is welcomed since it counteracts some potential pitfalls of 
multimorbidity. Further research should include a similar design in a different setting and 
should aim at developing best practice in multimorbidity management.
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INTRODUCTION
Multimorbidity is described as ‘the presence of multiple chronic conditions’.1, 2 Definitions 
of multimorbidity and the related concept of comorbidity lack uniformity, which hinders 
comparability of results of clinical and epidemiologic studies.3 Any prevalence estimate 
of multimorbidity heavily depends on the number of conditions considered and the 
population under study.4-6 Estimates in adults in general practice or population-based 
settings that are not confined to older age groups vary from 16 to 58%,4, 7-9 with outliers 
up to 90%.10 
With increasing numbers of medical conditions within one patient, hospital admission 
rates and healthcare expenditures raise dramatically.11 Patients with multimorbidity 
account for most consultations in primary care:4 they present more intercurrent morbidity 
in doctor visits than patients with single diseases,12 and GPs deal with the majority of 
these ‘additional’ patient visits.13 
For patients, multimorbidity has negative consequences in terms of quality of life as well 
as mortality.14-16 In recent years, a number of qualitative studies have been published, 
focusing on patients’ views of and experiences with multimorbidity. Specific aspects 
arising from these studies were problems with medication and management,17-20 
interaction of one condition with another,17 difficulty in perceiving and recognising 
symptoms,20 and problems with logistics or organisation of care.21
Studies of healthcare professionals’ experiences and management of multimorbidity 
reported lack of time for appropriate management and organisational and logistical 
challenges, but included small numbers of practitioners.22-24 Decisions on patients 
with multimorbidity demand a focus exceeding the single disease level. This makes it 
relevant to explore in depth the decision-making process among physicians. Managing 
multimorbidity is daily practice for most GPs, even though evidence and guidance is 
limited.1-3, 25 As a consequence, GPs’ experiences might provide useful insights for coping 
with patients with multimorbidity.
This qualitative study explored GPs’ considerations and main aims in the management 
of multimorbidity. The secondary objective was to explore factors influencing this 
management in daily practice.
METHOD
Study design and participants
Focus group interviews with Dutch GPs were carried out. In the Netherlands, all patients 
are enlisted with a GP, who on average deals with more than 95% of presented medical 
problems26 and arranges referral to secondary care when needed. For those who receive 
specialist care, the GP remains involved in their health care.
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Participants were recruited among GPs working within 40 miles of Nijmegen, in the 
eastern part of the Netherlands, through mail and telephone contact. A purposive 
sampling strategy was applied to ensure heterogeneity in characteristics such as age, 
sex, and urbanisation among the participants. Stepwise sampling was performed,27 as in 
qualitative research, sampling, data collection and analysis typically occur in an iterative 
process. Academic involvement was recognised as characteristic, possibly influencing a 
participant’s beliefs concerning the research question and led to sampling of participants 
with and without involvement of research or training in the GP residency programme.
As it was expected that GPs would contribute substantially to the discussion due to 
familiarity with the topic, the number of participants in each focus group was kept 
relatively low (four to six), thereby allowing all GPs to express their ideas. The groups 
were large enough to potentiate discussion and produce new insight. All GPs consented 
to participate and anonymity and confidentiality were ensured. Participants were offered 
a gift voucher and compensation of travel expenses in appreciation of their efforts. 
Interviewing healthcare professionals with respect to professional beliefs does not require 
approval of an ethics committee according to Dutch legislation.
Focus group interviews and data collection
Moderator of the focus groups was a GP-senior researcher with extensive experience 
in qualitative research and in moderating focus groups. An interview guide was used 
to cover items addressing the research question. (Further details are available from the 
author). Its construction was based on discussions in the research team and a test session 
with junior researchers and residents in the university department. Member checking to 
improve validity was performed informally during focus group sessions.28
One researcher observed all groups and made field notes of non-verbal communication. 
The interviews lasted 75–90 minutes.
All group interviews were audiotaped and transcribed verbatim by a medical student. The 
observer checked the transcripts during tape listening and corrected these when necessary.
Analysis
Analysis was performed using the technique of constant comparative analysis.29 Two 
data analysts first familiarised themselves with the data, and subsequently applied open 
coding, hereby conceptualising the data. Codes were tabulated and connected in the 
axial coding phase. Selective coding was used at the highest level of abstraction, in 
which the core variable guided further relevant coding, and the data were sought for 
invalidating examples.
The two analysts discussed the initial coding and consulted a senior researcher in case 
of disagreement. Interpretation of the main theme was discussed in the entire research 
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team. Data collection proceeded until saturation was reached, meaning that no new 
major themes arose from analysis. This was the case after the fifth focus group meeting. 
Analysis processing was supported by Atlas.ti software.
The methods applied were appropriate in light of the philosophical paradigm ‘realism’ 
we feel most aligned with.28 This paradigm fits the authors’ backgrounds as primary care 
physicians and as participants of quantitative as well as qualitative research.
RESULTS
Participants
Five focus group interviews were conducted between September 2010 and March 
2011 with 25 GPs, with a mean age of 50 years. Characteristics of the participants are 
presented in Table 1. Sufficient heterogeneity in their characteristics was reached.
TABLE 1: Characteristics of participating GPs1 
n (%)
Sex
 Male 18 (72)
 Female 7 (28)
Practice type
 Single2 4 (16)
 Duo or group 21 (84)
Urbanisation
 Rural area 2 (8)
 Urbanised rural area 16 (64)
 Urban area 7 (28)
GP trainer3
 At present 11 (44)
 In the past 1 (4)
 Never 13 (52)
Researcher
 Yes 5 (20)
 No 20 (80) 
Mean age, years (range) 50 (31-63)
Mean experience as GP, years (range) 20 (2-36)
1Sex, age, practice type and urbanisation were similarly distributed among participants in our sample as 
compared to the Dutch professional group of GPs.26
2Count of GPs settled solitary in a practice, i.e. without employment of, or professional collaboration 
with other GPs. 
3Trainer at the Nijmegen residency training programme, a qualification needed to supervise a GP trainee.
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Overview of results
The main themes in the management of multimorbidity were individualisation, applying an 
integrated approach, medical considerations placed in perspective, and sharing decision 
making and responsibility. A personal patient-doctor relationship was considered a major 
facilitator in the management of multimorbidity. Presence of mental health problems 
was regarded as complicating factor. Participants also experienced difficulties resulting 
from conditions interacting with each other and several practical problems. Overarching 
concept of the main findings is patient-centredness. 
Group discussions were focused on older and disabled people. The results are classified 
in two sections, ‘management of multimorbidity’ and ‘influencing factors’, and discussed 
in more detail below.
Management of multimorbidity
Individualisation
This theme was discussed at length in each focus group and reappeared in discussions 
on other themes. GPs agreed on the need to adapt management of multimorbidity 
to personal circumstances of these patients, such as vitality, personal preferences (for 
example retaining independence as the ultimate goal) and socioeconomic conditions. 
They stressed the importance of tailoring care to the individual and tried to understand 
the meaning of illness for a person:
‘There are people that take lots of risks in their lives and there are people that are 
very careful. I think that tendency carries over in medical decision-making.’ (GP7, 
male, 56 years)
‘From a medical perspective, I’d say don’t bother, eh, with hemiparesis and, uh, 
but he wanted to, and I know why. It’s because his wife has dementia and he’s her 
[caregiver].’ (GP19, female, 52 years, talking about resuscitation)
Integrated approach
GPs often stated that adhering to standard regimens or strict guidelines was unwanted, 
as it contradicts their integrated perception of a unique person with a specific 
combination of diseases. Particularly in multimorbidity, fragmentation of care is a pitfall. 
GPs perceived a disease-centred approach as insufficient, because multiple conditions 
and corresponding advices need integration and coordination. Many perceived a 
coordinating role appropriate for GPs:
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‘[Patients have] the sense that they’re a collection of organs and, uh, there’s 
someone that does some work on one part and someone else that does work on 
another part, and the whole, yeah, that’s your job as a GP, to keep an eye on the 
whole of the parts.’ (GP1, female, 36 years)
‘Precisely when there is multimorbidity, we as GPs have a role of increasing 
importance. So I think we all need to take responsibility here, and should not have 
the specialist responsible. […] I am the one who draws up the balance, because in 
the hospital, there is no generalist.’ (GP7, male, 56 years)
Participants brought up the need for a generalist approach in multimorbidity and 
explained how they attempted to achieve this. The total burden of diseases and other 
relevant problems were taken into account when patients present single diseases:
‘You can’t just quickly check for diabetes. That’s a useless endeavor as far as I’m 
concerned, because, in the meantime, there’s the gout and the arthritis and this 
and that. And you need to take that into account as well.’ (GP13, male, 45 years)
Medical considerations placed in perspective
It was noted that, in patients with multimorbidity, other considerations can become 
complementary or even superior to medical motives, although, unsurprisingly, 
multimorbidity management is primarily based on medical motives. Patients’ quality 
of life was the main focus of GPs’ professional performance. However, converting this 
aim into appropriate medical practice was a struggle for many GPs. They incorporated 
patients’ life-expectancy and age in medical decisions. Many GPs shifted their focus 
towards present comfort if prognosis was limited. In such cases, most GPs chose 
symptom relief over causal treatment:
‘When you are dealing with multiple conditions […] there’s increasingly more 
disability as the end of one’s life nears, so to speak. You then approach things 
differently, eh. All the medical stuff becomes relative. And reaching targets becomes 
less important and checking stats, and crossing the Ts and dotting the Is […] becomes 
less important.’ (GP13, male, 45 years)
In all groups, the search for a balance between the patient’s ‘disease’ and ‘illness’ was 
expressed in different wordings: 
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‘That’s difficult. See, it’s always a matter of finding a balance between what the 
patient wants, the burden of the treatment for him, and the potential good you 
think it will do. And what does the patient experience as good?’ (GP24, male, 56 
years)
Sharing decision making and responsibility
GPs agreed that they want to involve their patients’ perspectives and preferences into the 
decision-making process. Exploring and mutually explaining ideally resulted in ‘shared 
decision making’:
‘I don’t want anything, he said […] and, even then, you need to explain exactly what 
it is he’s opting for and then you can, in my opinion, even with very elderly people, 
you can jointly decide on things.’ (GP7, male, 56 years)
Involvement of patients and other caregivers implied that not only decisions, but also 
responsibilities, are shared. In general, GPs expressed a broad sense of responsibility:
‘Well, I think it pretty much means that I provide care to that patient and that I get 
an update every year and half on how his organs are doing. But I feel responsible 
for him.’ (GP7, male, 56 years)
‘I do indeed think that it’s simply our job to, uh, try to keep tabs on things - maintain 
an overview - and provide information and then check things, and to let the patient 
think with you, that is, if you think that’s realistic.’ (GP5, female, 33 years)
Most GPs agreed that shared responsibility implies that different viewpoints of doctor 
and patient should be anticipated:
‘You see, if someone repeatedly says, sure, nice idea doctor, and I know what it all 
means but it’s not for me, then, then I will, in time, support that patient’s choice.’ 
(GP14, male, 63 years)
They expressed variation in the responsibilities allocated to themselves when care 
provision to patients with multimorbidity was shared with medical specialists. GPs who 
felt comfortable with disease-management to be primarily arranged by specialists for 
‘independent’ patients, tended to act more as coordinator when a patient was more 
‘care dependent’.
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Influencing factors
Personal relationship
Over time, Dutch GPs build a longstanding, rather personal relationship with most 
patients, certainly in the case of multimorbidity:
‘But the fact that you’ve known the patient for a long time by then obviously makes 
a difference.’ (GP12, female, 58 years)
This was considered to facilitate multimorbidity management, with continuity of care as 
an elementary component. Apart from explicit comments GPs made on its importance, 
the personal relationship between GP and patient could be noticed implicitly from 
comments on personal events of patients:
‘I think that you need to gain the trust of the patient, and that trust can be gained, 
I think, by showing interest, eh, by talking with them about the social context.’ 
(GP14, male, 63 years)
‘We see how they interact with their children. We see how they interact with their 
neighbours. We sometimes have a much, uh, broader view.’ (GP2, male, 60 years)
‘Yeah, but this is my bicycle repairman […] It’s Harry!’ (GP5, female, 33 years)
Mental health problems
Most participants mentioned that a co-existing psychiatric disorder substantially 
complicated their management of chronic somatic illnesses. Diagnostics are hindered 
(‘overshadowed’) because these patients show a different symptom presentation. 
Moreover, GPs regarded patients with medically unexplained symptoms as another 
difficult group in the case of multimorbidity. Although precisely the presence of 
multimorbidity raised appreciation, patients suffering from anxiety about having various 
diseases seemed to be considered as more bothersome by some GPs. Furthermore, 
cognitive impairment of patients with multimorbidity heavily impedes the management 
as it results in limited feasibility of adherence to treatment regimens:
‘They come back another time with somatisation …-like complaints. And then I 
start to find it awfully complicated.’ (GP2, male, 60 years)
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‘You have [older people] who have 10 different health complaints, but they sit 
down and it’s clear they have one new problem — this and that is wrong with me. 
But chronically depressed patients, they come in and they tell you that but they also 
tell you about 10 other complaints, this is bothering me and could you just take a 
look at this […] That always makes it more difficult to consider new explanations 
for the complaints.’ (GP24,male, 56 years)
Interacting conditions
Interaction of several conditions when patients have multimorbidity resulted in difficulties 
in diagnostics as well as in therapeutics. Assignment to which condition specific symptoms 
should be attributed to could be difficult:
‘Often their complaints cannot easily be traced back to one single con dition.’ (GP6, 
female, 31 years)
‘What does this fit with? Which condition? […] He had intestinal ischemia of the 
mesenteric artery, and then he had abdominal pain so he came back with abdominal 
complaints, but he also has IBS [irritable bowel syndrome].’ (GP23, male, 51 years)
Some GPs described that an explanation is sought within known conditions and the 
option of an additional disease is easily overlooked. At a therapeutic level, multiple 
conditions might demand conflicting approaches, such as steroid administration to 
patients with diabetes:
‘I have someone […] whereby it’s clear that what helps one complaint harms 
another.’ (GP5, female, 33 years)
Another problem could be appropriate problem registration in the patient’s medical record.
Practical problems
GPs experienced several practical aspects as impeding multimorbidity management. In 
general, they felt there was insufficient time and compensation for consistently putting 
into practice their main objectives. Polypharmacy, considered a distinct issue associated 
with multimorbidity, was experienced by most as potentially harmful yet hard to reduce. 
Moreover, coordination and overview on medication were hard to maintain. Importance 
of the GP being well informed on a patient’s current medication was stressed:
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‘To me, it’s often difficult to ehh, maintain an overview. These patients see quite a 
number of different specialists, and to me it seems that one specialist still doesn’t 
know what the other ones are doing.’ (GP23, male, 51 years)
DISCUSSION
Summary
This study explored GPs’ considerations and main aims in managing multimorbidity. 
These were individualisation, applying an integrated approach, medical considerations 
placed in perspective, and sharing decision making and responsibility. A personal patient–
doctor relationship was considered beneficial. Major impediments in multimorbidity 
management, besides some practical problems, were mental health problems and 
interacting conditions. The main considerations of GPs perfectly fit in the concept of 
patient-centredness. The GPs in this study considered this as most important when 
managing patients with multimorbidity.
Strengths and limitations
The study sample has a high percentage of academically-engaged GPs but there were 
no important differences in opinions with GPs without academic involvement. Although 
qualitative research does not allow for generalisations, this sample’s resemblance to the 
Dutch GPs’ professional group improves the transferability of the study’s findings.26, 27
With this qualitative approach GPs’ considerations and main aims in multimorbidity 
management were explored. Conclusions cannot be drawn regarding actual behaviour; 
however, assessment of behaviour fell outside the scope of this study.
Rigorous qualitative methods were applied. A focus group study was considered to 
be an appropriate qualitative approach, since opposing perspectives could lead to a 
deeper exploration of GPs’ attitudes and experiences.30 Data collection continued until 
saturation was reached, as prescribed in qualitative methodology. 
Focus groups were conducted in the Dutch language. Illustration of representative 
quotations needed translation, which may have caused loss of some refining. This effect 
was reduced as much as possible as the translation was performed by a native English 
speaker who works as a healthcare scientist. 
To the authors’ knowledge, this is the first qualitative research paper focusing on 
multimorbidity from the perspective of primary care physicians specifically. An important 
and new finding was their strong emphasis on patient-centredness. In the authors’ 
opinion, this novelty is the major strength of this study. 
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Comparison with existing literature
Several conceptual models of patient-centredness in primary care exist.31, 32 Common 
factors in these models are ‘regarding the patient as whole person’, ‘attention to both 
disease and illness’, ‘sharing power and responsibility’ and a ‘personal doctor-patient 
relationship’.33 This last factor came up as facilitator to multimorbidity management in 
the current study. The considerations ‘individualisation’ and ‘integrated approach’ can 
jointly be regarded as matching ‘regarding the patient as whole person’, since they 
emphasise to apply a holistic, personalised approach. ‘Medical considerations placed in 
perspective’ corresponds with ‘attention to both disease and illness’ because both stress 
that the biomedical model needs to be complemented with the patient’s perspective. 
‘Sharing decision making and responsibility’ matches ‘sharing power and responsibility’.
This study’s findings can serve as examples showing that the participating Dutch GPs 
considered a patient-centred approach most important in their care for patients with 
multimorbidity.
The main barriers identified in multimorbidity management were associated with 
the complexity of diagnosis (interaction, mental health problems) and treatment 
(polypharmacy and interaction). From the viewpoint of patient-centredness, these 
can be perceived as compromising the achievement of shared decision making and 
the application of an integrated approach. It is possible that achieving ‘integration’ is 
more challenging as the number of dimensions that need to be integrated (such as, 
biomedical, psychological, and socioeconomic), increases. Ideally, clinicians display 
patient-centredness persistently, but the need to rely on it may grow with increasing 
complexity, for instance in multimorbidity. This idea is supported by the finding that 
professionals’ management of multimorbidity in heavily deprived areas has an even 
stronger emphasis on the ‘whole person’, seeming to overrule biomedical considerations 
completely.34 Other work showed that realising concurrent effective management 
of somatic and mental conditions is hard.35 Kendrick et al. have shown that patients 
with depressive symptoms with comorbidity were less likely to receive prescriptions or 
referral than those without comorbidity, accentuating the complex relationship between 
coexisting somatic and mental illness.36
Multimorbidity comes along with potential pitfalls, such as opposing treatment strategies 
and fragmentation of care, stimulated by disease-centred reimbursement systems, 
and it challenges our capacities for organisation of care including recording of clinical 
information; therefore patient-centredness is warranted.1, 37-43 Patient-centredness can be 
regarded as ‘tool’ to counteract multimorbidity’s potential pitfalls. It could be perceived 
as intuitively appropriate and thus a common sense result. However, it is an important 
finding that has not arisen from earlier studies. GPs, supported by a personal relationship 
with the patient, are the healthcare professionals with an excellent background to put 
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patient-centredness into practice. They have broad generalist knowledge, enabling them 
to balance patient level consequences from several conditions. Interaction of multiple 
diseases and medications demands integrated care with someone watching over it being 
coordinated. Who else than the familiar and accessible GP should be more suited to 
play this role? It would demand the flexibility to focus on general and patient level 
formulated outcomes, instead of disease-specific outcomes. Awareness can be raised 
and skills improved by paying attention to multimorbidity in training to both pre- and 
postgraduates. 
This study sampled only GPs while previous studies also included nurses and 
pharmacists.22-24 As a consequence, the current study allowed an in-depth focus on GPs’ 
considerations in multimorbidity management. Originating from a specific professional 
perspective and educational background, doctors, nurses and other professionals 
might well display different considerations and objectives in their care for patients 
with multimorbidity. This reasoning is supported by different accents displayed in 
GPs’ and practice nurses’ visions on multimorbidity.34 An in-depth identification of the 
considerations and perceived barriers and facilitators from specific professional groups 
separately could be considered a first step towards optimal integration of each group’s 
specific knowledge and skills. 
Earlier qualitative work identified expressions of uncertainty by professionals about 
their ability to manage the complexities following from multimorbidity.23 Although this 
study located certain similar remarks, it also identified opinions stressing that GPs are 
appropriate professionals to deal with multimorbidity due to their generalist approach, 
and should be considered as experts in this regard.
Perceived barriers to multimorbidity management in this study, contrasting with the 
earlier studies, were not confined for the greater part to practical consequences such as 
workload or inconvenience, but extended to the more conceptual level of multimorbidity 
and included diagnostic and therapeutic complexities.22–24 Some of these differences with 
other studies may be related to differences in the sample of healthcare professionals, or 
to differences in the extensiveness of the qualitative approach. Furthermore, it might be 
the case that the UK, with the Quality and Outcomes Framework, as well as the US have 
a stronger emphasis on adherence to disease-oriented guidelines than the Netherlands. 
Doctors may perceive fewer options to display or prioritise patient-centredness as this 
tendency increases. It urges us to assess which treatment strategies are effective and 
efficient for patients with multimorbidity specifically.
Implications for future research
The current findings show that GPs’ main objective in multimorbidity management is 
patient-centredness. Since such an approach seems appropriate, but has not arisen 
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earlier, it should be investigated whether a similar study design in a different setting 
would result in similar findings. It is not yet known to what extent these findings are 
related to specific primary care professions, such as GPs, or the (Dutch) primary care 
context. Furthermore, investigating professionals’ actual behaviour in multimorbidity 
management is among the main points of action to be employed in the nearby future. 
The current findings can serve as a starting point in this respect.
It is time to evolve expertise and develop best practice in multimorbidity management. 
Generalists in primary care are perfectly suited to start such a movement. 
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How GPs value guidelines applied to patients with multimorbidity – a qualitative study
ABSTRACT
Aims
To explore and describe the value GPs attribute to medical guidelines when applied 
to patients with multimorbidity, and to describe which benefits GPs experience from 
guideline adherence in these patients. Also we aimed to identify limitations from 
guideline adherence in patients with multimorbidity, as perceived by GPs, and to describe 
their empirical solutions to manage these obstacles. 
Design
Focus group study with purposive sampling of participants. Focus groups were guided 
by an experienced moderator, who used an interview guide. Interviews were transcribed 
verbatim. Data analysis was performed by two researchers using the constant comparison 
analysis technique and field notes were used in the analysis. Data collection proceeded 
until saturation was reached. 
Participants
Dutch GPs, heterogeneous in age, sex and academic involvement.
Results 
25 GPs participated in five focus groups. GPs valued the guidance that guidelines provide, 
but experienced shortcomings when applied to patients with multimorbidity. Taking these 
patients’ personal circumstances into account was regarded as important, but impeded 
by a consistent focus on guideline adherence. Preventative measures were considered 
less appropriate in (elderly) patients with multimorbidity. Moreover, the applicability of 
guidelines for patients with multimorbidity was questioned. GPs’ extensive practical 
experience with managing multimorbidity resulted in several empirical solutions, for 
example using their ‘common sense’ to respond to the perceived shortcomings. 
Conclusions
GPs applying guidelines for patients with multimorbidity integrate patient-specific 
factors in their medical decisions, aiming for patient-centred solutions. Such integration 
of clinical experience and best evidence is required to practice evidence-based medicine. 
More flexibility in pay-for-performance systems is needed to validate this integration. 
Several improvements in guideline reporting are necessary to enhance guidelines’ 
applicability to patients with multimorbidity.
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INTRODUCTION
Multimorbidity, the existence of multiple chronic conditions within a particular patient,1 
is very common.2-5 It has a substantial impact on health care utilisation and costs5-7 and 
on patient outcomes,7, 8 putting great demands on global health care. Care for patients 
with multimorbidity is complex, requiring coordinated care, management of chronic 
diseases and medication, which may be challenging for practitioners having only short 
consultations available.9 
Evidence-based medicine and guidelines have improved the quality of healthcare 
through better diagnostic and therapeutic treatment decisions. But their application can 
be problematic when a patient has more than one disease, as guidelines are generally 
written for single diseases, with limited suitability for multimorbidity.10-12 A focus on single 
disease guidelines brings the risk of ‘siloing of care’ for patients with multimorbidity.13, 14 
NICE is preparing a guideline on the clinical assessment and management of multi-
morbidity.15 The wide spectrum of multimorbidity is a practical limitation to develop 
guidelines for disease combinations. However, guidance in how to combine or prioritise 
guideline recommendations or when to stop recommended treatments could improve 
the care for patients with multimorbidity, but is missing in current guidelines.14, 16, 17
Given the high prevalence of multimorbidity, all clinicians may struggle with guideline 
application in patients with multimorbidity. Generalists however, who provide care to 
patients with any disease type without prioritising one disease over another beforehand, 
may specifically have well-formulated ideas on this issue. It is to be expected that GPs 
would have extensive experience in managing multimorbidity despite a gap in evidence-
based guidance, and have developed practical solutions to deal with this gap. Many papers 
investigating practitioners’ experiences with multimorbidity management however had a 
focus on the challenges they faced in the care for patients with multimorbidity, and not 
on their experiences with or solutions for handling guidelines in these patients.18 
In the Netherlands, the Dutch College of General Practitioners (DCGP; Nederlands 
Huisartsen Genootschap (NHG)) has produced evidence-based guidelines covering 
70-80% of the conditions presented in primary care. GPs play a leading role in the 
development and critical appraisal of these guidelines, of which 92 are currently available, 
and of which approximately one third concerns (potentially) chronic conditions.19 DCGP 
guidelines cover diseases, complaints, and risk factors, and are established in a team 
composed of GPs, both with and without specific expertise concerning the topic, and 
representatives of other professional groups. Dutch GPs receive capitation payment, 
and with a limited additional payment for the management of chronic diseases such as 
diabetes and COPD when quality indicators are met. The Dutch College of GPs’ guidelines 
are a main source of reference of diagnostic and therapeutic quality indicators. 
Our objective was to explore and describe the value GPs attribute to medical guidelines 
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when applied to patients with multimorbidity, and to describe which benefits GPs 
experience from guideline adherence in these patients. Also we aimed to identify 
limitations from guideline adherence in patients with multimorbidity, as perceived by 
GPs, and to describe their empirical solutions to manage these obstacles. 
METHOD
Study design and participants
As part of a larger research project on multimorbidity, focus group interviews with GPs 
have been held to explore GPs’ aims and priority setting in the care they deliver to 
patients with multimorbidity, and the factors that facilitate and impede this. 
We found that their main aim was to apply a patient-centred approach.20 It was anticipated 
that the role of guidelines as potential facilitator or barrier of the care delivery to patients 
with multimorbidity might be mentioned. In the iterative qualitative process, in which 
data collection and analysis alternate, the insight grew that discussions on the role of 
guidelines, applied to patients with multimorbidity, provided important information 
meriting deeper exploration on itself. This resulted in formulating the current, additional 
research question: exploring the value GPs attribute to guidelines for multimorbidity. This 
topic came up spontaneously in the first focus groups and it was probed in the following 
group interviews if it did not arise spontaneously again. The original interview guide 
was not altered. When the role of guidelines had not yet been discussed spontaneously 
after discussing which factors were perceived as impeding factors in the management 
of multimorbidity, participants were asked if they perceived guidelines as an impeding, 
or as a facilitating factor in this respect. A separate qualitative analysis was performed 
on the same qualitative data considering the current research question. In a purposive 
sampling strategy, GPs from the academic network of the Radboud university medical 
center and from the personal network of the research team members were invited to 
participate, ‘to gain more insight into GPs’ experiences with the care for patients with 
multimorbidity’. They were contacted by mail and telephone. The location of their 
practices covered a 40 miles area around the city Nijmegen, in the eastern part of the 
Netherlands. Heterogeneity in characteristics such as age, sex, academic involvement 
and urbanisation was ensured. After having conducted four focus groups, in all of which 
at least one GP with an academic affiliation (GP trainer or researcher) participated, 
we decided to organise a fifth focus group with only non-academic GPs, since we 
anticipated that an academic affiliation might influence their ideas regarding the initial 
and the current research question. All GPs consented to participate. Anonymity and 
confidentiality were ensured. According to Dutch legislation, interviewing healthcare 
professionals regarding their professional beliefs does not need approval of an external 
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ethics committee. Participants were offered a gift voucher and compensation of travel 
expenses in appreciation of their efforts. 
The focus groups were held between September 2010 and March 2011 and took 
place at the Radboud university medical center. One focus group was conducted in the 
practice of a research team member since this resulted in a shorter travel distance for the 
participating GPs. 25 GPs participated in five focus groups, each group containing four 
to six participants. Table 1 shows their characteristics. Some participating GPs knew the 
moderator, the observer, or other participating GPs in their focus group, whereas others 
didn’t. 
Focus groups can be regarded as appropriate qualitative methods, since the group 
process may help to explore and clarify views of participants, and facilitates different 
forms of communication, which could help in generating new insights.21 
TABLE 1: Characteristics of participating GPs1 
n (%)
Sex
 Male 18 (72)
 Female 7 (28)
Practice type
 Single2 4 (16)
 Duo or group 21 (84)
Urbanisation
 Rural area 2 (8)
 Urbanised rural area 16 (64)
 Urban area 7 (28)
GP trainer3
 At present 11 (44)
 In the past 1 (4)
 Never 13 (52)
Researcher
 Yes 5 (20)
 No 20 (80) 
Mean age, years (range) 50 (31-63)
Mean experience as GP, years (range) 20 (2-36)
1Sex, age, practice type and urbanisation were similarly distributed among participants in our sample as 
compared to the Dutch professional group of GPs.24 
2Count of GPs settled solitary in a practice, i.e. without employment of, or professional collaboration 
with other GPs. 
3Trainer at the Nijmegen residency training programme, a qualification needed to supervise a GP trainee.
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Focus group interviews and data collection
A GP-senior researcher with extensive experience in qualitative research moderated 
the focus groups, using an interview guide (available from the authors upon request). 
One researcher observed all group interviews and paid special attention to non-verbal 
communication. The observer’s field notes were used during analysis, for example to 
identify non-verbally expressed (dis)agreement to other comments. The interviews were 
audiotaped and transcribed verbatim by a medical student. 
Analysis
The constant comparative analysis technique was applied by two researchers to analyse 
the data for the current aims.22 Disagreement was resolved by discussion or consultation 
of other researchers. The transcripts were read intensively. Open coding was first applied 
to conceptualise the data. This was followed by axial coding, where codes were clustered, 
side issues were distinguished from essentials, and initial concepts were checked against 
newly collected data. Selective coding was applied in the final analysis stage to integrate 
data after initial fragmentation. Invalidating examples were sought for. Data collection 
proceeded until saturation was reached concerning the current research question, 
which was the case after the fifth focus group. At this stage, no new insights were 
gained regarding GPs’ evaluation of guidelines applied to patients with multimorbidity. 
ATLAS.ti (version 7, Berlin, Germany) supported the analysis. Citations illustrating 
important points discussed needed translation, which was performed by a native English 
speaker translator, familiar with qualitative research in healthcare. In this way, potential 
loss of refinement in translated citations was reduced as much as possible. 
RESULTS
Overview of the results
GPs commented on the value of guidelines they perceived when applied to patients with 
multimorbidity, and on benefits from guideline adherence. They also described potential 
limitations from guideline adherence in these patients, which have led to several empirical 
solutions to counteract these. A point-by-point description of these discussed items is 
outlined below. 
Value of guidelines applied to patients with multimorbidity 
GPs valued evidence-based guidelines in general, and felt that their wide implementation 
had brought clear improvements to the quality of general practice. They especially 
perceived guidelines useful in the case of younger, relatively healthy patients, particularly 
if they suffered just from the disease described in the guideline. Most GPs followed 
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guidelines also for the younger and ‘healthier’ patients with multimorbidity, particularly 
if their multiple diseases had similar therapeutic approaches. In these cases of multimor-
bidity, guidelines provided guidance to medical decision-making, for example prescription 
of medication. 
‘If someone like that has COPD, then I think the guideline is very welcome and the 
same applies for the diabetes guideline.’ (GP24, male, 56 years)
‘The DCGP guidelines are of course the standard that you can keep to as much as 
possible.’ (GP16, female, 44 years) 1
Reduction of patients’ perceived symptoms and complaints (pain, shortness of breath) 
was an important reason for GPs to adhere to guidelines in patients with multimorbidity.
‘And of course, you go for the things that people really suffer from. Strict diabetes 
control…these days, that’s not the main aim.’ (GP7, male, 56 years)
‘Look, there are two things: prescribing something because of complaints, or to 
prevent something that will happen, or may happen in the future; that makes a big 
difference.’ (GP 24, male, 56 years)
Guideline adherence also helped in working transparently, enabling comparison and 
quality control between GPs. GPs did express a need for guidelines despite the difficulties 
in translating these into the practical care for patients with multimorbidity.
‘Sometimes that should be left […] to the doctor’s judgement. (GP13, male, 45 
years)
‘Yes, but if you don’t emphasise the importance or the statistics, then it’s easy to 
stay in limbo […] So it’s actually good that one strives as much as possible towards 
evidence-based ideas over […] what’s the smart thing to do, or what is the wisest 
option to reach a good compromise.’ (GP15, male, 54 years)
‘It’s also dangerous, doing your own thing, because then it’s just like the way it used 
to be… and you do wish that some things were sorted out.’ (GP 7, male, 56 years)
1 DCGP: Dutch College of General Practitioners. In Dutch: ‘Nederlands Huisartsen Genootschap (NHG)’.
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GPs stated that it would be unrealistic that guidelines should specify for any possible 
disease combinations, but would feel better supported in the care for patients with 
multimorbidity when guidelines gave more details for diagnostic, treatment and 
management priorities. 
Limitations from guideline adherence in patients with multimorbidity
Limited usefulness of guideline adherence in multimorbidity
There was agreement that guidelines were less useful for elderly patients and ‘complex 
cases’ of multimorbidity. GPs commented that guidelines were essentially not designed 
for these complex patients and felt that in these cases implementation was not as 
straightforward as in younger patients.
‘The DCGP guidelines are […] not particularly applicable for the very aged, and also 
not for lots of things mixed up together.’ (GP24, male, 56 years) 2
‘The flipside of the coin is that these guidelines are not made for the 80 year olds.’ 
(GP 12, female, 58 years)
‘As patients get on in years, I tend to adhere less faithfully to the strict norms in 
the DCGP guidelines for blood pressure and such things. And to say, now, let’s just 
prescribe extra medicine on top of it all, I won’t do that.’ (GP23, male, 51 years) 2
A component of this limitation of guidelines was the issue of ‘prevention’. GPs felt that 
adherence to guideline-recommended preventative measures was less appropriate in the 
case of older patients with multimorbidity and patients with a limited life-expectancy. 
This was more pronounced if these measures were accompanied by side-effects. They 
also questioned whether similar benefits could be expected from preventative measures 
as for younger or healthier patients. When GPs felt less convinced of the advantages of 
prevention, they would put less emphasis on this topic in the consultation. A sense of 
acceptance of limited therapeutic or preventative benefits was expressed if it concerned 
older patients.
‘I think that I’d pay more attention to the preventative aspects with a younger 
patient, to see what’s possible. Someone who’s 55, who’s had a heart attack and 
COPD and still smokes, I’d push harder for them to quit smoking than with the 
same person who’s 75.’ (GP14, male, 63 years)
2 DCGP: Dutch College of General Practitioners. In Dutch: ‘Nederlands Huisartsen Genootschap (NHG)’.
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‘Many of those with multimorbidity take a substantial number of preventative 
medications [...] of which the benefit isn’t clear, at least not immediately, and it’s 
also the question whether you will experience that benefit, or whether you’ll mainly 
get side-effects, or both.’ (GP 1, female, 36 years)
‘With a 40-something year old, the treatment aim is clear… to reduce risk over a 
long term period. But for an 80-something year old, it becomes less clear cut […] 
What can the patient get out of it, and also, what are the possible side-effects?’ 
(GP6, female, 31 years)
‘With the aged, a long-term treatment is...dubious. If it doesn’t go well and 
smoothly, then there’s totally no motivation for you to go through with it.’ (GP 24, 
male, 56 years)
‘In my opinion, blood pressure treatment causes a lot of side-effects. Like dizziness 
and falls. […] I think, better to have [systolic] pressure of 160 and not fall - that’s 
more important.’ (GP7, male, 56 years)
Guideline adherence conflicts with a patient-centred approach
Despite the need for guidelines, GPs often saw good reasons to ignore guideline 
recommendations in individual circumstances or to omit treatments in patients with 
multimorbidity. Consistent guideline adherence was perceived as an impediment to 
deliver individualised, patient-centred healthcare to patients with multimorbidity, which 
emerged as GPs’ major objective in their care (described in detail in our previous paper20). 
This came forward in their inclusion of patients’ preferences and circumstances in their 
management decisions, even when this meant to ignore guideline recommendations. 
Some GPs expressed this explicitly while many agreed with such comments. 
‘And that’s the essence of what you’re talking about. Not that this lady has 
osteoporosis and which pills according to the guidelines are the best - that’s 
something I can look up myself, that’s not so difficult. But the point is, this lady, 
who lives all alone, what is best for her, when does she have to relocate? What 
do we do in this situation? Should we arrange home nursing, or does she need to 
move anyway?’ (GP 25, male, 56 years)
It was considered impossible to exhaustively grasp the complexity within guidelines that 
inevitably comes along with multimorbidity.
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‘The question is whether you can ever grasp the complexities of all the interactions 
between diseases in guidelines. […] And whether you can find something that 
applies to this specific patient in the guidelines, well, I fear the worst.’ (GP13, male, 
45 years) 
A perceived risk of working too much ‘guideline-driven’ is that items addressed in 
the guidelines will be automatically prioritised over patients’ other important health 
problems.
‘We have a strong tendency to keep working on the cardiovascular issues. […] And 
then you see these people leave the clinic and you think, OK, actually we should 
have done something about the osteoarthritis.’ (GP13, male, 45 years) 
Concerns about the applicability of guidelines for multimorbidity
Scepticism was articulated on the applicability of evidence-based guidelines to patients 
with multimorbidity. Concerns were expressed that patients included in research and their 
specific circumstances are not comparable to patients with multimorbidity. Guideline 
recommendations following research results are not simply generalisable to patients with 
multimorbidity. 
‘For example, such a guideline for diabetes or hypertension is based on, I don’t 
know, research on 40-60 year olds… with mono-morbidity, probably. I don’t know 
if this is like this in all cases. But in general, that’s what happens. And what’s that 
worth for an 80 year old patient with multimorbidity? Nothing, in my opinion.’ 
(GP7, male, 56 years) 
‘There is of course completely no evidence for these patients, because no one 
knows if they are going to treat [high] cholesterol in someone who’s 80 with 
asthma and who’s had chemotherapy, for example. There’s also nowhere where 
you can look that up.’ (GP7, male, 56 years) 
Also, GPs commented that combining therapeutic regimens, originating from evidence-
based guidelines written for single diseases, does not lead to an evidence-based 
combination for patients with multimorbidity. Guidelines can be conflicting, and often 
it is unclear how they relate to one another, which impedes using several guidelines for 
one particular patient. 
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‘I think, OK, I can go all-out on treating each and every disease, but whether the 
sum of the parts actually results in a better level of care from my side, that’s the 
question. So, that makes me a little more conservative, because I think, well - I’m 
not too sure about that.’ (GP13, male, 45 years)
‘All the indicators are for singular problems. That’s how those are often studied, 
right? But in combination, much less. […] And what you should focus on - that’s 
not really covered either.’ (GP14, male, 63 years)
Empirical solutions
The disadvantages GPs perceived from guideline application to patients with multimorbidity 
resulted in several practical solutions, enabling them to provide continuous healthcare to 
these patients. This paragraph summarises the empirical solutions mentioned. 
From their experience, GPs expressed a need to rely on their ‘common sense’ - a 
source of ‘knowledge’ that may complement the limitations of guideline application 
in multimorbidity. This implied making patient-centred decisions, accounting for the 
personal circumstances of patients with multimorbidity. However, relying on one’s 
‘common sense’ only was not considered acceptable anymore in the current era. 
Guideline adherence and applying ‘common sense’ needed to be in balance.
‘[Multimorbidity] gives you a lot of freedom to use your experience and own ideas 
as a doctor to help the patient’s problem. Otherwise you’d be much more tied to 
the evidence […] you get to a certain point when that’s not as challenging to do.’ 
(GP7, male, 56 years)
‘With all of the guidelines available, you can use your common sense to say, well, 
I’d choose this one for this and that reason, that’s easy to justify, or at least I think 
so. And then the guidelines are definitely not always followed, because common 
sense in the case of this patient… ‘ (GP11, male, 57 years)
‘No, but that’s not the reason that the guidelines shouldn’t exist.’ (GP15, male, 54 
years)
‘No, and the question is also, whether everyone’s common sense is the same?’ [All 
laugh] ‘Probably not, so we all probably make different choices. […] That’s how the 
guidelines arose. All the doctors, with their own common sense, thought that they 
were doing it right.’ (GP 14, male, 63 years)
One GP described that an authorised guideline is not the only source providing support 
to GPs in the difficult decisions they need to make in patients with multimorbidity. 
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He suggested that regular refresher courses on complex topics could provide more 
knowledge and insight leading to guidance in a different way. 
‘A few extra courses on this subject would be of help to GPs, I think. And to 
support our common sense. […] So I think that [more] knowledge, […] without 
immediately having to set up a guideline for it, but just using [that knowledge] I 
think can also help.’ (GP14, male, 63 years) 
Additionally, improvements could be made in guideline reporting, to increase their value 
for patients with multimorbidity. A GP proposed to have a ranking of importance made 
in recommended (preventative) measures for patients with multimorbidity, considering 
the seriousness of adverse results if they are not adhered to. The same GP proposed, with 
agreement of the other GPs in his group, that guidelines should more explicitly comment 
on their external validity. This could provide support to GPs not to adhere to guidelines 
for specified reasons or in specific situations – creating valid reasons to make patient-
centred decisions, by applying their ‘common sense’. 
‘You’d also want to know which interventions are actually the most critical, right? 
For example, administering an anti-coagulant with atrial fibrillation, that’s what you 
almost always should do, in any case that’s what I think, but I think you should also 
still do that with someone who’s 88, because a stroke is a drama of course. And I think 
cholesterol for example is a different story, as is hypertension.’ (GP7, male, 56 years)
‘Do you have the feeling that the guidelines help you to treat people with 
multimorbidity?’ (Moderator)
‘No. It would be great if the guidelines would mention for whom it doesn’t apply, 
and then I think you’d be shocked at the number of your patients that fall into this 
category.’ (GP7, male, 56 years)
Another GP tried to explain to his patients the evidence underlying guideline 
recommendations. In a conversation on how to translate guidelines into personal 
treatment choices, he let these well-informed patients’ opinions influence decisions on 
whether or not to start new treatments – again coming to a patient-centred solution. 
‘If you look at the numbers needed to treat, for many of these things, these are 
around 20, 30, would be considered great, right? But when you discuss with those 
people, many end up declining the treatment […] many people have their own 
[well-informed] opinion.’ (GP13, male, 45 years)
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Finally, permission to exclude patients with multimorbidity from regular pay-for-perfor-
mance systems could reduce the burden of imposed, but inappropriate guideline adheren-
ce, and improve the quality of care delivered to patients with multimorbidity. In those focus 
groups where the issue of pay-for-performance was discussed, GPs agreed that guideline-
derived incentives for patients with multimorbidity were undesirable and inappropriate.
‘The legislation and the incentives are just completely irrelevant and not to the 
point if you’re talking about quality.’ (GP15, male, 54 years)
‘It would be good if these people with multimorbidity, and especially with complex 
diseases combined, were to be excluded from the tables. […] So you’d need 
another set of criteria, separate from the criteria for [relatively] healthy people with 
only one disease.’ (GP13, male, 45 years)
‘What doesn’t help are the performance indicators for diabetes care where you 
are forced, at the end of the year, to submit all the statistics for diabetes care, and 
are judged on […] how well the HbA1c has been controlled. Because that doesn’t 
show that we take the patient [as a whole] and the prognosis into consideration.’ 
(GP 16, female, 44 years)
DISCUSSION
Summary
In this paper, we explored and described how GPs value evidence-based guideline 
application in patients with multimorbidity, i.e. patients for whom they had several 
potential guidelines to follow at the same time. GPs treasure the availability of guidelines 
in general, but at the same time expressed that guidelines do not cover the requirements 
needed to deliver complex care to patients with multimorbidity. They do not give 
sufficient opportunities to provide the desired individualised approach in multimorbidity, 
which may be considered as more important than adherence to the guidelines. 
Recommendations from single disease guidelines are not simply generalisable to patients 
with multimorbidity. When GPs apply guidelines for patients with multimorbidity, they 
incorporate patients’ specific circumstances. Guideline-supported care to patients with 
multimorbidity can therefore be regarded as a good illustration of the use of the core 
values of primary care. This paper provides a new insight that, from their practical 
experience with patients with multimorbidity, GPs apply empirical solutions, such as 
balancing guideline recommendations with their ‘common sense’ and a patient-centred 
approach, to counteract guidelines’ pitfalls. 
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Strengths and limitations
This study was performed by applying robust qualitative methods. Focus groups were 
guided by an experienced moderator with familiarity to the subject discussed. Participating 
GPs had been invited using a purposive sampling strategy. It is possible that GPs with a 
special interest in complex care, such as care for patients with multimorbidity, were more 
inclined to attend a focus group session than GPs without such an interest. This might 
have increased the vivacity of discussions, but participants were not selected on this 
criterion. Data collection proceeded until saturation was reached. The entire analysis was 
performed by two researchers, using the constant comparative analysis technique, which 
is an appropriate technique in qualitative research if new theory is to be generated.
Focus group discussions were held in Dutch and in the context of Dutch healthcare, 
thus providing views of participating Dutch GPs. The results do not allow generalisations 
to the primary care context in general. However, the resemblance of our GP sample 
to the Dutch professional GP group24 does increase transferability of our findings.25 
GPs in countries with a healthcare system comparable to that in the Netherlands may 
experience similar problems from guideline application to patients with multimorbidity, 
and their practical answers to such puzzles might show similarities to the empirical 
solutions described in the current study. Future research should elaborate this. Some 
time span existed between data collection and writing of this paper, because it had not 
been planned originally to produce a separate paper specifically focusing on the role of 
guidelines applied to patients with multimorbidity. In the mean time, the number of new 
publications on this theme was limited. It seems unlikely that this ‘publication delay’ 
importantly influenced our findings. The role attributed to comorbidity in new (Dutch) 
primary care guidelines was not obviously different than before our data collection. 
Our research question produced new insight into a research field without much preceding 
literature. This originality provides the major strength of our work. 
Fitting the iterative nature of qualitative research, the idea to analyse the data regarding 
the current research question arose gradually. Although this theme was an explicit subject 
of discussions, participants were not made aware of it as additional research question 
beforehand. Would this have been the case, participants might have been overthinking 
the specific issue of guideline application to patients with multimorbidity consciously, 
which could have resulted in the expression of beliefs that remained unrevealed now. 
We find it unlikely that with such a scenario participants would have expressed clearly 
deviant ideas from the ideas they expressed here. However, it is not possible to establish 
if and to what extent our results would have been expanded or altered were this research 
question announced explicitly. 
On most subjects discussed we found no obvious difference between beliefs expressed 
by GPs with different characteristics, with two exceptions. Discussions on the applicability 
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of guidelines for multimorbidity, and about the empirical solutions applied to overcome 
guidelines’ disadvantages were mainly brought up by GPs with an academic affiliation. 
GPs without academic involvement did not express opposing views but accepted these 
beliefs and agreed with them in general. As a consequence, we conclude that there were 
no contrasting beliefs between ‘academic’ and ‘non-academic’ GPs, but that academic 
GPs were better able to articulate the tensions between patient-centred and guideline-
directed care. This might be caused by a greater familiarity of researchers with the way 
guidelines are realised, and GP trainers’ custom to reflect on their own practice as they 
do in the GP residency programme, which makes them ‘trained’ in expressing their 
beliefs. This may have helped in gaining valuable insights from these participants. 
It came as some surprise that the collaboration with specialists did not feature strongly 
in the discussions. This may be due to the structure of the current study, focused on the 
role of guidelines, and the fact that GPs in the Netherlands identify strongly with the 
DCGP guidelines as ‘their own’.19 Our previous study, describing GPs’ considerations and 
main aims in multimorbidity management, did include GPs’ views on cooperation with 
specialists.20
Comparison with existing literature
The findings of this study help to reflect on the adequacy of ‘guideline-based’ modern 
medicine from the GP’s perspective. Evidence-based guidelines are perceived as useful 
in general but several shortcomings are experienced in patients with multimorbidity. 
Important problems arise from discrepancies between recommendations based on single-
disease guidelines, and that what is perceived by GPs as serving a particular patient 
with multimorbidity best. From a patient-centred work style GPs try to achieve shared 
decision making, they individualise treatments, and they may deliberately omit specific 
treatments. In the setting of a continuous clinical relationship, knowing the context of 
the patient informs intuitive judgements.26 This ‘knowing of the particular’ is at the heart 
of general practice - but may be seen as contrasting with the principles of biomedical 
science, where it is explained what patients have in common, and ignores in what they 
differ.27 However, the practice of evidence-based medicine requires integrating individual 
clinical experience with the best available external clinical evidence: good doctors need 
to rely on both.28, 29, 30 This integration is exactly what was expressed by our participating 
GPs as an empirical solution to deal with the discrepancy between guideline adherence 
and providing optimal care to patients with multimorbidity. 
To the best of our knowledge, no previous papers specifically analysed the value of 
guidelines for patients with multimorbidity as it is perceived by practitioners who use them 
in clinical practice. A few previous papers describing how GPs deal with multimorbidity 
reported briefly on the value of medical guidelines in this respect. Qualitative data have 
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been synthesised by Sinnott and colleagues, concluding that mixed feelings exist on the 
clinical utility of guidelines.18 
Some previous studies demonstrated guidelines’ limited suitability to patients with 
multi morbidity: they showed that the frequency and consistency of recommendations 
accounting for patients’ comorbidity are low, and that they provide limited guidance 
in making treatment priorities.10-12 These constraints, which were identified in literature 
reviews and on merely theoretic grounds, have now been exemplified by our qualitative 
data. 
Two original studies, focusing on GPs’ perspectives on care for older patients with 
multimorbidity, produced results that show similarities to our findings. Fried et al. 
described variable beliefs regarding benefits and harms of guideline-directed care among 
their participants. Those who expressed concerns did so regarding limited external validity, 
and the adverse events that may be caused by applying multiple guidelines. Additionally, 
guidelines’ target outcomes may not be most relevant for patients with multimorbidity.31 
In a Dutch focus group study exploring ‘GPs’ feelings on deprescribing medication’, 
participants also distinguished medication prescribed for symptomatic conditions and 
preventative medication. They experienced a lack of information regarding risks and 
benefits of preventative medication for patients with multimorbidity, and felt compelled 
to prescribe by the present guideline.32
The difficulties experienced in practice by our participating GPs led to suggestions how 
to make evidence-based guidelines better viable for patients with multimorbidity – a 
necessary step, since guidelines are indispensable in the current era, as was confirmed 
by the participants. Other papers describing barriers made some similar suggestions, 
for example accounting for the patient’s context,10, 30, 31, 33 focusing on generic 
instead of disease-specific outcomes,34, 35 providing guidance in prioritising guideline 
recommendations,16, 17, 32 and improving the external validity of clinical trials and 
guideline recommendations.16, 36 In addition, it has been recommended to include more 
elderly people and patients with comorbidity in future studies,16, 17 and to apply more 
cross-referencing between existing guidelines, in order to enhance guidelines’ usefulness 
for patients with multimorbidity.17 An innovative possibility is to apply the concept of 
‘pay-off time’, predicting if a patient with limited life expectancy is likely to benefit from 
adherence to a particular guideline, by calculating the minimum time until its cumulative 
benefits exceed its cumulative harms.37 These suggestions all address very well the 
guidelines’ limitations mentioned by our participants.
‘Complexity theory’ has been used to implement interventions in the primary care 
setting, and yielded sustained effects in individualising the structure and processes of 
care towards individual values.38, 39 This reflects the challenges GPs reported in our study 
to address the needs of patients. As their approach worked in different participating 
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practices, this would make ‘complexity theory’ a valuable approach to incorporate in the 
organisation culture of care of patients with multiple health problems. 
Reformulating ‘quality of care’ for patients with multimorbidity and adapting pay-
for-performance systems accordingly is a merely practical need to better address 
multimorbidity. It challenges current systems in which payment is based on adherence to 
guideline-based recommendations. This suggestion, raised by participants in our study, 
finds support in the literature.31, 40 A new proposal from the current study is to make 
more use of post academic trainings focused on multimorbidity. This reduces the need to 
rely on guidelines only as a resource providing guidance in difficult treatment decisions. 
Implications for research and/or practice
To conclude, inconsiderate adherence to guidelines is undesirable in the care for 
patients with multimorbidity, and would come at the risk of losing ‘the art of medicine’. 
Nevertheless, evidence-based guidelines are indispensable components of modern 
medicine. Several suggestions have now been summarised how to improve guidelines’ 
applicability to patients with multimorbidity, for example increasing and better reporting 
of the external validity in future research, and prioritising guideline recommendations. 
Patient-centred care provision demands adjusting professional tasks to a specific patient’s 
needs. This requires practitioners’ autonomy to deviate from guideline recommendations 
when appropriate, without negative financial consequences, especially in the case of 
multimorbidity. Facilitating such flexibility could help to accomplish the provision of 
patient-centred care to patients with multimorbidity, a much needed and desired pursuit 
by patients as well as GPs. 
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GENERAL DISCUSSION
With a mixed methods approach, this thesis generated more knowledge on the 
epidemiology of comorbidity, its associations with disease-specific outcomes, and on 
general practitioners’ (GPs’) experience with multimorbidity in daily practice. The focus 
of this thesis was on the GP’s perspective on multimorbidity, since this perspective had 
been relatively underexposed in the literature. The thesis had several aims: 
- To describe the prevalence and incidence density of comorbidity in type 2 diabetes 
patients. 
- To explore the long-term associations between comorbidity and longitudinal diabetes 
control parameters in type 2 diabetes. 
- To study the considerations and main aims of GPs in their care for patients 
with multimorbidity, and to explore factors influencing their management of 
multimorbidity. 
- To explore how GPs value guidelines when applied to patients with multimorbidity, 
and which benefits and barriers they experience from adherence to guidelines in 
these patients. 
The first part of this thesis (Chapters 2, 3, and 4) studied multimorbidity quantitatively. 
It used type 2 diabetes mellitus as a ‘case study’ to describe its epidemiology, and to 
describe associations between several disease combinations and disease-specific 
outcomes. The qualitative second part of this thesis (Chapters 5 and 6) described GPs’ 
experiences with and solutions for the management of multimorbidity in daily practice. 
For the interpretation of the overall study findings of this thesis, here the findings of the 
‘diabetes case study’ from the quantitative first part of this thesis will be related to the 
findings of the qualitative studies from the second part and generalised to GPs’ clinical 
decision making. 
First, an overview is presented of the results of the research questions, with a discussion 
of the interpretation of the overall findings. The relevance of the findings in relation 
to the literature, and some strengths and limitations are discussed. Furthermore, the 
implications of the findings, both for future research and for daily practice in GPs’ 
management of multimorbidity are described.
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OVERVIEW OF THE RESULTS
Chapter 2 reported the prevalence and incidence density of a broad range of chronic 
comorbid diseases in representative, newly diagnosed type 2 diabetes patients in primary 
care. Both concordant (related - that is, cardiovascular) and discordant (unrelated) 
comorbidity were shown to be very common. It demonstrated that the diabetes patient 
population is heterogeneous in terms of comorbidity, and that the diabetes patient 
without (discordant) comorbidity is relatively rare. Chapter 3 explored the associations 
between longitudinal diabetes control parameters and the number and specific types 
of comorbidity in a primary care cohort of patients with type 2 diabetes. The simple 
sum of comorbid diseases did not show an unfavourable association with trends of 
HbA1c or systolic blood pressure over five years, but specific types of comorbidity (i.e., 
musculoskeletal disease, cardiovascular disease) did. Chapter 4 showed that diabetes 
patients with comorbid COPD have different trends of systolic blood pressure over five 
years compared to diabetes patients without COPD, an effect that was modified by 
socioeconomic status and body mass index.
Chapter 5 described that applying a patient-centred approach is the main aim of GPs 
in their care for patients with multimorbidity, which helps to oppose some potential 
pitfalls of multimorbidity. Patient-centredness was achieved by individualising decisions 
and placing medical considerations in a broader perspective. Fragmentation of care was 
identified as an important risk in multimorbidity, and the combined presence of somatic 
and mental health conditions was perceived as a particularly difficult combination. The 
existence of a personal relationship between doctor and patient was supportive for the 
management of multimorbidity. In Chapter 6 it was explored how GPs value guidelines 
when these are utilised for patients with more than one disease. Guidance from guidelines 
was appreciated in general, but guidelines were perceived as insufficient to guide the 
complex care needed for patients with multimorbidity. GPs doubted the applicability of 
guidelines for patients with multimorbidity and often considered preventative measures 
as inappropriate. They integrate clinical experience with the best available evidence in 
patients with multimorbidity. 
INTERPRETATION OF THE OVERALL FINDINGS IN THIS THESIS
Most of the work in this thesis was explorative research without much similar literature 
preceding it. In this thesis, mixed methods were applied. Especially in a research area 
with many blanks, as is the case in multimorbidity,1 both information on the frequency 
of the issue under study and information on how and why things occur under daily 
practice circumstances is needed. A mixed methods approach helps in gaining a deeper 
understanding on both types of missing information, and precisely the combination of 
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quantitative and qualitative results can produce a broader insight into the complex issue 
of multimorbidity. In the observational research in the first, quantitative part of this 
thesis, type 2 diabetes was chosen as a case study to examine the epidemiology of 
comorbidity, and the associations of comorbidity with the outcomes of an index disease 
among patients receiving regular healthcare. Type 2 diabetes is a common chronic 
disease, generally taken care of in primary care. It has quantifiable outcome measures 
enabling comparison between patients with and without (specific types of) comorbidity. 
Such outcome comparisons were made in Chapters 3 and 4. A causal relation of the 
findings reported in this thesis’ first part cannot be inferred from observational research. 
Neither does the explorative nature of the studies in this part justify the suggestion 
of concrete recommendations to change daily practice instantly. However, it has 
become clear that diabetes patients who also have (discordant2) comorbidity are the 
rule rather than the exception. Moreover, the findings emphasise that the presence of 
comorbidity can interact with diabetes outcomes. Nevertheless, evidence-based medical 
guidelines derive their recommendations from randomised controlled trials (RCTs), but 
patients with (discordant) comorbidity are generally excluded from these RCTs.3, 4 Within 
the framework of this thesis, it was not possible to analyse additional index diseases 
and make analogous examinations of associations between their comorbidity and 
disease-specific outcomes. But it is to be expected that, with a different index-disease, 
interactions between some types of comorbidity and other disease-specific outcomes 
will also exist. This could be an area for further study. Distinct associations found in early 
explorative work may define the focus for deeper investigations in future research, and 
the methods applied and findings reported in the current thesis may be considered as a 
starting point in this respect. Notwithstanding, current guidelines do not yet specify how 
comorbidity may influence management of diabetes or other chronic diseases.5-7 As has 
been suggested for diabetes7, 8 and for COPD,9 guidelines for other diseases should also 
regard a patients’ comorbidity as a patient characteristic that should be accounted for in 
personalised disease management.10 
Hence, it is obvious that comorbidity has interference with the management of other 
chronic diseases, but evidence-based recommendations how best to address this issue 
in daily practice, yielding optimal health outcomes, are not yet available. Current clinical 
guidelines hardly provide guidance in how to prioritise recommendations when patients 
have multiple diseases.11, 12 Therefore, the second part of this thesis, containing the 
results of qualitative research, sought to employ GPs’ empirical knowledge on the 
daily practice management of multimorbidity. Patients desire patient-centred care that 
explores their needs, pursues an integrated understanding of them, and promotes 
health, in a mutual agreement and a continuous relationship with the doctor.13, 14 
Patients with multimorbidity desire continuous, individualised, communicative care, and 
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need help in prioritising competing demands,15 while they experience problems with 
fragmented care.16-24 Studies of the perspective of healthcare professionals who deal with 
multimorbidity on a daily basis have been relatively absent in the literature. The viewpoints 
of GPs, accessible gatekeepers with an overview on a patient’s entire health status, were 
expected to produce valuable new insights into the care for patients with multimorbidity. 
Such a professional frame of reference was necessary to gain understanding in how 
generalists apply their broad knowledge and skills to guide patients with multimorbidity 
in the healthcare system.
After articulating GPs’ goals in the management of patients with multimorbidity 
(Chapter 5) and GPs’ views on the value of guidelines in this respect (Chapter 6), 
the qualitative part of this thesis provided insight in how to address dilemmas and 
complexities resulting from multimorbidity based on this empiricism. In this way it 
complements some gaps in evidence-based multimorbidity management. By prioritising 
patient-centredness and using their ‘common sense’, GPs avoid fragmentation of care 
and insensible implementation of disease-specific recommendations from guidelines that 
are not directed at patients with multimorbidity, and not expected to provide them more 
benefits than harm. GPs perceived strict (‘uncritical’) guideline adherence as a barrier 
to provide patient-centred care to patients with multimorbidity. In the management of 
multimorbidity in daily clinical practice, they rely on their knowledge of the particular 
patient and their continuous relationship with him or her, and aim to achieve shared 
decision making. This empirical, patient-centred strategy helps them to overcome several 
barriers that the GPs in this study linked to multimorbidity. The existing shortcomings in 
evidence-based guidance on how to provide best care to patients with multimorbidity 
(described in Chapter 1 and above) are thus overcome by making clinical judgement, 
informed by knowledge of the patient, and GPs’ practical experience. This is what has 
happened in primary care throughout the decades and what should be retained in 
future care for patients with multimorbidity. It can be seen as practising evidence-based 
medicine at its best: it necessitates the integration of best available clinical evidence with 
individual clinical experience.25-27 From the GP’s perspective, this is how knowledge on 
multimorbidity meets daily practice. 
RELEVANCE OF THE FINDINGS IN RELATION WITH THE LITERATURE
The recording of outcome data of type 2 diabetes in primary care has been performed over 
a long period of time in the Nijmegen Monitoring Project (NMP) practices in the Nijmegen 
region. These practices have shown to provide good quality diabetes care.28 Combining 
this with the longitudinal morbidity recording in the Nijmegen Continuous Morbidity 
Registration (CMR), existing since 1967, resulted in a unique research facility to study 
CHAPTER 7
124
associations between diabetes control parameters and a wide range of chronic comorbid 
diseases.29, 30 A dynamic cohort was realised, in which the presence of comorbidity in 
diabetes patients could be studied over time, that is, pre-existing comorbidity could be 
distinguished from incident comorbidity, and these different types of comorbidity could 
be linked to longitudinal diabetes control parameters with an extensive follow-up period. 
No previous studies were identified that provide a thorough description of comorbidity 
and its development over time in patients with diabetes. Incidence data of (discordant) 
comorbidity in diabetes had not been reported at all. Pre-existing (i.e., prevalent) and 
incident comorbidity may interfere with the management of diabetes - or another 
index disease - in different ways, which makes it important to distinguish between the 
two types of comorbidity. Medical records in general practice have an overview of the 
full range of morbidity, which makes the primary care setting ideally suited to study 
comorbidity of an index disease extensively.
The cohort comprised an unselected group of adult patients in primary care with a 
recent diagnosis of type 2 diabetes, and no exclusion based on age. In addition, any type 
of chronic comorbidity was included. These methodological choices made this cohort 
representative for the type 2 diabetes population at large. Including only newly diagnosed 
diabetes patients facilitated the incidence reporting of comorbidity before and after the 
diabetes diagnosis. Moreover, it resulted in a prevalence estimation of comorbidity which 
was different from a design that would have included patients with diabetes since many 
years. The prevalence of comorbidity in diabetes patients reported in Chapter 2 of this 
thesis was equal to31 or higher than32, 33 prevalence rates reported previously. The high 
prevalence and incidence density of comorbidity found in this study are notable, precisely 
since this cohort was not a selected population in secondary care, where a higher burden 
of comorbidity may be expected. The most important explanation is that in the studies 
in this thesis, any type of chronic disease was included as comorbidity, in contrast with 
other studies.33, 34 Some papers published after the work in Chapter 2 reported similar 
rates of comorbidity in type 2 diabetes patients.35-37 
Including only a (random) selection of comorbidity gives an underestimation of the total 
amount of comorbidity. In the studies reported in this thesis, chronic diseases that are not 
very prevalent on itself were also included as comorbidity. This allowed, for example, the 
summing up of diseases that, all in a different way, may affect patients’ possibilities for 
self-management of diabetes - resulting altogether in a prevalence of 4%, a substantial 
proportion of the diabetes population. Chapter 2 furthermore reported that discordant 
conditions altogether outnumbered concordant conditions in diabetes patients, a finding 
that was confirmed in later publications that also considered a broad range of comorbid 
conditions.35-38 These findings emphasise that presuming the existence of the ‘typical’ 
diabetes patient is unjustified. 
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Chapters 3 and 4 elaborated on these observations, by showing different patterns of 
diabetes control parameters according to diabetes patients’ comorbidity profiles. They 
demonstrated for example differences in these parameters over time for diabetes 
patients with different numbers of comorbid diseases, and for diabetes patients with 
or without cardiovascular disease, musculoskeletal disease, and COPD. Some of these 
associations were modified by patients’ socioeconomic status and/or body mass index. 
Among the few papers that also examined associations between comorbid diseases 
and diabetes control parameters, analysis of patients characteristics such as SES was 
generally absent.39, 40 This stresses that a lot of research remains to be performed on the 
personalisation of the management of chronic diseases.
 
In Chapters 5 and 6 it was described that patient-centredness is GPs’ priority in their care 
for patients with multimorbidity. They allow their ‘common sense’ to interfere when it is 
questionable if adhering to evidence-based recommendations would increase patients’ 
health status. The approach pursued by GPs fits well to what patients with multimorbidity 
themselves prioritise in their healthcare.15, 16 Later qualitative studies focusing on the GPs’ 
perspective of the management of multimorbidity in daily practice also emphasised the 
importance of patient-centredness.41 Similar to the findings in the qualitative part of this 
thesis, a balance between adherence to prescription recommendations from guidelines 
and providing patient-centred care to patients with multimorbidity was expressed in a 
recent qualitative paper studying GPs’ decisions related to prescribing medication for this 
patient group.42 
Patient-centredness in primary care has been defined as containing several dimensions, 
namely regarding the patient as a whole person from the biopsychosocial perspective, 
looking for a common ground between doctor and patient, and building a therapeutic 
alliance (continuous doctor-patient relationship).43 Shared decision making is a 
component of patient-centred care. It implies partnership between doctor and patient, the 
provision of medical and personal information, communication (including negotiation), 
and agreement.44-46 Another component of patient-centredness is continuity of care. 
Patients with multimorbidity have high consultation rates.47 In 1980 already, McWhinney 
described that clinical decision making requires both individualisation and generalisation. 
He defined several factors in the clinical decision making process that are typical for 
primary care, including the use of knowledge of the patient and his context, and a 
continuous relationship with the patient.48 Two decades later, Starfield and colleagues 
showed that healthcare utilisation is larger for a patient’s comorbidity than for a specific 
index condition, and that comorbidity has a greater burden on primary care than on 
specialist care. They consequently stressed the importance of a continuous primary care 
context for patients with multimorbidity, and of focussing on patients’ overall healthcare 
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needs, not just on all separate disease needs.49 A recent study showed that greater 
continuity of care for patients with multimorbidity can be promising in the current era 
with its increasing burden on financial resources, since it was associated with lower 
hospital utilisation.50 
The principles of patient-centredness - listening to patients, informing and respecting 
them, involving patients in their care, and valuing their wishes without mindlessly 
enacting them - are not in contradiction with evidence-based medicine, which requires 
both generalisations and the art of knowing the particular of individual patients.25, 26, 51 
In the care for patients with multimorbidity, both components are indispensable.52 
STRENGTHS AND LIMITATIONS OF THE THESIS
Some important strengths of the work presented in this mixed methods thesis have 
been discussed in detail earlier in this chapter. A major strength is the robustness of the 
methods applied, both in the quantitative and in the qualitative parts of this thesis. In 
the quantitative part, this consisted of the utilisation of data originating from a reliable 
primary care research network, resulting in representative, longitudinal data, and a long 
follow-up period. Diabetes control parameters were combined with comorbidity data, 
and clear definitions were used. In the qualitative part, an iterative process of participant 
sampling, data collection and analysis was applied, as required in qualitative research. The 
composition of the purposive sample of participating GPs increased the transferability of 
the findings. Data collection proceeded until saturation was reached. 
Several limitations of the work described in this thesis need to be acknowledged too. 
Due to changes in diagnosis and treatment of diabetes over time, patients in the early 
phase of the dynamic cohort of diabetes patients (in the quantitative part of the thesis) 
may not be fully comparable to those later in the cohort. This type of limitation however 
is inherent to any type of observational research with a long follow-up period. Sensitivity 
analyses correcting for the time period did not result in significant changes of the major 
outcomes. 
The longitudinal outcomes in the diabetes case-study in the first part of this thesis are 
influenced by prescribed medication and non-pharmacological interventions for the 
treatment of diabetes and comorbid diseases. It was not possible to compare medication 
and lifestyle interventions between diabetes patients with and without specific types of 
comorbidity in this dynamic cohort study. As a result, if and how potential differences in 
therapeutic regimes may have contributed to the outcomes observed cannot be explained. 
However, this observational work aimed to explore associations occurring under daily 
practice circumstances (in the absence of an intervention), and comparison of therapeutic 
regimens between groups fell beyond its scope. Current guidelines recommend similar 
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targets for all diabetes patients, regardless of their comorbidity profile. GPs may however 
deliberately adapt the therapeutic goals based on patients’ comorbidity.41, 53 Therefore, 
should it be found in future studies that the presence of a specific number or type 
of comorbidity appears to be a reason for not prescribing the recommended diabetes 
treatment intensity (i.e. less strict glucose-lowering or antihypertensive treatment), then 
this would be an interesting finding to report on itself. When prescriptions occur more 
flexible by intention, as a result of existing comorbidity, medication prescriptions should 
preferably be analysed as outcome measures instead of handled as a covariate. 
Inherent to qualitative studies is that it reveals the ideas, perceptions and intentions of 
participants in the study. It does not assess actual behaviour. Consequently, the results in 
the qualitative second part of this thesis describes GPs’ ideas, not measurements of their 
actual behaviour. These are important to assess first when their content is not yet well 
known. Assessment of GPs’ actual behaviour regarding multimorbidity management 
could be subject to further research. This could occur for example by analysis of clinical 
reasoning when GPs would be asked to articulate their lines of reasoning in providing 
care to patients with multimorbidity. 
The most important strength of the research reported in this thesis is its innovative 
aspect. Both the quantitative and the qualitative part of this thesis did not have much 
comparable work preceding it. The research reported here generated more knowledge 
on the epidemiology of multimorbidity, and identified associations between specific 
combinations of diseases and longitudinal disease outcomes. It also applied GPs’ 
empirical solutions how to deal with multimorbidity’s complexities. By applying these 
mixed methods, this thesis provided suggestions for improvements in the care for 
patients with multimorbidity. Multimorbidity is nowadays often considered a research 
priority, after the prosperous days of evidence-based medicine with its focus on single 
diseases, and in the light of the ageing population. The thesis contributed to the research 
field and implications for future research are defined. 
FUTURE PERSPECTIVES
Based on the studies presented in this thesis, some important points of action can be 
defined for further research in multimorbidity and for the improvement of care for 
patients with multimorbidity. The findings also have implications for future medical 
guidelines. 
Implications for research
The explorative quantitative research in this thesis may be followed by further examination 
of distinct associations found. For example, the interaction between type 2 diabetes, 
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COPD, longitudinal diabetes control parameters, and patient characteristics such as 
socioeconomic status and body mass index could be studied in more detail in larger 
primary care cohorts of patients with both diseases present. COPD-specific and generic 
outcomes could be added as outcome measures. Associations between diabetes and 
musculoskeletal diseases, diabetes and cardiovascular diseases, and diabetes and the 
number of comorbid diseases could also be elaborated, focusing on their interaction 
with demographic patient characteristics. Other diseases than diabetes could be studied 
as index disease too. Now that the importance of comorbidity as a patient factor 
possibly influencing outcomes of other diseases is increasingly being recognised, but 
little representative data quantifying such associations are available, it is important that 
disease-specific outcomes are studied in relation to comorbidity. Such actions could 
help in the development of personalised disease management, with recommendations 
accounting for specific types of comorbidity and other patient characteristics. 
Some observations regarding research in multimorbidity in general practice need to be 
made. Although the management of multimorbidity is inherent to primary care, and 
publications on this topic have been appearing since a long time, the impressive increase 
in the interest for this issue in the scientific literature in the last two decades demands clear 
definitions and careful reporting of methodology, in order to optimise comprehensibility. 
Improvements can and need to be made in this respect. The concepts of ‘chronicity’ and 
‘chronic disease’ lack a generally accepted definition. Consistent application of a code 
list with chronic conditions that was designed for primary care could enhance uniformity, 
although this list lacks a desirable elaboration of ‘personalisation’ of a chronic disease.54 
Chapter 2 of this thesis provided an example of how personalisation of ‘chronicity’ 
was implemented, by making a distinction between invariable and conditional chronic 
conditions. Information in the electronic medical records in a practice-based research 
network can be employed to distinguish whether or not a specific patient experiences 
a chronic course of a ‘conditionally’ chronic disease, i.e. from which either episodic or 
chronic courses occur (for example, asthma and gout), or from which patients may 
recover (for example, depression). 
Comparison between multimorbidity studies is hampered by inconsistent use of 
definitions of ‘chronic disease’ and ‘multimorbidity’, which influences prevalence data.55-57 
The absence of a PubMed MeSH term for ‘multimorbidity’ further complicates this and 
it should therefore be introduced to improve consistency and tracing of literature. In the 
mean time, researchers should adhere to definitions for ‘comorbidity’ (referring to the 
presence of an additional condition in a patient with an index disease) and ‘multimorbidity’ 
(the co-existence of several diseases at the same time) that are widespread and generally 
accepted in primary care multimorbidity research, such as proposed by Van den Akker 
et al.57-59 
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When studying the impact of comorbidity on an index disease, it is important not to 
include just a (random) selection of comorbid diseases, but rather a broad range of 
comorbidity, which reflects the entire comorbidity burden in patients with the index 
disease, resulting in better representativeness. 
Researchers who consciously reflect on the issue of multimorbidity are more likely to 
adhere to such recommendations. However, a shift also needs to be made by researchers 
oriented on specific diseases, since many patients with any type of chronic disease will 
have multimorbidity. After the introduction of ‘evidence based medicine’ as a new 
paradigm, the focus on single diseases has brought the risk of ‘siloing’ of care for 
patients with multimorbidity.12 A new direction in evidence based medicine is important 
so that it yields research results that are more relevant, useful and valid to patients with 
multimorbidity – which is not the case with the current focus on following single disease 
algorithmic rules, aimed at improving disease-specific outcomes.26, 60, 61 
Research in multimorbidity is complex, due to the vast heterogeneity in the spectrum 
of disease combinations. This is further complicated by the possible influence of patient 
characteristics such as age, sex, socioeconomic status, etcetera, on various outcomes. 
There is a need for more generic research outcomes, such as physical functioning and 
quality of life, in order to increase its relevance for patients with multimorbidity.12, 62 
Possibly the ideal setting for studying multimorbidity is primary care. Collection of routine 
daily practice data in primary care, in the absence of an intervention, may yield longitudinal 
data containing patients’ full range of morbidity. Such data have a higher percentage 
of missing values than data collected in a randomised trial, although when collected 
in experienced registration networks this can be largely reduced. Under randomised 
controlled trial circumstances, data collected both in intervention and in control groups 
have a higher chance of being slightly influenced by altered behaviour of doctors and / 
or patients. In the primary care setting, it would be possible to use wide inclusion criteria. 
These possibilities offer the advantage of producing data with good representativeness, 
since routine care is provided, which would be reflected in the data. Strict exclusion criteria 
limit the external validity of the findings. Future intervention studies designed under such 
primary care circumstances would ensure better generalisability of the results for patients 
with multimorbidity: they give a better representation of the general population (with 
multimorbidity) than a secondary care population. In this way they could address a major 
pitfall of current trials and subsequent guideline recommendations.60, 63
To facilitate research comparing outcomes between patients with and without comorbidity 
in addition to an index disease, collection of disease-specific outcomes should ideally 
occur in addition to generic outcomes. This requires extensive recording of routine data 
in well-equipped practices. Primary care research networks are a perfect setting for the 
collection of this type of data. Ongoing investments in primary care research networks 
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are needed to allow the generation of such extensive datasets, and are important to 
improve the relevance of future research for patients with multimorbidity. 
Supported by sophisticated ICT systems with powerful analytic possibilities, the realisation 
of ‘big healthcare data’ (large datasets with patients’ routinely collected health status 
data) in research facilities is currently experiencing an exponential increase. These ‘big 
datasets’ offer opportunities for large-scale observational research, and may result in more 
knowledge on the epidemiology of multimorbidity, its effects on disease control para-
meters, and more evidence-based personalised therapeutic recommendations accounting 
for comorbidity and other patient characteristics. An important condition for these ‘big 
data’ to produce applicable evidence for patients with multimorbidity is that they will be 
sensibly organised for this purpose. Not only the capacity to collect data, but also the 
availability of appropriate methods to analyse them need to be well developed to result 
in an optimal benefit. The quantitative methods applied in this thesis, such as the clear 
definitions applied including a distinction between invariable and conditional chronicity; 
categorising diseases in clusters; and distinguishing between concordant and discordant 
comorbidity, may serve as a starting point for further developing such methods. 
Implications for guidelines
Research results inform clinical guidelines. Given the results in this thesis, the relative 
ignorance of (discordant) comorbidity in evidence-based diabetes guidelines is 
inappropriate and should be improved. Guidelines should better explicate how comorbidity 
may interfere with the management of chronic diseases and adjust recommendations 
accordingly. The findings in this thesis can give an incentive to this shift, although further 
investigation of associations between comorbidity, disease specific outcomes, and other 
patient characteristics is needed to justify concrete recommendations. It may contribute to 
the development of personalised chronic disease management, by formulating different 
therapeutic approaches that are appropriate, or should be prioritised, for patients with a 
specific comorbidity burden. 
If evidence justifying concrete comorbidity-specific recommendations in guidelines is 
not available, then this should be made explicit. It is important that guidelines start to 
better explain their external validity so that it is clear to what extent recommendations 
are covered. A disease-specific focus in evidence-based guidelines would in general be 
more promising when no or only concordant comorbidity exists, than when discordant 
comorbidity is present. Importance of personalisation of disease management for 
patients with discordant comorbidity (e.g., a patient with mental health problems and a 
malignancy plus a chronic respiratory disease) should receive more emphasis in guidelines. 
Current single disease guidelines provide numerous recommendations for patients 
with multimorbidity. Empirical suggestions from the second part of this thesis on how 
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to improve guidelines for patients with multimorbidity included the formulation of a 
ranking of importance in guideline recommendations when these add up if patients 
have multiple diseases. The abovementioned adjustments would help practitioners when 
assigning priorities in their care for patients with multimorbidity. 
Implications for practice
The diabetes case study showed that type 2 diabetes and COPD, both common chronic 
diseases with substantial combined occurrence, interfere with one another. The same 
applied for diabetes patients with comorbid musculoskeletal disease, an interaction 
possibly originating from a reduced ability of these patients to do physical exercise. 
Diabetes patients with comorbid cardiovascular disease showed to have consistent 
unfavourable courses of longitudinal systolic blood pressure from the diabetes onset 
onwards compared to diabetes patients without cardiovascular disease. In these cases 
of concordant comorbidity, concordant treatment strategies (all addressing metabolic / 
cardiovascular control) may be more important and more promising than in cases of 
discordant comorbidity. For the discordant types of comorbidity (e.g., diabetes and COPD, 
and diabetes and musculoskeletal disease), disease management needs to be more 
personalised. Ongoing research is needed to elaborate on the practical consequences 
of the specific associations found in the studies in this thesis. It is likely that future 
studies, describing other index-diseases than diabetes, will similarly result in an extensive 
co-occurrence of chronic diseases, and will show interactions between disease-specific 
outcomes. What needs to be added to the knowledge on multimorbidity, is if and 
how generic patient outcomes, such as quality of life, are influenced by the presence 
of comorbidity. Evidence lags behind in defining which approach suits best to which 
multimorbidity profile – and since the possible disease combinations are endless this is 
likely to remain the case. 
However, the observation in the quantitative part of this thesis that not just an increasing 
number of diseases negatively influenced long-term diabetes control parameters, but 
that specific types of comorbidity did, stresses that diabetes care provided by GPs is part 
of general healthcare. Patient-specific factors intervene in the care that is directed to 
‘whole persons’. With an increasing amount of morbidity, the complexity of providing 
healthcare to a particular patient increases. This was especially perceived by GPs when 
somatic and mental health conditions co-exist in a patient. The substantial presence of 
comorbidity in type 2 diabetes patients - as shown in this thesis - implies that managing 
one common chronic disease requires simultaneous management of comorbidity. Hence 
a ‘one-size-fits-all’ approach is insufficient. When multimorbidity exists, it is necessary to 
deviate from the single-disease focus, and to provide patient-centred care by following 
a specific patient’s needs. 
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Knowing that the evidence-base of guideline recommendations for patients with 
multimorbidity is often limited, preventative measures were considered inappropriate 
by GPs in many cases, especially when concerning older patients with multimorbidity. 
Based on the findings described in this thesis, adopting a reserved attitude towards 
preventative measures that are suggested in single disease guidelines seems sensible 
when these are administered to primary care patients with multimorbidity - as long as 
the evidence for expected benefits from these measures is insufficient for patients with 
multimorbidity, and care is provided in a patient-centred way. 
GPs’ empirical solutions to respond to the evidence gap for multimorbidity are to 
integrate clinical experience and a good ‘common sense’ with the best available 
evidence. This strategy is what defines ‘evidence-based medicine’, and it deserves more 
attention in clinical training. Also clinical decision making deserves more attention in 
doctors’ professional development. 
Providing patient-centred care to patients with multimorbidity helped GPs to counteract 
some potential pitfalls of multimorbidity, such as fragmentation of care. It may seem 
an obvious goal in the management of complex problems. However, to bring this into 
practice, advanced skills in communication and shared decision making are needed. Broad 
(generalist) medical knowledge needs to be complemented with the ability to integrate 
knowledge on diverse topics. By increasing the attention for these necessary skills, the 
care for patients with multimorbidity could be improved. This requires intensive training 
during medical education, and doctors’ personal dedication to provide continuous care. 
Post academic trainings for GPs on topics related to multimorbidity and complex care (for 
example, courses on polypharmacy or multidisciplinary case reviews) could be employed 
more frequently, and could supplement single disease guidelines, which have obvious 
shortcomings for multimorbidity.
In addition, for GPs to be able to provide sensible care to patients with multimorbidity, it 
demands from policymakers the flexibility and approval that GPs may deviate from single 
disease oriented management strategies in patients with multiple diseases, without 
negative financial consequences. 
Modern technology such as telemedicine, introduced for various specific conditions, 
improves quick access to healthcare64 and patients’ health behaviour and health status.65 
For patients with multimorbidity, ‘e-health’ could be of added value if it would address 
specific needs arising from multimorbidity. Patients with multimorbidity would like to 
make use of such tools in an integrated way, so that it covers not just the needs of 
one specific disease among their total disease burden.66 The technology should facilitate 
communication, enhance a shared decision making process, and improve coordination 
of care. Strategies have been developed to promote patient-centred aspects in primary 
care consultations with patients with multimorbidity.67 In future interventions, the core 
GENERAL DISCUSSION
7
133
values of primary care should be retained to optimise multimorbidity management.68, 69 
This means commitment to the person instead of a focus on specific diseases, continuity 
of care and responsibility, and clinical freedom allowing practitioners the flexibility to 
make difficult choices between competing priorities.70 
CONCLUSIONS
This thesis studied multimorbidity from the GP’s perspective. It showed a high pre-
valence and incidence density of comorbidity in type 2 diabetes, implying that the 
‘typical’ diabetes patient does not exist. Management of one chronic disease requires 
simultaneous management of comorbidity, both the concordant and the discordant types. 
Ongoing research is needed to further disentangle associations between specific types of 
comorbidity. Studies in this thesis described some distinct disease combinations affecting 
longitudinal diabetes control parameters under routine primary care circumstances. 
From the viewpoint of Dutch GPs, disease-specific guidelines do not sufficiently address the 
complexities occurring when patients have multimorbidity. A patient-centred approach 
is pursued in the management of multimorbidity, but contrasting with close adherence 
to current guidelines. Complementing evidence-based guideline recommendations with 
clinical experience and with knowledge of the individual patient, in a patient-centred 
way, is necessary for the care for patients with multimorbidity in primary care. 
Future research and guidelines should be improved so that they have better applicability 
for patients with multimorbidity. At the same time, necessary skills to bring the 
abovementioned recommendations into practice should be taught in medical training 
programmes. 
To summarise the implications for multimorbidity from the GP’s perspective: ongoing 
research is needed to gain better insight into patterns of comorbidity and their 
consequences for patients, both on disease-specific and on generic health outcomes. 
Yet practice is likely to remain ahead of science. Relevant and applicable evidence 
evolving for any multimorbidity profile is an unrealistic scenario. Precisely when there 
is multimorbidity, a patient-centred approach is important - focusing on the needs, 
preferences, and risks of a specific patient. Supported by a continuous relationship with, 
and knowledge of the patient, an accessible GP may be the designated professional to 
help the patient with multimorbidity navigate through the abundance of diagnostic and 
therapeutic options, and help to prioritise options in order to establish the best ‘fit’ to a 
particular patient’s situation. 
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SUMMARY
This mixed methods thesis described multimorbidity in primary care with a focus on the 
general practitioner’s (GP’s) perspective. The aims were:
- To describe the prevalence and incidence density of comorbidity in type 2 diabetes 
patients. 
- To explore the long-term associations between comorbidity and longitudinal diabetes 
control parameters in type 2 diabetes. 
- To study the considerations and main aims of GPs in their care for patients with 
multimorbidity, and to explore factors influencing their management of multi-
morbidity.
- To explore how GPs value guidelines when applied to patients with multimorbidity, 
and which benefits and barriers they experience from adherence to guidelines in 
these patients. 
In the first part of this thesis, associations between type 2 diabetes and chronic comor-
bid diseases were described as a case study. In the second part of this thesis, GPs’ 
experiences with and solutions for multimorbidity in daily practice were explored.
Chapter 1 gave an introduction to the theme of multimorbidity. It sketched some pro -
blems arising from multimorbidity on the patient and the practice level. The description 
of the evolvement of knowledge on multimorbidity in the research field and the remaining 
gaps in knowledge led to the formulation of the research questions for this thesis. 
Chapter 2 reported the prevalence and incidence density of a full range of chronic 
comorbid diseases in a representative cohort of type 2 diabetes patients in primary care. 
Both concordant (related - that is, cardiovascular) and discordant (unrelated) comorbidity 
were shown to be very common. Once diabetes is diagnosed, almost 85% of these 
patients had one or more other chronic diseases, and after excluding the concordant 
cardiovascular diseases this was still over 70% of patients. A high comorbidity burden 
(defined as three or more additional diseases on top of the diabetes) was present in 
approximately a half or a quarter of the diabetes patients when any type of comorbidity, or 
discordant comorbidity only was counted, respectively. In the first year after the diabetes 
diagnosis, a first comorbid disease was diagnosed in a quarter of the patients who had 
no comorbidity during the diabetes diagnosis. Only chronic diseases were counted as 
comorbidity. For those diseases that may but do not need to follow a chronic course, such 
as gout or migraine, chronicity was identified on the patient level based on information 
from patients’ electronic medical record. Diseases were categorised in disease clusters, 
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based on the ICPC-classification with separate clusters for malignancies and infectious 
diseases. Prevalence and incidence density of comorbidity was also calculated for disease 
clusters. Highest prevalence rates at the time of the diabetes diagnosis were reported for 
cardiovascular diseases (64%) and musculoskeletal diseases (31%). This study showed 
that the diabetes patient population is heterogeneous in terms of comorbidity, and that 
the diabetes patient without (discordant) comorbidity is relatively rare. Consequently, 
the relative ignorance of (discordant) comorbidity in evidence-based diabetes guidelines 
is inappropriate. Guidelines should better explicit how comorbidity may interfere with 
diabetes management, which may be the case for discordant comorbidity especially, and 
should adjust recommendations accordingly. 
In the same primary care cohort of patients with type 2 diabetes, Chapter 3 explored 
the associations between longitudinal diabetes control parameters and the number and 
specific types of chronic comorbidity. A mixed model analysis technique was applied to 
compare longitudinal trends of HbA1c and systolic blood pressure (SBP) during five years 
of follow-up between groups of diabetes patients with different comorbidity profiles. 
The simple sum of comorbid diseases did not show an unfavourable association with 
diabetes control parameter trends over five years, but specific types of comorbidity did. 
Diabetes patients with comorbid musculoskeletal disease had statistically significantly 
higher HbA1c values after five years, with lower values around the diabetes diagnosis, 
compared to patients without comorbid musculoskeletal disease. Diabetes patients 
with comorbid cardiovascular disease had significantly sustained elevated values of 
SBP from the diabetes diagnosis onwards, compared to diabetes patients without 
comorbid cardiovascular disease. The number of comorbid diseases was significantly 
associated with the five year trend of SBP (not that of HbA1c), with highest values 
after five years for diabetes patients without comorbidity, and effect modification 
by socioeconomic status. Causal relations cannot be inferred from the explorative, 
observational design of this study. It was hypothesised that the reduced ability for 
physical exercising could explain the increasing HbA1c values over five years among 
the patients with comorbid musculoskeletal disease, and that the concordance of the 
cardiovascular comorbidity explained the results among this comorbidity group on the 
longitudinal SBP outcomes. The observation that not just the sum of diseases negatively 
influenced the course of diabetes control parameters, but that this did occur under 
presence of specific types of comorbidity, emphasised that the diabetes care provided 
by GPs is part of general healthcare delivered to ‘whole persons’, i.e. ‘person-centred 
care’. Apparently, the patient-specific context intervened. GPs integrated disease-
specific and generic patient characteristics and treatment goals as part of diabetes-
specific care. After further investigation of the patterns observed, these findings may 
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contribute to the development of personalised diabetes management by formulating 
different therapeutic approaches that are appropriate for diabetes patients with a 
specific comorbidity burden. 
In Chapter 4, associations between comorbid COPD and longitudinal diabetes control 
parameters over five years of follow-up were explored in the type 2 diabetes patients 
cohort. Trends in HbA1c and SBP were compared with mixed model analyses between 
patients with and without comorbid COPD. Subgroup effect analyses explored potential 
effect modification of these trends (according to presence or absence of COPD) by 
age, sex, body mass index, and socioeconomic status. It showed that diabetes patients 
with comorbid COPD have different trends of SBP over five years compared to diabetes 
patients without COPD, an effect that was modified by socioeconomic status and body 
mass index. In contrast to diabetes patients without COPD, in whom an increasing body 
mass index is associated with increasing SBP levels, the trend of SBP in diabetes patients 
with comorbid COPD is defined more by the socioeconomic status than by the body 
mass index. Type 2 diabetes and COPD, both common chronic diseases with substantial 
combined occurrence, interfere with one another. Ongoing research is needed to further 
disentangle the complex associations between comorbidity of diabetes, COPD, diabetes 
control parameters, and the other patient characteristics; and to define how this translates 
into practical recommendations. It is clear however that the interference of these two 
common chronic diseases deserves attention from healthcare professionals taking care 
of patients with either disease, and that comorbidity needs to be recognised as a patient 
characteristic with possible influence on disease-specific outcomes of an index-disease.
The second part of this thesis contained qualitative research. A focus group study 
was performed with a purposive sample of Dutch GPs to ensure heterogeneity in 
characteristics such as age, sex, and urbanisation among the participants. Exploration 
of their considerations and main objectives in the management of multimorbidity, and 
factors influencing this management was the first aim. Second aim was to explore how 
GPs value guidelines when applied to patients with multimorbidity, and which benefits 
and barriers they experience from adherence to guidelines in these patients. In the 
iterative qualitative process, in which data collection and analysis alternate, the insight 
grew that discussions on the role of guidelines, applied to patients with multimorbidity, 
provided important information meriting deeper exploration on itself. This resulted in 
formulating the second, separate research question. The focus groups were guided by 
an experienced moderator, who used an interview guide. Interviews were transcribed 
verbatim. Data collection proceeded until saturation was reached. Data analysis was 
performed by two researchers using the constant comparison analysis technique. 
SUMMARY
8
143
Separate qualitative analyses were performed considering the two distinct research 
questions.
Chapter 5 described that applying a patient-centred approach is the main aim of GPs 
in their care for patients with multimorbidity. By individualising decisions and placing 
medical considerations in a broader perspective, they adjust their care to the specific 
person in front of them. Delivering integrated care helps to prevent fragmentation 
of care, which was identified by the participating GPs as an important risk when 
patients have multimorbidity. The existence of a personal relationship between doctor 
and patient, built over time, helps in the complex management of patients with 
multimorbidity, and may facilitate shared decision making. The combined presence 
of somatic and mental health conditions was especially perceived as a difficult 
combination in patients with multimorbidity, since diagnosis and management of 
somatic and mental health conditions may mutually influence one other. Applying a 
patient-centred approach helps to counteract some potential pitfalls of multimorbidity, 
but demands the flexibility to deviate from disease-specific management strategies in 
patients with multiple diseases. 
In Chapter 6 it was described that guidance from guidelines was appreciated in 
general by GPs, but that they were perceived as insufficient to guide the complex care 
needed for patients with multimorbidity. They do not provide sufficient opportunity 
to take account of patients’ personal circumstances, which was perceived as highly 
important in the care for patients with multimorbidity. Especially for the older patients 
with multimorbidity, preventative measures, often recommended in evidence-based 
guidelines, were considered inappropriate in many cases. GPs doubted the applicability 
of guidelines for patients with multimorbidity. GPs described that they complement 
the gaps in applicability and usefulness of guidelines for patients with multimorbidity 
by using their common sense. They formulated suggestions how the applicability of 
guidelines for patients with multimorbidity could be improved, for example by making 
a ranking of importance in guideline recommendations appropriate for (specific groups 
of) patients with multimorbidity. GPs practice evidence-based medicine for patients with 
multimorbidity by integrating clinical experience with the best available evidence. 
Chapter 7 gave an overview of the results, and discussed the interpretation of the overall 
findings in this mixed methods thesis. It furthermore described the relevance of these 
findings in relation to the existing literature and addressed methodological issues. The 
implications from this thesis for research, guidelines and practice were discussed. It was 
concluded that more research is needed to gain better insight into patterns of comorbidity 
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and their consequences for patients, both on disease-specific and on generic outcomes. 
The primary care setting may be an ideal setting for ongoing research in multimorbidity 
since it can produce representative results. Blanks in relevant and applicable evidence 
for patients with multimorbidity will probably remain, and therefore it is important to 
provide patient-centred care to patients with multimorbidity, focusing on the needs, 
preferences, and risks of a specific patient. GPs may be perfectly suited to help a patient 
assign priorities, and to provide individualised, integrated, continuous care to patients 
with multimorbidity.
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Dit proefschrift beschreef multimorbiditeit in de eerste lijn met een focus op het perspectief 
van de huisarts. Er werd gebruik gemaakt van mixed methods. De doelstellingen waren:
- Het beschrijven van de prevalentie en incidentiedichtheid van comorbiditeit bij 
patiënten met diabetes type 2. 
- Het exploreren van associaties tussen comorbiditeit en longitudinale diabetes 
controleparameters op de lange termijn bij patiënten met diabetes type 2. 
- Het bestuderen van de overwegingen en belangrijkste doelen van huisartsen in hun 
zorg aan patiënten met multimorbiditeit, en het exploreren van factoren die hun 
handelen bij multimorbiditeit beïnvloeden. 
- Het exploreren van de waarde die huisartsen toekennen aan richtlijnen als deze 
toegepast worden op patiënten met multimorbiditeit, en van de voordelen en 
belemmeringen die zij ervaren van het opvolgen van richtlijnen bij deze patiënten. 
In het eerste deel van dit proefschrift werden de associaties tussen diabetes type 2 en 
chronische comorbide aandoeningen als een ‘case study’ beschreven. In het tweede 
deel van dit proefschrift werden de ervaringen van huisartsen met, en oplossingen in de 
dagelijkse praktijk voor het omgaan met multimorbiditeit beschreven. 
In Hoofdstuk 1 werd een introductie op het thema multimorbiditeit gegeven. Diverse 
problemen voortkomend uit multimorbiditeit werden geschetst, zowel voor patiënten 
als voor de praktijkvoering. De beschrijving van de ontwikkeling van kennis over 
multimorbiditeit in het onderzoeksveld en de resterende kennishiaten leidden tot de 
formulering van de onderzoeksvragen van dit proefschrift.
Hoofdstuk 2 beschreef de prevalentie en incidentiedichtheid van een grote verscheiden-
heid aan chronische comorbide aandoeningen in een representatief cohort van patiënten 
met diabetes type 2 in de eerste lijn. Hieruit bleek dat zowel concordante (gerelateerde, 
dat wil zeggen, cardiovasculaire) en discordante (ongerelateerde) comorbiditeit veelvuldig 
voorkwam. Op het moment dat diabetes werd vastgesteld had bijna 85% van deze 
patiënten een of meer andere chronische aandoeningen, en na exclusie van concordante 
cardiovasculaire aandoeningen gold dit nog voor ruim 70% van de patiënten. Uitgebreide 
comorbiditeit, gedefinieerd als drie of meer ziektes naast de diabetes, was aanwezig bij 
circa de helft of een kwart van de diabetespatiënten, wanneer alle soorten, respectievelijk 
alleen discordante comorbiditeit werd meegeteld. In het eerste jaar na de diabetes 
diagnose werd een eerste comorbide aandoening gediagnosticeerd bij een kwart van 
de patiënten die ten tijde van de diabetes diagnose nog geen comorbiditeit hadden. 
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Alleen chronische aandoeningen werden als comorbiditeit geteld. Voor ziektes die een 
chronisch beloop kunnen, maar niet hoeven te hebben, zoals jicht of migraine, werd 
chroniciteit op patiëntniveau vastgesteld, gebaseerd op informatie uit het elektronisch 
medisch dossier van patiënten. Ziektes werden gecategoriseerd in ziekteclusters, 
gebaseerd op de ICPC-classificatie, met aparte clusters voor oncologische en infectieuze 
aandoeningen. Prevalentie en incidentiedichtheid van comorbiditeit werd ook berekend 
voor ziekteclusters. De hoogste prevalenties ten tijde van de diabetes diagnose werden 
gevonden voor cardiovasculaire (64%) en musculoskeletale aandoeningen (31%). Deze 
studie liet zien dat de diabetespopulatie heterogeen is in termen van comorbiditeit, en 
dat de diabetespatiënt zonder (discordante) comorbiditeit relatief zeldzaam is. Daarom 
is de nagenoeg afwezige aandacht voor (discordante) comorbiditeit in evidence-based 
richtlijnen onterecht. Richtlijnen moeten beter kenbaar maken hoe comorbiditeit kan 
interfereren met de behandeling van diabetes – wat met name het geval kan zijn bij 
discordante comorbiditeit – en zouden hun aanbevelingen hierop moeten aanpassen. 
In hetzelfde eerstelijns cohort van patiënten met diabetes type 2 werden in Hoofdstuk 3 
de associaties tussen longitudinale diabetes controleparameters, en het aantal en 
speci fieke soorten van comorbiditeit geëxploreerd. Met behulp van een mixed model 
analyse techniek werden longitudinale trends van HbA1c en systolische bloeddruk 
(SBD) gedurende vijf jaar follow-up vergeleken tussen groepen diabetespatiënten met 
verschillende comorbiditeit profielen. De simpele som van comorbide aandoeningen 
liet geen ongunstige associatie met de trends van diabetes controleparameters over vijf 
jaar zien, maar bepaalde soorten comorbiditeit wel. Diabetespatiënten met comorbide 
musculoskeletale aandoeningen hadden statistisch significant hogere HbA1c waarden 
na vijf jaar, met lagere waarden ten tijde van de diabetes diagnose, vergeleken met 
patiënten zonder musculoskeletale aandoeningen. Diabetespatiënten met comorbide 
cardiovasculaire aandoeningen hadden significant verhoogde waarden van de SBD, 
aan houdend vanaf de diabetes diagnose, in vergelijking met patiënten zonder 
comorbide cardiovasculaire aandoeningen. Het aantal comorbide aandoeningen was 
significant geassocieerd met de trend van SBD (niet die van HbA1c) over vijf jaar, met 
de hoogste waarden na vijf jaar bij diabetespatiënten zonder comorbiditeit, en met 
effectmodificatie door de socio-economische status. Uit het exploratieve, observationele 
design van deze studie kunnen geen causale verbanden worden afgeleid. Verondersteld 
werd dat de verminderde mogelijkheid tot fysieke inspanning de verklaring kon zijn 
voor de oplopende HbA1c waardes over vijf jaar bij de patiënten met comorbide 
musculoskeletale aandoeningen, en dat de concordantie van cardiovasculaire comor-
biditeit de resultaten van deze patiëntengroep op de longitudinale SBD uitkomsten 
verklaarde. De vaststelling dat niet slechts de som der ziektes een negatieve invloed 
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op de diabetes controleparameters had, maar aanwezigheid van specifieke typen 
comorbiditeit wel, benadrukt dat de diabeteszorg die door huisartsen geleverd wordt 
onderdeel is van algemene gezondheidszorg gericht op ‘personen als geheel’, dat wil 
zeggen ‘persoonsgerichte zorg’. Blijkbaar intervenieerde de patiënt-specifieke context. 
Huisartsen integreerden ziekte-specifieke en generieke patiëntkarakteristieken en 
behandeldoelen in de zorg voor diabetes. Na vervolgonderzoek van de geobserveerde 
patronen kunnen deze bevindingen bijdragen aan de ontwikkeling van gepersonaliseerde 
diabetesbehandeling, door verschillende behandelmogelijkheden te formuleren die 
passend zijn voor diabetespatiënten met een specifiek comorbiditeit profiel. 
In Hoofdstuk 4 werden in het cohort met diabetes type 2 patiënten associaties tussen 
comorbide COPD en longitudinale diabetes controleparameters gedurende vijf jaar follow-
up geëxploreerd. Met mixed model analyses werden trends in HbA1c en SBD vergeleken 
tussen patiënten met en zonder comorbide COPD. Met subgroep effect analyses werd, 
onder aan- of afwezigheid van COPD, potentiële effectmodificatie van deze trends 
door leeftijd, geslacht, body mass index en socio-economische status geëxploreerd. 
Gevonden werd dat diabetespatiënten met comorbide COPD andere trends van SBD 
over vijf jaar hadden dan patiënten zonder COPD, met effectmodificatie door socio-
economische status en body mass index. In tegenstelling tot diabetespatiënten zonder 
COPD, bij wie een hogere body mass index geassocieerd was met hogere SBD waarden, 
werd bij diabetespatiënten met comorbide COPD de SBD trend meer door de socio-
economische status dan door de body mass index bepaald. Diabetes type 2 en COPD, 
twee veel voorkomende chronische aandoeningen met een substantieel gecombineerd 
optreden, interfereren met elkaar. Vervolgonderzoek is nodig om de complexe associaties 
tussen comorbiditeit bij diabetes en COPD, diabetes controleparameters en overige 
patiëntkarakteristieken verder te ontrafelen; en om vast te stellen hoe deze vertaald 
dienen te worden naar praktische aanbevelingen. Wat duidelijk is, is dat de interactie 
tussen deze twee veel voorkomende aandoeningen aandacht van zorgprofessionals 
die zorg dragen voor patiënten met deze aandoening(en) vereist, en dat comorbiditeit 
erkend moet worden als een patiëntkarakteristiek met mogelijke invloed op ziekte-
specifieke uitkomstmaten van een index-ziekte.
Het tweede deel van dit proefschrift bevatte kwalitatief onderzoek. Een focusgroep 
studie werd uitgevoerd met een ‘purposive sample’ van Nederlandse huisartsen om 
heterogeniteit in karakteristieken als leeftijd, geslacht en urbanisatie onder de deelnemers 
te verkrijgen. Het eerste doel was te exploreren wat hun overwegingen en belangrijkste 
doelen in de zorg voor patiënten met multimorbiditeit zijn, en factoren die dit handelen 
beïnvloeden. Verkennen van de waarde die huisartsen aan richtlijnen toekennen als 
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deze worden toegepast op patiënten met multimorbiditeit, en welke voor- en nadelen 
zij ervaren van het volgen van de richtlijnen bij deze patiëntengroep, was het tweede 
doel. Tijdens het iteratieve kwalitatieve proces, waarbij dataverzameling en analyse 
elkaar afwisselen, groeide het inzicht dat discussies over de rol van richtlijnen, toegepast 
op patiënten met multimorbiditeit, belangrijke informatie opleverden die op zichzelf 
nadere exploratie verdiende. Dit resulteerde in het formuleren van de tweede, separate 
onderzoeksvraag. De focusgroepen werden geleid door een ervaren moderator die 
gebruik maakte van een interview guide. Interviews werden verbatim getransscribeerd. 
Dataverzameling werd gecontinueerd totdat saturatie was bereikt. Analyse van de data 
werd uitgevoerd door twee onderzoekers die gebruik maakten van de analysemethode 
met constante vergelijking. Voor de twee verschillende onderzoeksvragen werden aparte 
analyses uitgevoerd. 
In Hoofdstuk 5 werd beschreven dat het hoofddoel van huisartsen bij hun zorgverlening 
aan patiënten met multimorbiditeit het aanwenden van een patiëntgerichte benadering 
is. Door beslissingen te individualiseren en medische overwegingen in een breder 
perspectief te plaatsen, stemmen zij hun zorg af op de specifieke patiënt tegenover hen. 
Het verlenen van geïntegreerde zorg helpt om versnippering, wat door de deelnemende 
huisartsen werd aangemerkt als een belangrijk risico bij multimorbiditeit, te voorkomen. 
Aanwezigheid van een persoonlijke relatie tussen arts en patiënt die door de jaren heen 
is opgebouwd helpt bij de complexe zorg voor patiënten met multimorbiditeit, en kan 
shared decision making faciliteren. Het bestaan van zowel somatische als psychische 
aandoeningen tegelijkertijd werd ervaren als een moeilijke combinatie, aangezien de 
diagnostiek en behandeling van somatische en psychische aandoeningen elkaar over 
en weer kunnen beïnvloeden. Het toepassen van een patiëntgerichte benadering helpt 
om een aantal potentiële valkuilen bij multimorbiditeit te voorkomen, maar vereist de 
flexibiliteit om een ziektegerichte benadering te verlaten bij patiënten met meerdere 
ziektes. 
Hoofdstuk 6 beschreef dat sturing uit richtlijnen in het algemeen werd gewaardeerd door 
huisartsen, maar dat richtlijnen als niet toereikend werden ervaren om de complexe zorg 
die nodig is bij multimorbiditeit te kunnen bieden. Ze bieden onvoldoende mogelijkheid 
om rekening te houden met de persoonlijke omstandigheden van patiënten, en dit werd 
juist als zeer belangrijk ervaren in de zorg voor patiënten met multimorbiditeit. Met 
name voor oudere patiënten met multimorbiditeit werden preventieve maatregelen, 
die vaak worden aanbevolen in evidence-based richtlijnen, nogal eens als ongepast 
beschouwd. Huisartsen twijfelden aan de toepasbaarheid van richtlijnen voor patiënten 
met multimorbiditeit. Ze beschreven dat zij hiaten in bruikbaarheid en toepasbaarheid 
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van richtlijnen voor patiënten met multimorbiditeit aanvullen door hun gezonde verstand 
te gebruiken. Huisartsen gaven suggesties hoe de toepasbaarheid van richtlijnen voor 
patiënten met multimorbiditeit verbeterd zou kunnen worden, bijvoorbeeld door een 
hiërarchie aan te brengen in het belang van de aanbevelingen in richtlijnen die van 
toepassing zijn voor (specifieke groepen van) patiënten met multimorbiditeit. Door 
klinische ervaring met het best beschikbare bewijs te combineren, passen huisartsen 
evidence-based medicine toe bij patiënten met multimorbiditeit.
Hoofdstuk 7 gaf een overzicht van de resultaten uit dit proefschrift en besprak de 
interpretatie van de bevindingen, die met behulp van mixed methods werden 
verkregen. Ook werd de relevantie van deze bevindingen in relatie tot de bestaande 
literatuur beschreven en werden methodologische kwesties besproken. De betekenis 
voor onderzoek, richtlijnen en praktijk werd besproken. Geconcludeerd werd dat meer 
onderzoek nodig is om beter inzicht te verkrijgen in de patronen van comorbiditeit en 
de consequenties hiervan voor patiënten, zowel op ziekte-specifieke als op generieke 
uitkomstmaten. De eerste lijn kan een ideale setting zijn voor aanhoudend onderzoek naar 
multimorbiditeit omdat hier representatieve resultaten verkregen kunnen worden. Hiaten 
in relevante en toepasbare wetenschappelijke kennis voor patiënten met multimorbiditeit 
zullen waarschijnlijk blijven bestaan. Daarom is het belangrijk om patiëntgerichte zorg te 
verlenen aan patiënten met multimorbiditeit, die zich richt op de behoeften, voorkeuren 
en risico’s van een specifieke patiënt. Huisartsen zijn goed toegerust om een patiënt te 
helpen bij het stellen van prioriteiten, en om geïndividualiseerde, geïntegreerde, continue 
zorg te verlenen aan patiënten met multimorbiditeit.
SAMENVATTING
153

Dankwoord
DANKWOORD
156
DANKWOORD
Het doorlopen van dit promotietraject is teamwork geweest. De steun van de volgende 
mensen is hierbij heel belangrijk geweest voor mij.
Beste Chris, velen voor mij hadden de eer om bij je te mogen promoveren, en ruim 
na je emeritaat valt ook mij dit genoegen ten deel. Je hebt de gave om precies op 
het goede moment de juiste dingen te zeggen. Je feedback was altijd constructief en 
ontzettend snel, ongeacht waar ter wereld je je bevond. Je internationale reputatie, 
je wetenschappelijke verdiensten en je netwerk zijn indrukwekkend. Dank dat ik daar 
deelgenoot van mocht zijn, en dank voor het vertrouwen dat je me gaf om mijn eigen 
promotietraject uit te stippelen.
Beste Toine, jouw bevlogenheid is inspirerend. Je bent een betrokken huisarts en in deze 
rol ben je altijd een voorbeeld voor me geweest. Maar daarnaast was jij degene die 
me heeft aangezet om onderzoek te gaan doen. Het begon met een klein projectje en 
bleek de aanzet tot een promotietraject. Je jarenlange praktijkervaring, waaronder die 
met multimorbiditeit, en je kennis van de CMR zijn hierbij zeer waardevol geweest. Ik 
bewonder je tomeloze energie en je scherpe geheugen, en ik waardeer je betrokkenheid, 
je benaderbaarheid en je nooit aflatende attentie.
Beste Tjard, jij bent de rode draad door mijn promotietraject. Je bent een echte 
wetenschapper. Je leerde mij te beginnen bij het begin, en wanneer dat halverwege 
nodig was weer een stapje terug te zetten. Als het tegenzat wist jij me ervan te overtuigen 
dat dat erbij hoort en dat het met doorzetten weer goed zou komen, en je hebt gelijk 
gekregen. Dank voor de grote steun die je voor me bent geweest en voor je vertrouwen 
in me.
Beste Marion, jouw analytische blik en methodologische kennis zijn onmisbaar geweest 
bij de complexe studies die we gedaan hebben. Op de momenten dat het nodig was hielp 
je me vooruit, en wanneer dat kon bood je me de ruimte om zelfstandig beslissingen te 
nemen. Dank voor je altijd waardevolle adviezen.
Beste Hans, zonder jouw hulp was dit proefschrift er nooit geweest. Ik heb al vaker 
gezegd dat je je gewicht in goud waard bent. Vanaf het begin van mijn promotietraject 
heb je me bijgestaan. Eerst door me wegwijs te maken in SPSS, vervolgens in de CMR, en 
uiteindelijk heb je me geleerd wat een mixed model analyse is. Heel wat uurtjes bracht 
ik op je kamer door. Samen broedden we op nieuwe analyses om onze vragen mee te 
kunnen beantwoorden. Het was soms uiterst complex en vaak genoeg moest iets over, 
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maar nooit was een vraag van mij te gek en altijd was je bereid tot geduldige uitleg. 
Ontzettend bedankt hiervoor.
Beste Wim, als ‘diabetesman’ van de afdeling en grondlegger van de NMP raakte jij al 
in een vroege fase betrokken bij mijn promotietraject en jouw kennis bleek onmisbaar. 
Dank voor je waardevolle input en je persoonlijke adviezen.
Beste Peter, jij hebt me op weg geholpen in het kwalitatief onderzoek en hield daarbij 
altijd het belang van het onderzoek voor de dagelijkse praktijk voor ogen. Je bent een 
huisarts pur sang, en een betere moderator voor onze focusgroepen hadden we niet 
kunnen hebben. Ondanks dat we nooit een kamer hebben gedeeld en vaak zelfs niet 
eens een werkdag, was je betrokkenheid altijd merkbaar.
Dear members of the Doctoral Thesis Committee, thank you for the effort to evaluate my 
thesis. I am looking forward to our discussions during my defence.
Special thanks to Professor Mercer and your colleagues for a most hospitable welcome 
in Scotland last year, and for our fruitful discussions on multimorbidity.
Ook de overige opponenten wil ik graag bedanken voor het werk ter voorbereiding op 
mijn verdediging. 
Dank aan alle huisartsen die hebben deelgenomen aan de focusgroepen. De discussies 
waren heerlijk, echt huisartsgeneeskunde op zijn best. Ze zijn van enorme waarde 
geweest bij het tot stand komen van dit proefschrift.
De CMR en NMP praktijken hebben in de afgelopen decennia een schat aan data 
verzameld. Dit proefschrift is het bewijs dat al deze extra inspanningen echt ergens toe 
leiden! Dank aan alle praktijkmedewerkers en patiënten die hieraan hebben bijgedragen.
Dames van het secretariaat, jullie deur staat letterlijk altijd open. Twanny, Tilly, Marike, 
Loes, Annelies, dank voor jullie nooit aflatende hulp en goede humeur. Tilly, zonder jouw 
hulp met het bundelen en versturen van het manuscript tijdens mijn verlof had ik hier 
niet vandaag gestaan.
Als je een aantal jaren meedraait op een grote afdeling waar ook lustig verhuisd wordt 
ben je aan het eind van een promotietraject heel wat (oud)kamer- en ganggenoten rijker. 
Dank voor de koffie, taart, lunches en gezellige praatjes.
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De ‘eerste generatie’ aiotho’s wil ik bedanken voor het uitvinden van het wiel en de 
goede adviezen aan de ‘tweede generatie’ waartoe ik mezelf reken. Mede-aiotho’s ‘van 
mijn lichting’, door onze immer wisselende aanwezigheid, volle agenda’s en verspreide 
werkplekken zagen we elkaar veelvuldig óf zelden, maar het was altijd fijn om van 
gedachten te wisselen met gelijkgestemden! Wouter, jij was mijn maatje van het eerste 
uur, altijd behulpzaam en geïnteresseerd. Maartje, het was fijn om met jou samen de 
focusgroepen te analyseren, dank daarvoor. Sabine, ik ken weinig mensen die zo attent 
zijn als jij. Eerst wisselden we ervaringen uit over de combi onderzoek en opleiding en 
daarna leende je me je zwangerschapskleding.
Doordat mijn promotie-onderwerp nou juist niet in een van de oorspronkelijke 
onderzoekslijnen paste dreigde ik reddeloos verloren te raken. Dank aan de astma / 
COPD onderzoeksgroep dat jullie mij hebben geadopteerd!
Om onderzoek te kunnen doen naar multimorbiditeit in de huisartspraktijk moet je weten 
hoe het er in die praktijk aan toe gaat. En wat is het vak van de huisarts toch prachtig. 
Wessel, met groot enthousiasme begon je eraan mij te leren kijken en denken als een 
huisarts. Erna en Charles, jullie mochten die ‘klus’ afmaken. Ik ben blij dat ik drie opleiders 
heb getroffen bij wie het huisartsenbloed door de aderen stroomt en met wie ik veel van 
gedachten heb kunnen wisselen over de zorg voor mensen die van alles mankeren. Dank 
voor de ruimte die jullie me hebben geboden mijn opleiding te combineren met onderzoek 
doen. Erna en Charles, wat leuk dat we uiteindelijk HAGRO collega’s zijn geworden!
Ook aan de SBOH en VOHA medewerkers ben ik dank verschuldigd voor het faciliteren 
van het aiothotraject. Het plannen hiervan moet soms een onmogelijke klus zijn geweest!
Mijn collega’s in de praktijk, wat is het een feest en een voorrecht om met jullie te werken. 
Agnes, Bernadette, Aniek, Dominique, Marije, Saskia, Esmee, Marloes, Sacha, Jolanda, 
Tine, Carla en Karin, we registreren er iedere dag op los, maar de patiëntenzorg staat 
altijd voorop. Floris, Rogier, Henk, Harriët en Julian. Lieve collega’s, beste maten, ik voel me 
vereerd dat ik, zwanger en wel, met jullie kon associëren in deze prachtige praktijk. Nota 
bene de praktijk die de basis vormde voor een groot deel van het onderzoek in dit proef-
schrift. Dank voor de ruimte die jullie me bieden en jullie collegialiteit. Nynke, ook al treffen 
we elkaar zelden op de werkvloer, ook met jou is het altijd fijn samenwerken. Noortje, 
dank dat ik de praktijk zorgeloos in jouw handen kon achterlaten tijdens mijn verlof.
Volleybal, I love it! Een beter medicijn in stressvolle tijden dan een lekker potje ballen 
bestaat er niet. Lieve teamies en trainers van de afgelopen jaren, dank voor de 
broodnodige afleiding en de gezelligheid buiten de lijnen.
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Dames ’01, lieve Marije, Anne-Els, Saskia, Lenny, Desirée, Hilde, Yvette en Lotte. 
We begonnen tegelijkertijd aan geneeskunde, inmiddels hebben we al een aardige 
gezamenlijke kroost, een mooi scala aan specialismen, en een klein stapeltje proefschriften 
(in wording). Daar tussenin zijn er ontzettend veel feestjes, borrels, theekransjes, 
weekendjes en sportieve activiteiten geweest, en ik hoop dat we daar nog lang mee 
doorgaan. Dank voor jullie vriendschap en luisterend oor. 
Ook de heren (en dames) die ik via Stefan tot onze vriendenkring mag rekenen wil ik 
danken voor de gezellige uurtjes die het leven zo veel aangenamer maken.
Lieve familie Bouwense, een fijnere schoonfamilie kan ik me niet wensen. Jullie zijn mijn 
tweede thuis geworden. Dank voor jullie steun en betrokkenheid.
Lotte en Yvette, mijn lieve paranimfen. Wat is het een genot om te weten dat sommige 
mensen er altijd zullen zijn. Of jullie nu allebei aan de andere kant van de A2 wonen 
of niet! We hebben al zo veel gedeeld samen. Nu ons leven serieus volwassen vormen 
aanneemt gaat daar ongetwijfeld nog veel moois bij komen. De gedachte dat jullie 
vandaag naast mij staan stelt mij gerust. Dank jullie wel!
En wat is het toch een rijkdom om lieve familie te hebben. Ik hoop nog lang van jullie 
te mogen genieten. Ik ben trots om nog twee oma’s en een opa te hebben. Het zou 
fantastisch zijn als het lukt om er vandaag bij te zijn, maar ook zonder dat weet ik dat 
jullie mee genieten. Een promotietraject klonk misschien soms wat abstract. Ome Jan, als 
‘peetoom’ heb je altijd en overal meegeleefd. Lianne, ook jij bent er op grote momenten 
altijd bij. Dank jullie wel. 
Anke, de liefste zus ben jij! Jouw eigen drukke leven heeft het precies volgen van mijn 
bezigheden nooit in de weg gestaan. Ik hoop op veel nieuwe quality time samen nu er 
in ieder geval in mijn agenda wat meer ruimte komt. Martijn, met jou aan Anke’s zijde 
heb ik er een fijne zwager bij. Dank voor jullie support.
Lieve pap en mam, aan jullie heb ik alles te danken! Zonder de basis die jullie me gegeven 
hebben was ik nooit geweest waar ik nu sta. Ik heb van jullie alle ruimte gekregen om 
me te ontwikkelen. Altijd hebben jullie me gesteund en zijn jullie er voor me geweest. 
Wat mooi om deze dag samen te kunnen vieren!
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Lieve Joost, niemand was zo dicht bij mij als jij terwijl ik dit boekje afrondde. Je hebt 
precies lang genoeg op je laten wachten om alles net voor jouw komst in te leveren. We 
genieten enorm van jou en dat zal vast alleen maar meer worden. Nu ‘de promoties’ 
achter de rug zijn gaan we daar gelijk mee beginnen op onze eerste vakantie met zijn 
drietjes!
Lieve Stefan, mijn grootste steun in dit promotietraject was jij, maar jij bent zo veel meer 
dan dat. We zijn een goed team samen en halen het beste in elkaar boven. Maar bovenal 
ben jij degene met wie ik eerst de wereld wil ontdekken en dan rustig oud wil worden. 
Wat heerlijk dat het gelukt is om samen deze fase van ons leven af te ronden. Het smaakt 
naar veel meer moois samen!
DANKWOORD
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CHRONIC DISEASES (‘OBLIGATORY CHRONIC DISEASES’)
Total number: 67
E-list code Disease ICPC equivalent
0044 HIV; AIDS B90
0500 Cancer of the mouth / pharynx D77.02, D77.03, R85
0510 Oesophageal cancer D77.01
0520 Cancer of the stomach D74
0530 Colon cancer D75
0540 Rectal cancer D75
0550 Pancreatic cancer D76
0560 Laryngeal / throat cancer R85
0570 Lung / bronchial cancer R84
0580 Breast cancer X76
0590 Uterine cervical cancer X75
0600 Endometrial cancer X77.01
0610 Prostate cancer Y77
0620 Bladder cancer U76
0632 Ovarian cancer X77.02
0639 Genitourinary cancer, other U75, U77, X77, Y78
0650 Brain cancer / tumour N74
0660 Hodgkin disease B72.01
0670 Leukaemia B73
0681 Lymphoma / multiple myeloma B74.01
0682 Metastases; unknown origin A79
0689 Carcinoma, other D77.04, L71, T71, W72
0640 + 0641  
+ 0642 + 0649
Skin cancer S77
0890 Hypothyroidism T86
1101 Pernicious anaemia B81.02
1141 Polycythaemia B75
1142 Haemophilia B83.01
1192 Haemolytic anaemia, congenital B78
1250 Schizophrenia P72
1270 Alzheimer’s disease P70
1380 Personality disorder P80
1401 + 1402 Mental retardation P85 
1403 Child development disorders, pervasive P99
1551 TIA (transient ischemic attack) K89
1559 CVA (cerebrovascular accident) K90
1560 MS (multiple sclerosis) N86
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1570 Parkinson’s disease N87.01
1800 Glaucoma F93
1811 Blindness / amblyopia F94
1841 Cholesteatoma H74.03
1880 Otosclerosis H83
1890 Deafness H84, H86
2080 Heart valve disease K83
2090 Heart valve disease (rheumatic) K71.02
2110 Myocardial infarction K75
2120 Angina pectoris K74
2131 (Congestive) heart failure K77
2132 Atrial fibrillation / flutter K78
2133 Pulmonary heart disease K82
2180 + 2181  
+ 2189 
Hypertension K86, K87
2231 Intermittent claudication K92.01
2480 COPD (chronic obstructive pulmonary disease) R95
2530 Pneumoconiosis R99.06
2540 Bronchiectasis R91.02
2852 Crohn’s disease; ulcerative colitis D94
2881 Hepatic cirrhosis D97
3820 Psoriasis S91
4050 + 4051  
+ 4052
Rheumatoid arthritis; ankylosing spondylarthritis L88.01, L88.02
4061 Osteoarthritis, hip L89
4062 Osteoarthritis, knee L90
4063 Lumbar osteoarthritis L84
4064 Osteoarthritis, cervical spine 
L84.01
4069 Osteoarthritis, other L91
4154 Osteoporosis L95.02
4300 Multiple congenital abnormalities A90
4310 Spinal dysraphism N85.01
4389 Down syndrome / other specified congenital 
abnormalities
A90(.01)
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CONDITIONALLY CHRONIC DISEASES1 
Total number: 63
Code Disorder ICPC equivalent
0010 Pulmonary tuberculosis R70 (ex. A70)
0020 Tuberculosis, other organs A70 (ex. R70)
0030 Syphilis X70 / Y70
0162 Hepatitis B D72.02
0164 Hepatitis C D72.03
0169 Hepatitis D72
0460 Sarcoidosis R83.02
0470 Lyme disease A78.05
0631 Testis cancer Y78.02
0710 Uterine fibroid X78.01
0821 Neoplasm malignant / benign S80
0860 Asthma R96
0880 Hyperthyroidism T85
0930 Gout T92
0949 Endocrine disease, other T99
1109 Anaemia, other deficiency B81
1221 Lymphadenitis, chronic, not specified B71
1260 + 1341  
+ 1342
Depressive disorder P76
1280 Organic psychosis P71
1290 Psychosis P98
1311 Anorexia nervosa T06
1312 Somatoform disorder P75
1321 Phobia P79.01
1322 Anxiety disorder P74
1330 Obsessive-compulsive disorder P79.02
1351 Irritable bowel syndrome D93
1359 (Chronic) functional somatic symptoms2 P01, P78
1580 Epilepsy N88
1590 Migraine N89
1790 Cataract F92
1849 Chronic otitis media H74.01
1860 Meniere disease H82.01
2072 Restless legs syndrome N04
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2100 Rheumatic fever K71.01
2232 Pulmonary embolism K93
2239 Peripheral arterial disease; Raynaud’s disease K99
2240 Varicose veins; venous insufficiency K95, K99.04
2280 Varicose ulcer S97.01
2472 Bronchitis R78
2500 Chronic sinusitis R75.02
2764 Oesophageal disease D84
2770 Stomach ulcer D86.01
2780 Duodenal ulcer D85
2790 Peptic ulcer, other D86
2841 Diaphragmatic hernia D90
2851 Colonic diverticula; diverticulitis D92
2884 Pancreatic disease; other D99
3101 Glomerulonephritis U88
3102 Glomerulonephrosis U88
3120 Urinary calculi / urinary tract stones U95
3140 Urinary tract infection, chronic / recurrent U71
3180 Prostatic hyperplasia / hypertrophy Y85
3390 Urinary incontinence U04
3722 Hidradenitis S92.02
3780 Seborrhoeic dermatitis S86
3790 Atopic dermatitis S87
3801 Contact dermatitis S88.01
3900 Chronic skin ulcer S97
4152 Polymyalgia rheumatica; giant cell arteritis K99.05, L99.12
4170 Autoimmune diseases K99, L99, S99, U99
4320 Hydrocephalus N85.02
4330 Congenital cardiovascular anomaly K73
4340 Cleft palate D81.01
1Note: For conditionally chronic diseases, only episodes assigned ‘ongoing attention’ are counted as 
chronic disease. 
2Chronic functional somatic symptoms are chronic symptoms in patients who experience functional 
impairment and for which a medical (organic) explanation cannot be found. GPs in the Continuous 
Morbidity Registration tended to classify patients as such after three episodes of presenting with functional 
somatic symptoms. (Reference: Olde Hartman TC, Lucassen PL, Van de Lisdonk EH, Bor HH, Van Weel C: 
Chronic functional somatic symptoms: a single syndrome? Br J Gen Pract 2004, 54: 922-927.) 
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Cluster of chronic diseases Disease
Cardiovascular TIA (transient ischemic attack)
CVA (cerebrovascular accident)
Heart valve disease
Myocardial infarction
Angina pectoris
(Congestive) heart failure / heart decompensation
Atrial fibrillation / flutter
Hypertension
Intermittent claudication
Peripheral arterial disease; Raynaud’s disease1 
Varicose veins / venous insufficiency1
Congenital heart defects1
Musculoskeletal Rheumatoid arthritis; ankylosing spondylarthritis
Osteoarthritis, hip
Osteoarthritis, knee
Lumbar osteoarthritis
Osteoarthritis, cervical spine 
Osteoarthritis, other
Polymyalgia rheumatica; giant cell arteritis1
Osteoporosis
Mental health Schizophrenia
Depressive disorder1
Alzheimer’s disease
Organic psychosis1
Psychosis1
Phobia1
Anxiety disorder1
Obsessive-compulsive disorder1
(Chronic) functional somatic symptoms1
Personality disorder
Mental retardation
Eye & Ear Cataract1
Glaucoma
Blindness / amblyopia
Chronic otitis media1
Meniere disease1
Otosclerosis
Deafness 
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(Male and female) urogenital Uterine fibroid / uterine leiomyoma1
Glomerulonephritis1
Glomerulonephrosis1
Urinary calculi / urinary tract stones1
Urinary tract infection, chronic / recurrent1
Prostatic hyperplasia / hypertrophy1
Urinary incontinence1
Respiratory Sarcoidosis1
Asthma1
COPD (chronic obstructive pulmonary disease)
Chronic sinusitis1 
Pneumoconiosis
Bronchiectasis
Skin Hidradenitis1
Seborrhoeic dermatitis1
Atopic dermatitis1
Contact dermatitis1
Psoriasis
Chronic skin ulcer1
Digestive Irritable bowel syndrome1
Oesophageal disease1
Stomach ulcer1
Duodenal ulcer1
Diaphragmatic hernia1
Colonic diverticula; diverticulitis1
Crohn’s disease; ulcerative colitis
Hepatic cirrhosis
Pancreatic disease; other1
Cleft palate1
Endocrine and metabolic Hyperthyroidism1
Hypothyroidism
Gout1
Endocrine disease, other1
Neurological MS (multiple sclerosis)
Parkinson’s disease
Epilepsy1
Migraine1
Blood(forming organs)  
and lymphatics 
Pernicious anaemia
Anaemia, other deficiency1
General and unspecified Down syndrome / other specified congenital abnormalities
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Infectious Pulmonary tuberculosis1
Syphilis1
Malignancies Cancer of the mouth / pharynx
Oesophageal cancer
Cancer of the stomach
Colon cancer
Rectal cancer
Pancreatic cancer
Laryngeal / throat cancer
Lung / bronchial cancer
Breast cancer
Uterine cervical cancer
Endometrial cancer
Prostate cancer
Bladder cancer
Ovarian cancer
Genitourinary cancer, other 
Skin cancer
Brain cancer / tumour
Leukaemia
Lymphoma / multiple myeloma
Metastases; unknown origin
Carcinoma, other
Note: Only chronic comorbid diseases occurring at least once in the study population were classified into 
clusters.
1Conditionally chronic disease: requiring physician-assigned ‘ongoing episodes’ at the patient level in 
order to be assigned as chronic disease. 
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CLASSIFICATION OF COMORBIDITY
The following clusters of chronic diseases were distinguished:
- Cardiovascular disease
- Malignancy
- Musculoskeletal disease
- Mental health disease
- Respiratory disease
- Eye and ear disease
- (Male and female) urogenital disease
- Skin disease
- Digestive system disease
- Endocrine and metabolic disease
- Neurological disease
- Blood(forming organs) and lymphatics disease
- Infectious disease
- General and unspecified disease
Each disease cluster contains several chronic diseases. Within any cluster of diseases, 
presence of at least one chronic disease classified in this cluster was required in order to 
be counted as presence of this disease cluster in a particular patient. For each separate 
cluster it was defined whether or not a particular patient classified for this disease cluster. 
Any single chronic disease present in any of the abovementioned clusters contributed 
to the total sum of comorbidity as distinguished in this study (‘number of comorbid 
diseases’). 
This study included only chronic diseases as comorbidity. Some diseases can be regarded 
as invariably chronic diseases (e.g. rheumatoid arthritis, schizophrenia). Other diseases 
may have a chronic course in a particular patient but do not necessarily do so in all cases 
(e.g. gout, migraine, depression). These diseases were defined as ‘conditionally chronic’ 
diseases and were included as comorbidity in this study only when it had a chronic 
course in this particular patient. These methods have been elaborated in a previous 
paper of the same research group.1
In the current study, five selected clusters of diseases were analysed separately, in 
addition to the analysis of the number of comorbid diseases. These disease clusters were 
cardiovascular disease, malignancy, musculoskeletal disease, mental health disease, and 
COPD as selected disease from the respiratory disease cluster. 
The following diseases were included within the disease clusters of special interest 
(conditionally chronic disease are marked with an asterisk*):
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Cardiovascular disease:
- Angina pectoris
- Atrial fibrillation / flutter
- Myocardial infarction
- (Congestive) heart failure
- Intermittent claudication
- TIA (transient ischemic attack)
- CVA (cerebrovascular accident)
- Heart valve disease
- Peripheral arterial disease / Raynaud’s disease*
- Chronic venous insufficiency / chronic varicosis*
- Congenital heart defects*
- Hypertension†
† In the current study, with SBP as one of the primary outcome measures, presence of 
hypertension as diagnostic label in the CMR registry had to be complemented with 
at least one other cardiovascular disease diagnostic label for patients to be analysed 
longitudinally within the cardiovascular disease cluster. 
Malignancy:
- Breast cancer
- Prostate cancer
- Endometrial cancer
- Skin cancer (only the types with potential to metastasise, e.g. basal cell carcinoma 
was excluded)
- Colon cancer
- Rectal cancer
- Lung / bronchial cancer
- Bladder cancer
- Ovarian cancer
- Uterine cervical cancer
- Brain cancer
- Leukaemia
- Lymphoma / multiple myeloma
- Cancer of the stomach
- Oesophageal cancer
- Pancreatic cancer
- Cancer of the mouth / pharynx
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- Laryngeal / throat cancer
- Other specified types of cancer or metastases of unknown origin
Musculoskeletal disease:
- Rheumatoid arthritis; ankylosing spondylarthritis
- Osteoarthritis of the knee
- Osteoarthritis of the hip
- Osteoarthritis of the lumbar or cervical spine
- Other specified osteoarthritis
- Osteoporosis
- Polymyalgia rheumatica; giant cell arteritis*
Mental health disease:
- Depression*
- Anxiety disorder*
- Personality disorder
- Obsessive-compulsive disorder*
- Schizophrenia
- Psychosis*
- Phobia*
- (Chronic) functional somatic symptoms*
- Alzheimer’s disease
- Mental retardation
Respiratory disease:
As fifth separate disease group of special interest, COPD as a single disease was analysed 
for associations with the longitudinal study outcomes, since within the cluster of 
respiratory diseases, COPD constituted the large majority of diseases (79%), and with that 
its prevalence was large enough to be studied on itself. This ensured good homogeneity 
within this comorbidity group, since COPD has a distinct therapeutic approach from 
the other diseases. The following diseases were considered within the entire cluster of 
respiratory diseases and could contribute to the total number of comorbid diseases:
- COPD (chronic obstructive pulmonary disease)
- Sarcoidosis*
- Asthma*
- Pneumoconiosis
- Bronchiectasis
- Chronic sinusitis* 
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